0001193125-18-323795.txt : 20181109 0001193125-18-323795.hdr.sgml : 20181109 20181109162318 ACCESSION NUMBER: 0001193125-18-323795 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181109 DATE AS OF CHANGE: 20181109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 181173388 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 10-Q 1 d635570d10q.htm 10-Q 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

COMMISSION FILE NUMBER 000-51122

 

 

EyePoint Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   26-2774444

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

480 Pleasant Street

Watertown, MA

  02472
(Address of principal executive offices)   (Zip Code)

(617) 926-5000

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

There were 94,855,705 shares of the registrant’s common stock, $0.001 par value, outstanding as of November 5, 2018.

 

 

 


Table of Contents

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

 

         Page  
PART I:   FINANCIAL INFORMATION   
Item 1.   Unaudited Financial Statements   
 

Condensed Consolidated Balance Sheets – September  30, 2018 and June 30, 2018

     3  
 

Condensed Consolidated Statements of Comprehensive Loss – Three Months Ended September 30, 2018 and 2017

     4  
 

Condensed Consolidated Statements of Stockholders’ Equity – Three Months Ended September 30, 2018 and 2017

     5  
 

Condensed Consolidated Statements of Cash Flows – Three Months Ended September 30, 2018 and 2017

     6  
 

Notes to Condensed Consolidated Financial Statements

     7  
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations      22  
Item 3.   Quantitative and Qualitative Disclosures about Market Risk      28  
Item 4.   Controls and Procedures      29  
PART II:   OTHER INFORMATION   
Item 1A.   Risk Factors      29  
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds      29  
Item 3.   Defaults Upon Senior Securities      29  
Item 4.   Mine Safety Disclosures      29  
Item 5.   Other Information      29  
Item 6.   Exhibits      30  
Signatures      31  
Certifications   

 

2


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Financial Statements

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands except share amounts)

 

     September 30,
2018
    June 30,
2018
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 55,764     $ 38,776  

Accounts and other receivables

     489       353  

Prepaid expenses and other current assets

     1,389       780  
  

 

 

   

 

 

 

Total current assets

     57,642       39,909  

Property and equipment, net

     320       253  

Intangible assets, net

     30,743       31,358  

Restricted cash

     150       150  
  

 

 

   

 

 

 

Total assets

   $ 88,855     $ 71,670  
  

 

 

   

 

 

 

Liabilities and stockholders' equity

    

Current liabilities:

    

Accounts payable

   $ 4,075     $ 2,940  

Accrued expenses

     3,343       3,723  

Accrued development milestone

     15,000       15,000  
  

 

 

   

 

 

 

Total current liabilities

     22,418       21,663  

Long-term debt

     17,463       17,309  

Derivative liability

     —         19,780  

Other long-term liabilities

     1,269       1,231  
  

 

 

   

 

 

 

Total liabilities

     41,150       59,983  
  

 

 

   

 

 

 

Stockholders' equity:

    

Preferred stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding

     —         —    

Common stock, $.001 par value, 150,000,000 shares authorized, 94,696,272 and 74,512,048 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively

     95       74  

Additional paid-in capital

     443,671       374,766  

Accumulated deficit

     (396,899     (363,991

Accumulated other comprehensive income

     838       838  
  

 

 

   

 

 

 

Total stockholders' equity

     47,705       11,687  
  

 

 

   

 

 

 

Total liabilities and stockholders' equity

   $ 88,855     $ 71,670  
  

 

 

   

 

 

 

See notes to condensed consolidated financial statements

 

3


Table of Contents

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands except per share amounts)

 

     Three Months Ended
September 30,
 
     2018     2017  

Revenues:

    

Collaborative research and development

   $ 56     $ 140  

Royalty income

     430       245  
  

 

 

   

 

 

 

Total revenues

     486       385  
  

 

 

   

 

 

 

Operating expenses:

    

Research and development

     6,233       3,819  

Sales and marketing

     3,646       —    

General and administrative

     4,161       2,572  
  

 

 

   

 

 

 

Total operating expenses

     14,040       6,391  
  

 

 

   

 

 

 

Operating loss

     (13,554     (6,006

Interest and other income, net

     129       23  

Interest expense

     (815     —    

Change in fair value of derivative liability

     (18,886     —    
  

 

 

   

 

 

 

Net loss

   $ (33,126   $ (5,983
  

 

 

   

 

 

 

Net loss per common share:

    

Basic and diluted

   $ (0.44   $ (0.15
  

 

 

   

 

 

 

Weighted average common shares:

    

Basic and diluted

     75,170       39,430  
  

 

 

   

 

 

 

Net loss

   $ (33,126   $ (5,983
  

 

 

   

 

 

 

Other comprehensive income:

    

Foreign currency translation adjustments

     —         4  
  

 

 

   

 

 

 

Other comprehensive income

     —         4  
  

 

 

   

 

 

 

Comprehensive loss

   $ (33,126   $ (5,979
  

 

 

   

 

 

 

See notes to condensed consolidated financial statements

 

4


Table of Contents

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

(Unaudited)

(In thousands, except share amounts)

 

    

 

Common Stock

     Additional
Paid-In
Capital
     Accumulated
Deficit
    Accumulated
Other

Comprehensive
Income
     Total
Stockholders'
Equity
 
     Number of
Shares
     Par
Value
Amount
 

Balance at July 1, 2017

     39,356,999      $ 39      $ 323,284      $ (310,820   $ 833      $ 13,336  

Net loss

     —          —          —          (5,983     —          (5,983

Other comprehensive income

     —          —          —          —         4        4  

Issuance of stock, net of issue costs

     843,784        1        962        —         —          963  

Stock-based compensation

     —          —          681        —         —          681  
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Balance at September 30, 2017

     40,200,783      $ 40      $ 324,927      $ (316,803   $ 837      $ 9,001  
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Balance at July 1, 2018

     74,512,048      $ 74      $ 374,766      $ (363,991   $ 838      $ 11,687  

Cumulative effect adjustment for adoption of new accounting principle

     —          —          —          218       —          218  

Net loss

     —          —          —          (33,126     —          (33,126

Exercise of warrants

     20,184,224        21        28,842        —         —          28,863  

Settlement of derivative liability

     —          —          38,666        —         —          38,666  

Stock-based compensation

     —          —          1,397        —         —          1,397  
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Balance at September 30, 2018

     94,696,272      $ 95      $ 443,671      $ (396,899   $ 838      $ 47,705  
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

See notes to condensed consolidated financial statements

 

5


Table of Contents

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

     Three Months Ended
September 30,
 
     2018     2017  

Cash flows from operating activities:

    

Net loss

   $ (33,126   $ (5,983

Adjustments to reconcile net loss to cash flows used in operating activities:

    

Amortization of intangible assets

     615       182  

Depreciation of property and equipment

     43       39  

Amortization of debt discount

     154       —    

Stock-based compensation expense

     1,397       681  

Change in fair value of derivative liability

     18,886       —    

Changes in operating assets and liabilities:

    

Accounts receivable and other current assets

     (529     129  

Accounts payable and accrued expenses

     756       (972

Deferred revenue

     —         (40

Deferred rent

     38       (4
  

 

 

   

 

 

 

Net cash used in operating activities

     (11,766     (5,968
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property and equipment

     (109     (64
  

 

 

   

 

 

 

Net cash used in investing activities

     (109     (64
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from exercise of warrants

     28,863       —    

Proceeds from issuance of stock, net of issuance costs

     —         963  
  

 

 

   

 

 

 

Net cash provided by financing activities

     28,863       963  
  

 

 

   

 

 

 

Effect of foreign exchange rate changes on cash and cash equivalents

     —         4  
  

 

 

   

 

 

 

Net increase (decrease) in cash, cash equivalents and restricted cash

     16,988       (5,065

Cash, cash equivalents and restricted cash at beginning of period

     38,926       17,048  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash at end of period

   $ 55,914     $ 11,983  
  

 

 

   

 

 

 

Supplemental cash flow information:

    

Cash interest paid

   $ 583     $ —    

See notes to condensed consolidated financial statements

 

6


Table of Contents

EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Operations and Basis of Presentation

The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the “Company”) as of September 30, 2018 and for the three months ended September 30, 2018 and 2017 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (“fiscal 2018”). In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2018, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.

The Company is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Following U.S. Food and Drug Administration (“FDA”) approval of DEXYCU™ and YUTIQ™, the Company is targeting the direct U.S. commercial launch of YUTIQ in the first quarter of calendar 2019 and DEXYCU in the first half of calendar 2019.

DEXYCU™ (dexamethasone intraocular suspension) 9%, approved by the FDA in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes the Company’s proprietary Verisome® drug-delivery platform, which allows for a single injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and the Company expects to launch DEXYCU in the U.S. in the first half of 2019 with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (“Icon”) in March 2018.

YUTIQ™, a non-erodible fluocinolone acetonide insert for the treatment of chronic non-infectious posterior uveitis affecting the posterior segment of the eye (chronic “NIPU”), was approved by the FDA on October 12, 2018. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis (zero order release) for approximately three years. YUTIQ is based on the Company’s proprietary Durasert™ sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. NIPU is the third leading cause of blindness in the U.S. and is estimated to affect between 55,000 to 120,000 people. The Company expects to launch YUTIQ in the U.S. in the first quarter of calendar 2019.

ILUVIEN® for diabetic macular edema (“DME”), the Company’s lead licensed product, was also developed from the Durasert technology platform and is sold directly in the U.S. and several European Union (“EU”) countries by Alimera Sciences, Inc. (“Alimera”). Retisert®, one of the Company’s earlier generation products, was approved in 2005 by the FDA for the treatment of chronic NIPU and is sold in the U.S. by Bausch & Lomb Incorporated (“Bausch & Lomb”). The Company’s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company’s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.

The Company has financed its operations primarily from sales of equity securities, issuance of debt and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company’s anticipated recurring use of cash to fund operations in combination with no probable source of additional capital raises substantial doubt about its ability to continue as a going concern for one year from the issuance of its financial statements. The Company received proceeds of $28.9 million in late

 

7


Table of Contents

September 2018 from the exercise of investor warrants (the “Second Tranche Warrants) (see Note 8) and had total cash and cash equivalents of $55.8 million at September 30, 2018. The Company believes that its cash and cash equivalents of $55.8 million at September 30, 2018, and expected proceeds from existing collaboration agreements, will enable the Company to maintain its current and planned operations (including continuation of its two Phase 3 clinical trials for YUTIQ and plans for the U.S. commercial launch of both DEXYCU and YUTIQ) into the second quarter of calendar year 2019. In order to extend the Company’s ability to fund its operations beyond then, management’s plans include obtaining additional equity financing and/or additional debt financing and/or, as applicable, reducing or deferring operating expenses. The timing and extent of the Company’s implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaborations or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant revenues from its planned commercialization of DEXYCU or YUTIQ, or from its product license revenues under existing collaboration agreements or be able to obtain financing from any other sources.

Recently Adopted and Recently Issued Accounting Pronouncements

New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.

The Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, with a date of initial application of July 1, 2018. As a result, the Company has updated its accounting policy for revenue recognition to reflect the new standard (see Note 2). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company’s services and will provide financial statement readers with enhanced disclosures. The Company applied ASC 606 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard resulted in a $218,000 reduction to the opening balance of accumulated deficit at July 1, 2018.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Based on the change in the Company’s fiscal year (see Note 14), ASU 2016-02 will become effective on January 1, 2019. A modified retrospective transition approach is required for lessee capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. The standard aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but not before an entity adopts the new revenue guidance. ASU 2018-07, which was early adopted on July 1, 2018, did not have a significant impact on the Company’s financial statements.

2. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the

 

8


Table of Contents

consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

Collaborative research and development revenue — The Company analyzes each element of its collaborative arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of September 30, 2018.

Reimbursement of costs — The Company may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. The Company acts primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. The Company records the expenses incurred and reimbursed on a gross basis.

Royalties — The Company recognizes revenue from license arrangements with its commercial partners’ net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. The Company’s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial.

Feasibility Studies — The Company recognizes revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the feasibility study agreement.

Please refer to Note 4 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.

 

9


Table of Contents

3. Acquisition of Icon Bioscience, Inc.

On March 28, 2018, the Company and its newly-created wholly-owned subsidiary, Oculus Merger Sub, Inc., acquired Icon, a specialty biopharmaceutical company, through a reverse triangular merger (the “Icon Acquisition”) pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) between the Company, Icon, and Shareholder Representative Services LLC (“SRS”), solely in its capacity as representative of Icon’s securityholders. The Icon Acquisition was accounted for as an asset acquisition because substantially all of the fair value of the gross assets acquired were deemed to be concentrated in a group of similar identifiable assets related to Icon’s lead product, DEXYCU. A portion of the Icon Acquisition was funded by an equity financing and a debt financing, both of which closed concurrently with the Icon Acquisition (see Notes 7 and 8).

Pursuant to the Merger Agreement, the Company made a closing payment of $15.0 million to SRS, net of an estimated $127,000 working capital adjustment, and is obligated to pay certain post-closing contingent cash payments upon the achievement of specified milestones and based upon certain net sales and partnering revenue standards, in each case subject to the terms and conditions set forth in the Merger Agreement. These include but are not limited to (i) a one-time development milestone of $15.0 million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0 million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare & Medicaid Services (“CMS”) reimbursement conditions set forth in the Merger Agreement, (iii) quarterly earn-out payments equal to 12% on net sales of DEXYCU in a given year, which earn-out payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual DEXYCU consideration exceeds $200.0 million in such year, (iv) quarterly earn-out payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v) single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition.

The purchase price on the date of the Icon Acquisition was $32.0 million, comprising the closing consideration of $15.0 million, including the assumption of an estimated $127,000 of net current liabilities of Icon, the contingent development milestone payment of $15.0 million and transaction costs of approximately $2.0 million. Given the stage of development of DEXYCU, the Company determined these payments did not represent research and development costs. The contingent consideration in the form of sales milestones will be capitalized as additional intangible assets when any such consideration becomes probable and can be reasonably estimated. Sales-based royalty payments will be expensed as incurred.

The $32.0 million purchase price was allocated to a single finite-lived intangible asset with an expected amortization life of approximately 13 years. The intangible asset is being amortized on a straight-line basis over that period. The acquisition did not have a net tax impact due to a full valuation allowance against the acquired net deferred tax assets.

4. License and Collaboration Agreements

Alimera

Under a collaboration agreement with Alimera, as amended in March 2008 (the “Prior Alimera Agreement”), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN for DME, and Alimera assumed all financial responsibility for the development of the licensed products. In addition, the Company was entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a quarter-by-quarter and country-by-country basis. Alimera was entitled to recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company’s net profit share to 16% in each country until those net losses were recouped. In the event that Alimera sublicensed commercialization in any country, the Company was entitled to 20% of royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company was also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.

On July 10, 2017, the Company entered into a further amended and restated collaboration agreement (the “Amended Alimera Agreement”), pursuant to which the Company (i) licensed its three-year NIPU product candidate (called YUTIQ in the U.S. and planned to be called ILUVIEN in Europe, the Middle East and Africa (“EMEA”)) to Alimera for the EMEA and (ii) converted the net profit share arrangement for each licensed product (including ILUVIEN) under the Prior Alimera Agreement to a sales-based royalty on a calendar quarter basis commencing July 1, 2017, with payments from Alimera due 60 days following the end of each quarter.

 

10


Table of Contents

Sales-based royalties start at the rate of 2%. Commencing January 1, 2019, the sales-based royalty will increase to 6% on aggregate calendar year net sales up to $75 million and 8% in excess of $75 million. Alimera’s share of contingently recoverable accumulated ILUVIEN commercialization losses under the Prior Alimera Agreement, capped at $25 million, are to be reduced as follows: (i) $10.0 million was cancelled in lieu of an upfront license fee on the effective date of the Amended Alimera Agreement; (ii) for calendar years 2019 and 2020, 50% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments otherwise due from Alimera; (iii) on January 1, 2020, another $5 million will be cancelled, provided, however, that such date of cancellation may be extended under certain circumstances related to Alimera’s regulatory approval process for the ILUVIEN three-year NIPU product candidate, with such extension, if any, subject to mutual agreement by the parties; and (iv) commencing in calendar year 2021, 20% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments due from Alimera until such time as the balance of the original $25 million of recoverable commercialization losses has been fully recouped.

Following the completion of the Amended Alimera Agreement, the Company withdrew its previously filed EU marketing approval application and its EU orphan drug designation for YUTIQ, and Alimera was responsible for filing a Type II variation for ILUVIEN for the treatment of NIPU. In January 2018, Alimera received validation of a Type II variation submitted in December 2017 in all seventeen European countries in which it previously received regulatory approval for ILUVIEN for DME. If the variation is approved, Alimera plans to commercialize the indication for NIPU under its ILUVIEN trademark.

Revenue under the Prior Alimera Agreement and/or the Amended Alimera Agreement totaled $249,000 and $90,000 for the three months ended September 30, 2018 and 2017, respectively. In addition to patent fee reimbursements in both periods, revenue included (i) $215,000 of accrued sales-based royalty income for the three months ended September 30, 2018 under the Amended Alimera Agreement and (ii) $50,000 of net profits received in the three months ended September 30, 2017 attributable to the fourth quarter of fiscal 2017 (recorded as collaborative research and development revenue under the Prior Alimera Agreement).

Prior to the July 1, 2018 adoption of ASC 606, the Company had recorded royalties earned from Alimera one quarter in arrears. Under ASC 606, the Company is required to accrue royalty income based on an estimate of royalties earned in each fiscal quarter, with a true-up to actual in the following quarter. As a result, $218,000 of royalties earned for the quarter ended June 30, 2018 that would have been recorded as royalty income in the three months ended September 30, 2018 have been accounted for as a cumulative effect adjustment to beginning accumulated deficit at July 1, 2018.

Bausch & Lomb

Pursuant to a licensing and development agreement, as amended, Bausch & Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Royalty income totaled $215,000 and $245,000 for the three months ended September 30, 2018 and 2017, respectively. Accounts receivable from Bausch & Lomb totaled $225,000 at September 30, 2018 and $306,000 at June 30, 2018.

OncoSil Medical

The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly owned subsidiary of OncoSil Medical Ltd (“OncoSil”) for the development of BrachySil, the Company’s BioSilicon product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and certain milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year, the most recent of which was received in December 2017. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any licensed patent maintenance costs, sales-based royalties and sub-licensee sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. As of September 30, 2018, OncoSil has not received regulatory approval in any jurisdiction, although an application for CE Mark approval in Europe is pending. There was no revenue related to the OncoSil agreement in either of the three-month periods ended September 30, 2018 and 2017. As of September 30, 2018, no deferred revenue was recorded for this agreement.

 

11


Table of Contents

Evaluation Agreements

The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized by the Company as revenue over the term of the feasibility study agreement. Revenues under evaluation agreements totaled $15,000 and $50,000 for the three months ended September 30, 2018 and 2017, respectively. At September 30, 2018 no deferred revenue was recorded for these agreements.

5. Intangible Assets

The reconciliation of intangible assets for the three months ended September 30, 2018 and for the year ended June 30, 2018 was as follows (in thousands):

 

     Three Months
Ended
September 30,
2018
     Year Ended
June 30,
2018
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 68,322      $ 35,610  

Acquisition of Icon Bioscience Inc.

     —          31,973  

Foreign currency translation adjustments

     —          739  
  

 

 

    

 

 

 

Gross carrying amount at end of period

     68,322        68,322  
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

     (36,964      (35,246

Amortization expense

     (615      (981

Foreign currency translation adjustments

     —          (737
  

 

 

    

 

 

 

Accumulated amortization at end of period

     (37,579      (36,964
  

 

 

    

 

 

 

Net book value at end of period

   $ 30,743      $ 31,358  
  

 

 

    

 

 

 

The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $615,000 and $182,000 for the three months ended September 30, 2018 and 2017, respectively.

In connection with the Icon Acquisition (see Note 3), the initial purchase price of $32.0 million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of 12.5 years at the rate of approximately $2.5 million per year.

6. Accrued Expenses

Accrued expenses consisted of the following at September 30, 2018 and June 30, 2018 (in thousands):

 

     September 30,
2018
     June 30,
2018
 

Clinical trial costs

   $ 1,039      $ 742  

Personnel costs

     1,204        1,763  

Professional fees

     722        926  

Interest

     332        254  

Other

     46        38  
  

 

 

    

 

 

 
   $ 3,343      $ 3,723  
  

 

 

    

 

 

 

 

12


Table of Contents

7. Term Loan Agreement

On March 28, 2018 (the “Closing Date”), the Company entered into a Credit Agreement (the “Credit Agreement”) among the Company, as borrower, SWK Funding LLC, as agent (the “Agent”), and the lenders party thereto from time to time (the “Lenders”), providing for a senior secured term loan of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was advanced (the “Initial Advance”). The remaining $5 million of the Loan was advanced on June 26, 2018 following satisfaction of the Minimum Capital Raise (as defined in the Credit Agreement) (the “Additional Advance”). The Loan may be increased by $10 million upon the request of the Company, subject to the Agent obtaining additional loan commitments and satisfaction of certain conditions in the Credit Agreement.

The Loan is due and payable on March 27, 2023 (the “Maturity Date”). The Loan bears interest at a per annum rate of the three-month LIBOR rate (subject to a 1.5% floor) plus 10.50%. The Credit Agreement permits the Company to pay interest only on the principal amount for the first eight payments (payments are due on a quarterly basis commencing May 15, 2018). Following the interest-only period, the Company will be required to make quarterly payments of interest, plus repayments of the principal in an aggregate amount of up to $1.67 million per quarter (the “Quarterly Principal Repayment Cap”). Subject to the Quarterly Principal Repayment Cap, the amount of any quarterly principal payments during any fiscal year of the Company is based on (x) a percentage of the year-to-date net revenue of the Company through the end of such quarter less (y) any prior quarterly principal and interest payments made during such fiscal year. In addition, the Company paid an upfront fee of 1.5% of the aggregate principal amount of the Loan. The Company is required to pay an exit fee equal to 6% of the aggregate principal amount advanced under the Credit Agreement (the “Exit Fee”), which amount is included in other long-term liabilities in the accompanying condensed consolidated balance sheet.

Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the Credit Agreement), all or any amounts outstanding with respect to the Loan may become due and payable upon request of the Agent or majority Lenders. Additionally, subject to certain exceptions, the Company is required to make mandatory prepayments of the Loan with the proceeds of assets sales and insurance proceeds. The Company may make a voluntary prepayment of the Loan, in whole, but not in part, at any time on or after the first anniversary of the Closing Date. All mandatory and voluntary prepayments of the Loan are subject to the payment of prepayment premiums as follows: (i) in the case of mandatory prepayments, if prepayment occurs prior to the first anniversary of the Closing Date, a customary make-whole amount equal to the amount of interest that would have accrued on the principal amount so prepaid had it remained outstanding through the first anniversary of the Closing Date, (ii) if prepayment occurs on or after the first anniversary of the Closing Date, but prior to the second anniversary of the Closing Date, 6% of the aggregate amount of the principal prepaid and (iii) if prepayment occurs on or after the second anniversary of the Closing Date, but prior to the third anniversary of the Closing Date, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid on or after the third anniversary of the Closing Date.

In connection with the Loan, the Company issued a warrant (the “SWK Warrant”) to the Agent to purchase (a) 409,091 shares of Company common stock (the “Initial Advance Warrant Shares”) at an exercise price equal to $1.10 and (b) 77,721 shares of Company common stock (the “Additional Advance Warrant Shares”) at an exercise price of $1.93 per share. The SWK Warrant is exercisable (i) with respect to the Initial Advance Warrant Shares, any time on or after the Closing Date until the close of business on the 7-year anniversary of the Initial Advance and (ii) with respect to the Additional Advance Warrant Shares, any time on or after the closing of the Additional Advance until the close of business on the 7-year anniversary of the Additional Advance. The Agent may exercise the SWK Warrant on a cashless basis at any time. In the event the Agent exercises the SWK Warrant on a cashless basis the Company will not receive any proceeds.

The total debt discount related to the Initial Advance was $2.1 million and was comprised of (1) $1.8 million which included the 1.5% upfront fee, the Exit Fee and legal and other transaction costs, which were ratably allocated to each of the two tranches of the Loan based upon the total principal amount available to the Company under each tranche and (2) $353,000 related to the aggregate fair value of the Initial Advance Warrant Shares and the Additional Advance Warrant Shares. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest method.

The total debt issue costs related to the Additional Advance was $299,000 and was comprised of the allocated portions of the 1.5% upfront fee and the Exit Fee. This amount was recorded as a prepaid expense to be amortized ratably from the Closing Date through December 31, 2018. Through the date of the Additional Advance, $97,000

 

13


Table of Contents

was amortized and the remaining balance of $202,000 was reclassified to debt discount. Together with the 6% Exit Fee on the Additional Advance and other transaction costs, total debt discount of $652,000 associated with the Additional Advance is being amortized over the remaining life of the Additional Advance portion of the Loan using the effective interest method.

8. Stockholders’ Equity

2018 Equity Financing

On the Closing Date, the Company entered into a Securities Purchase Agreement (the “First Tranche Securities Purchase Agreement”) with EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. (collectively, the “First Tranche Investors”), pursuant to which the Company offered and sold to the First Tranche Investors an aggregate of 8,606,324 shares of the Company’s common stock at a purchase price of $1.10 per share (the “First Tranche Purchase Price”) for aggregate gross proceeds of approximately $9.5 million (the “First Tranche Transaction”).

On the Closing Date, the Company entered into a Second Securities Purchase Agreement (the “Second Tranche Securities Purchase Agreement” and together with the First Tranche Securities Purchase Agreement, the “Securities Purchase Agreements”) with the First Tranche Investors and certain other accredited investors (collectively, the “Second Tranche Investors”). Following approval of the Company’s stockholders on June 22, 2018, the Company sold to the Second Tranche Investors an aggregate of 20,184,224 Units at a purchase price of $1.265 per Unit for gross proceeds of approximately $25.5 million. Each Unit consisted of (a) one share of the Company’s common stock and (b) one warrant to purchase a share of the Company’s common stock (the “Second Tranche Transaction” and together with the First Tranche Transaction, the “Equity Transactions”).

The warrants issued in the Second Tranche Transaction (each a “Second Tranche Warrant,” and collectively, the “Second Tranche Warrants”) were exercisable any time until on or prior to the close of business on the 15th business day following the date on which the holders of the Second Tranche Warrants received written notice from the Company that CMS had announced that a new C-Code had been established for DEXYCU. CMS approved transitional pass-through status and reimbursement through a C-code with an effective date of October 1, 2018. Following written notice of such approval to the holders of the Second Tranche Warrants on September 7, 2018, the Second Tranche Warrants were exercised in September 2018 at a purchase price of $1.43 per share for proceeds of approximately $28.9 million.

The Company determined that the Second Tranche Warrants were considered puttable warrants that represented an obligation indexed to a repurchase of the Company’s shares and would require a transfer of assets that require classification as liabilities. The initial valuation of the Second Tranche Warrants on June 25, 2018 of $18.2 million was re-measured at June 30, 2018, resulting in a change in fair value of derivative liability of approximately $1.6 million and a derivative liability balance of $19.8 million at June 30, 2018. The Second Tranche Warrants were revalued immediately prior to exercise and resulted in a change in fair value of approximately $18.9 million. The change in fair value was determined as the excess of the closing share price of the Company’s common stock on the respective dates of exercise notice submitted by each of the Second Tranche Investors over the $1.43 per share exercise price. Upon exercise of the Second Tranche Warrants, the resulting derivative liability balance of approximately $38.7 million was reclassified to equity.

ATM Facility

In February 2017, the Company entered into an ATM program pursuant to which, under its Form S-3 shelf registration statement, the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $20.0 million. The Company will pay the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares.

During the three months ended September 30, 2017, the Company sold 843,784 shares of its Common Stock under the ATM program at a weighted average price of $1.24 per share for gross proceeds of approximately $1.0 million. Share issue costs, including sales agent commissions, totaled $81,000 for the three months ended September 30, 2017. The Company did not sell any shares of its common stock pursuant to the ATM program during the three months ended September 30, 2018. At September 30, 2018, approximately $3.8 million of aggregate proceeds remains available to be utilized under the current ATM program.

 

14


Table of Contents

Warrants to Purchase Common Shares

The following table provides a reconciliation of warrants to purchase shares of the Company’s common stock for the three months ended September 30, 2018 and 2017:

 

     Three Months Ended September 30,  
     2018      2017  
     Number of
Warrants
     Weighted
Average
Exercise
Price
     Number of
Warrants
     Weighted
Average
Exercise
Price
 

Balance at beginning of period

     486,812      $ 1.23        623,605      $ 2.50  

Expired

     —          —          (623,605      2.50  
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance and exercisable at end of period

     486,812      $ 1.23        —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

In connection with the Loan (see Note 7), the Company issued a warrant to purchase (i) 409,091 shares of Company common stock on March 28, 2018 at an exercise price of $1.10 per share with a seven-year term and (ii) 77,721 shares of Company common stock on June 26, 2018 at an exercise price of $1.93 per share with a seven-year term. At September 30, 2018 the weighted average remaining life of the warrants was 6.54 years.

At June 30, 2018 a total of 20,184,224 Second Tranche Warrants were outstanding with a variable exercise price and, accordingly, were excluded from the above table. These warrants were exercised in full in late September 2018.

9. Share-Based Payment Awards

Equity Incentive Plans

The 2016 Long-Term Incentive Plan (the “2016 Plan”), approved by the Company’s stockholders on December 12, 2016 (the “Adoption Date”), provides for the issuance of up to 3,000,000 shares of the Company’s common stock reserved for issuance under the 2016 Plan plus any additional shares of the Company’s common stock that were available for grant under the 2008 Incentive Plan (the “2008 Plan”) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At September 30, 2018, a total of 1,497,886 shares were available for new awards.

Stock Options

The following table provides a reconciliation of stock option activity under the Company’s equity incentive plans for the three months ended September 30, 2018:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     6,460,244      $ 2.79        

Granted

     166,575        2.31        

Forfeited

     (10,600      2.76        

Expired

     (156,750      2.85        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     6,459,469      $ 2.76        7.26      $ 6,203  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     3,151,142      $ 3.34        5.20      $ 1,747  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

15


Table of Contents

During the three months ended September 30, 2018, the Company granted 115,000 options to employees with ratable annual vesting over 3 years, 1,667 options to a non-executive director with 1-year cliff vesting and 49,908 options to an external consultant with 1-year cliff vesting. All option grants have a 10-year term. The weighted-average grant date fair value of these options was $1.31 per share. In determining the grant date fair value of option awards under the 2016 Plan during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   5.50 - 6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.78% -2.90%

Expected dividends

   0.0%

Options to purchase a total of 401,558 shares of the Company’s common stock vested during the three months ended September 30, 2018.

Time-Vested Restricted Stock Units

Time-vested restricted stock unit awards (“RSUs”) issued to date under the 2016 Plan generally vest on a ratable annual basis over 3 years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Company’s common stock on the date of grant.

The following table provides a reconciliation of RSU activity under the 2016 Plan for the three months ended September 30, 2018:

 

     Number of
Restricted
Stock Units
     Weighted
Average
Grant
Date Fair
Value
 

Nonvested at July 1, 2018

     898,129      $ 1.58  

Forfeited

     (2,300      1.81  
  

 

 

    

 

 

 

Nonvested at September 30, 2018

     895,829      $ 1.58  
  

 

 

    

 

 

 

At September 30, 2018, the weighted average remaining vesting term of the RSUs was 1.09 years.

Performance-Based Stock Units

Performance Stock Units (“PSUs”) were previously awarded to certain employees. The performance conditions associated with the PSU awards are as follows: (a) for one third of the PSUs, upon an FDA acceptance of the Company’s NDA submission of YUTIQ for review on or before March 31, 2018 and (b) for two-thirds of the PSUs, upon an FDA approval of YUTIQ on or before March 31, 2019. For each performance criteria that is achieved, 50% of the PSUs that are associated with that performance condition vest at the achievement date and 50% vest on the first anniversary of such date, in each case subject to continued employment through such date. As a result of the achievement of the first performance condition on March 19, 2018, 48,332 PSUs vested at that date and the other 48,334 PSUs became subject to a service-based condition with a vesting date of March 19, 2019. On October 12, 2018, the second performance condition associated with the PSUs was achieved and, accordingly, cumulative stock-based compensation from the PSU award date through September 30, 2018 was recorded for that portion of the PSUs during the three months ended September 30, 2018.

There were 241,668 PSUs outstanding at each of September 30, 2018 and June 30, 2018. The weighted average remaining vesting term of the time-based RSUs associated with achievement of the first performance condition was approximately 5.6 months at September 30, 2018.

 

16


Table of Contents

Deferred Stock Units

The following table provides a reconciliation of deferred stock units (“DSUs”) for the three months ended September 30, 2018:

 

     Number of
Deferred
Stock Units
     Weighted
Average
Grant Date
Fair Value
 

Outstanding at July 1, 2018

     35,001      $ 1.95  

Granted

     417        2.32  
  

 

 

    

 

 

 

Outstanding at September 30, 2018

     35,418      $ 1.95  
  

 

 

    

 

 

 

Each DSU vests one year from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company’s common stock upon the earliest to occur of (i) each director’s termination of service on the Company’s Board of Directors and (ii) the occurrence of a change of control as defined in the award agreement.

At September 30, 2018, the weighted average remaining vesting term of the DSUs was approximately 8.8 months.

Market-Based Restricted Stock Units

At September 30, 2018 and June 30, 2018, there were 500,000 market-based RSUs (“market-based RSUs”) outstanding that were issued on September 15, 2016 as an inducement award to the Company’s President and CEO Subject to a service condition through September 15, 2019, the number of shares underlying the market-based RSUs that will vest will be based upon a relative percentile rank of the 3-year change in the closing price of the Company’s common stock compared to that of the companies that make up the Nasdaq Biotechnology Index. The grant date fair value of the market-based RSUs of $1.45 per share was determined using a Monte Carlo valuation model at the date of grant.

Other Inducement Grants

In connection with the August 1, 2018 hire of the Company’s Chief Financial Officer, the Company granted as inducement awards (i) 385,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.22 per share; and (ii) 225,000 PSUs. The PSUs are subject to proportional vesting based on cumulative measurement for the 3-year period ending June 30, 2021, with two-thirds of the award based upon defined amounts of the Company’s product revenues and one-third based upon the net present value of each applicable business development transaction measured as of the date that each such transaction is consummated by the Company.

In connection with the August 14, 2018 hire of the Company’s Senior Vice President of Regulatory and Quality, the Company granted as an inducement award 100,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.10 per share.

In determining the grant date fair value of inducement option awards during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.81% - 2.92%

Expected dividends

   0.0%

The inducement option grants have a 10-year term and, although not awarded under the 2016 Plan, are subject to and governed by the terms and conditions of the 2016 Plan. The weighted average grant date fair value of the inducement grants was $1.27.

 

17


Table of Contents

The following table provides a reconciliation of the Company’s inducement stock option awards for the three months ended September 30, 2018:

 

     Number of
options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     1,290,000      $ 3.06        

Granted

     485,000        2.20        

Forfeited

     (250,000      1.95        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     1,525,000      $ 2.96        7.60      $ 975  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     615,000      $ 3.11        5.58      $ 308  
  

 

 

    

 

 

    

 

 

    

 

 

 

Stock-Based Compensation Expense

The Company’s consolidated statements of comprehensive loss included total compensation expense from stock-based payment awards for the three months ended September 30, 2018 and 2017, as follows (in thousands):

 

     Three Months
Ended
September 30,
 
     2018      2017  

Compensation expense included in:

     

Research and development

   $ 486      $ 304  

Sales and marketing

     263        —    

General and administrative

     648        377  
  

 

 

    

 

 

 
   $ 1,397      $ 681  
  

 

 

    

 

 

 

In connection with termination benefits provided to the Company’s former Executive Vice President and General Manager, US, the vesting of certain options was accelerated in accordance with the terms of the options, with an exercise period through December 26, 2018. All remaining non-vested options were forfeited. The option modifications and forfeitures were accounted for in the quarter ended September 30, 2018, the net effect of which resulted in a $171,000 increase of stock-based compensation expense included in sales and marketing for the three months ended September 30, 2018 in the table above.

At September 30, 2018, there was approximately $5.2 million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan and the inducement awards that is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.

 

18


Table of Contents

10. Fair Value Measurements

The following tables summarize the Company’s assets and liabilities carried at fair value measured on a recurring basis at September 30, 2018 and June 30, 2018 by valuation hierarchy (in thousands):

 

     September 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
     June 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Derivative liabilities

   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 

Financial instruments that potentially subject the Company to concentrations of credit risk have historically consisted principally of cash and cash equivalents. At September 30, 2018 and June 30, 2018, substantially all of the Company’s interest-bearing cash equivalent balances were concentrated in one U.S. Government institutional money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. These deposits may be redeemed upon demand and, therefore, generally have minimal risk. The Company’s cash equivalents are classified within Level 1 on the basis of valuations using quoted market prices.

Upon the closing of the Second Tranche Transaction on June 25, 2018, the Company issued the Second Tranche Warrants, which were determined to be liability classified, which required that the liability be measured at fair value each period with changes in fair value being recorded as a component of net loss in the consolidated statement of comprehensive loss. This valuation was determined to be a level 3 valuation because it included unobservable inputs. The Second Tranche Warrants were valued using a Monte Carlo simulation valuation model. This model incorporated several inputs, including the closing price of the Company’s common stock on the date of valuation, the historical share price volatility over the expected term and the risk-free interest rate. The resulting derivative liability at June 30, 2018 was $19.8 million. Significant assumptions used to re-measure this liability at June 30, 2018 included volatility of 85.40%, risk free interest rate of 2.10%, a term of 6 months and the valuation date stock price of $2.08.

The Second Tranche Investors delivered exercise notices covering all of the Second Tranche Warrants during the period from September 25 - 28, 2018 (see Note 8). The Company revalued the Second Tranche Warrants liability immediately prior to the respective exercise notice dates of the Second Tranche Investors, measured as the excess of the closing share price on the exercise notice date over the actual warrant exercise price of $1.43 per share times the number of shares purchased. The resulting liability balance was then reclassified to equity.

 

19


Table of Contents

The following table sets forth a summary of changes in the fair value of the Company’s derivative liability for which fair value is determined by Level 3 inputs (in thousands):

 

     Second Tranche
Warrants
 

Balance at June 30, 2018

   $ 19,780  

Change in fair value

     18,886  

Reclassification to equity

     (38,666
  

 

 

 

Balance at September 30, 2018

   $ —    
  

 

 

 

11. Income Taxes

The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management’s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company did not record any income tax expense or benefit for the three months ended September 30, 2018 and 2017.

For the three months ended September 30, 2018 and 2017, the Company had no significant unrecognized tax benefits. At September 30, 2018 and June 30, 2018, the Company had no accrued penalties or interest related to uncertain tax positions.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted which, amongst other corporate and individual tax law changes, lowered the federal corporate income tax rate from 34% to 21% effective January 1, 2018. Because the Company provides a full valuation allowance for all of its net deferred tax assets, there is no effect of the Tax Act on the Company’s consolidated financial statements as of and for the three months ended September 30, 2018.

12. Commitments and Contingencies

Operating Leases

On May 17, 2018, the Company entered into a Second Amendment (the “Second Amendment”) to its lease in Watertown, Massachusetts. The original 5-year lease for approximately 13,650 square feet of combined office and laboratory space (the “Existing Space”) of the building located at 480 Pleasant Street, Watertown, MA 02472 (the “Premises”) and was set to expire in April 2019. Under the Second Amendment, the Company leased an additional 6,590 square feet of rentable area (the “Additional Space”, and together with the Existing Space, the “Total Space”) on the Premises, with a commencement date of September 10, 2018 (the “Additional Space Effective Time”). The landlord agreed to provide the Company a construction allowance of up to $670,750 to be applied toward the aggregate work to be conducted on the Total Space. The Second Amendment extended the term of the lease, which will now expire on May 31, 2025; provided, however, that the base rent for the Total Space will be abated during the first four months following the Additional Space Effective Time. The Company also has an option to extend the term of the lease for one additional five-year period. The Company previously provided a cash-collateralized $150,000 irrevocable standby letter of credit as security for the Company’s obligations under the lease, which was extended for a period of four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.

Commencing July 1, 2017, the Company leased approximately 3,000 square feet of office space in Liberty Corner, New Jersey under a lease term extending through June 2022, with two five-year renewal options at 95% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional 1,381 square feet of adjoining space from Caladrius Biosciences, Inc. (“Caladrius”) through May 2022. The Chief Executive Officer of Caladrius is a director of the Company.

 

20


Table of Contents

Legal Proceedings

The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company’s financial position, results of operations or cash flows.

13. Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive. Potentially dilutive shares were not included in the calculation of diluted net loss per share for each of the three months ended September 30, 2018 and 2017 as their inclusion would be anti-dilutive.

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended
September 30,
 
     2018      2017  

Options outstanding

     7,984,469        5,740,155  

Warrants outstanding

     486,812        —    

Restricted stock units outstanding

     1,395,829        948,500  

Performance stock units outstanding

     466,668        210,000  

Deferred stock units outstanding

     35,418        —    
  

 

 

    

 

 

 
     10,369,196        6,898,655  
  

 

 

    

 

 

 

14. Subsequent Event

On November 1, 2018, the Board of Directors approved a change in the Company’s fiscal year from June 30 to December 31, effective immediately. The Company will file a transition report on Form 10-KT for the six months ending December 31, 2018 with the U.S. Securities and Exchange Commission in connection with its newly adopted fiscal year.

 

21


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Note Regarding Forward-Looking Statements

Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements give our current expectations or forecasts of future events and are not statements of historical or current facts. These statements include, among others, statements about:

 

   

the planned U.S. launch of YUTIQ™ in the first quarter of calendar year 2019 and DEXYCU™ in the first half of calendar year 2019;

 

   

the potential advantages of DEXYCU, YUTIQ and our other product candidates;

 

   

our ability to manufacture DEXYCU, YUTIQ, or any future products or product candidates in sufficient quantities and quality;

 

   

our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;

 

   

the sufficiency of our cash and cash equivalents to fund our operations into the second quarter of calendar year 2019;

 

   

our ability to obtain additional capital in sufficient amounts and on terms acceptable to us, and the consequences of failing to do so;

 

   

future expenses and capital expenditures;

 

   

our expectations regarding the timing and design of our clinical development plans;

 

   

our ability to establish or maintain collaborations and obtain milestone, royalty and/or other payments from any such collaborators;

 

   

the ability of Alimera Sciences, Inc., or Alimera, to obtain regulatory approval of and commercialize ILUVIEN® for the three-year treatment of non-infectious posterior uveitis, or NIPU, in Europe, the Middle East and Africa;

 

   

the implication of results from pre-clinical and clinical trials and our other research activities;

 

   

our intentions regarding our research into other uses and applications of our Durasert™ and Verisome® technology platforms;

 

   

our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for DEXYCU, YUTIQ and our other product candidates, and to avoid claims of infringement of third party intellectual property rights;

 

   

our expectation that we will continue to incur significant expenses and that our operating losses and our net cash outflows to fund operations will continue for the foreseeable future;

 

   

the scope and duration of intellectual property protection; and

 

   

the effect of legal and regulatory developments.

Forward-looking statements also include statements other than statements of current or historical fact, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. We often, although not always, identify forward-looking statements by using words or phrases such as “likely”, “expect”, “intend”, “anticipate”, “believe”, “estimate”, “plan”, “project”, “forecast” and “outlook”.

The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce commercial supply of YUTIQ and DEXYCU and commercialize YUTIQ and DEXYCU in the U.S.; our ability to successfully build a commercial infrastructure and enter into and maintain

 

22


Table of Contents

commercial agreements for the launch of YUTIQ and DEXYCU; the development of our next-generation YUTIQ short-acting treatment for uveitis; potential off-label sales of ILUVIEN for non-infectious posterior segment uveitis, or NIPU; consequences of fluocinolone acetonide side effects; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME, which depends on Alimera’s ability to continue as a going concern; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to obtain marketing approval for ILUVIEN in its licensed territories for NIPU; potential declines in Retisert® royalties; our ability to market and sell products; the success of current and future license agreements, including our agreement with Alimera; termination or breach of current license agreements, including our agreement with Alimera; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential exit of the United Kingdom from the European Union; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission, or the SEC. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. The risks set forth under Item 1A of our Form 10-K for the year ended June 30, 2018 describe major risks to our business, and you should read and interpret any forward-looking statements together with these risks. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements.

Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Our Business

We are a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Following U.S. Food and Drug Administration, or FDA, approval of DEXYCU and YUTIQ, we are targeting the direct U.S. commercial launch of YUTIQ in the first quarter of calendar 2019 and DEXYCU in the first half of calendar 2019.

DEXYCU (dexamethasone intraocular suspension) 9%, approved by the FDA in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes our proprietary Verisome® drug-delivery platform, which allows for a single injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and we expect to launch DEXYCU in the U.S. in the first half of 2019 with a primary focus on its use following cataract surgery. We acquired DEXYCU in connection with the acquisition of Icon Bioscience, Inc., or Icon, in March 2018.

YUTIQ™, a non-erodible fluocinolone acetonide insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIPU), was approved by the FDA on October 12, 2018. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis (zero order release) for approximately three years. YUTIQ is based on our proprietary Durasert™ sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. NIPU is the third leading cause of blindness in the U.S. and is estimated to affect between 55,000 to 120,000 people. We expect to launch YUTIQ in the U.S. in the first quarter of calendar 2019.

ILUVIEN® for diabetic macular edema, or DME, our lead licensed product, was also developed from our Durasert technology platform, and is sold directly in the U.S. and several European Union, or EU, countries by Alimera Sciences, Inc., or Alimera. Retisert®, one of our earlier generation products, was approved in 2005 by the FDA for the treatment of chronic NIPU and is sold in the U.S. by Bausch & Lomb Incorporated, or Bausch & Lomb. Our development programs are focused primarily on developing

 

23


Table of Contents

sustained release products that utilize our Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. Our strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.

DEXYCU™, YUTIQ™ and Durasert™ are our trademarks. Retisert® is Bausch & Lomb’s trademark. ILUVIEN® is Alimera’s trademark. Verisome® is Ramscor, Inc.’s trademark. Information with respect to ILUVIEN, including regulatory and marketing information, and Alimera’s plans and intentions, reflects information publicly disclosed by Alimera.

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with GAAP requires that we make certain estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates, judgments and assumptions on historical experience, anticipated results and trends, and on various other factors that we believe are reasonable under the circumstances at the time. By their nature, these estimates, judgments and assumptions are subject to an inherent degree of uncertainty. Actual results may differ from our estimates under different assumptions or conditions. In our Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (the “2018 Annual Report”), we set forth our critical accounting policies and estimates, which included revenue recognition and recognition of expense in outsourced clinical trial agreements. There have been no material changes to our critical accounting policies from the information provided in our 2018 Annual Report.

Results of Operations

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017:

 

     Three Months Ended
September 30,
     Change  
     2018      2017      Amounts      %  
     (In thousands except percentages)  

Revenues:

           

Collaborative research and development

   $ 56      $ 140      $ (84      (60)%  

Royalty income

     430        245        185        76%  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

     486        385        101        26%  
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses:

           

Research and development

     6,233        3,819        2,414        63%  

Sales and marketing

     3,646        —          3,646        na  

General and administrative

     4,161        2,572        1,589        62%  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

     14,040        6,391        7,649        120%  
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating loss

     (13,554      (6,006      (7,548      (126)%  

Interest and other income, net

     129        23        106        461%  

Interest expense

     (815      —          (815      na  

Change in fair value of derivative liability

     (18,886      —          (18,886      na  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net loss

   $ (33,126    $ (5,983    $ (27,143      (454)%  
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues

Collaborative research and development revenues totaled $56,000 for the three months ended September 30, 2018 compared to $140,000 for the three months ended September 30, 2017. This decrease was attributable primarily to a $35,000 decrease in revenues recognized from feasibility study agreements and a $50,000 decrease in net profits received in the prior year period under the collaboration agreement with Alimera, as amended in March 2008 (the “Prior Alimera Agreement”).

 

24


Table of Contents

In July 2017, we restructured the Prior Alimera Agreement to (a) license our Durasert three-year uveitis product candidate (called YUTIQ in the U.S and planned to be called ILUVIEN in the EMEA) in the EMEA to Alimera and (b) convert the net profit share arrangement to a sales-based royalty for all ILUVIEN licensed indications. Starting with the three months ended September 30, 2017, these sales-based royalties earned from Alimera have been recorded as royalty income, whereas amounts previously earned pursuant to the net profit share arrangement were classified as collaborative research and development revenue.

Royalty income for the three months ended September 30, 2018 increased by $185,000, or 76%, to $430,000 compared to $245,000 for the three months ended September 30, 2017. The increase was attributable primarily to $215,000 of accrued sales-based royalties due from Alimera under the Amended Alimera Agreement, partially offset by a $30,000 decrease in Retisert royalty income. We expect Retisert royalty income to remain flat, and it may decline.

Research and Development

Research and development expenses increased $2.4 million, or 63%, to $6.2 million for the three months ended September 30, 2018 from $3.8 million for the same period in the prior year. This increase was attributable primarily to (i) approximately $970,000 related to the scale up of Dexycu manufacturing, (ii) a $768,000 increase in personnel and related expenses for the build-out of our medical affairs group, and expansion of regulatory and quality staffing, including $182,000 of stock-based compensation, (iii) a $433,000 increase in amortization of intangible assets, attributable primarily to $615,000 of amortization of the DEXYCU / Icon intangible asset partially offset by the completed amortization of our previous patented technology intangible assets as of December 2017 and (iv) a $409,000 increase for medical affairs related expenses including advisory board meetings and pharmacovigilance, partially offset by decreases of (i) $203,000 of contract research organization costs for our YUTIQ Phase 3 clinical development program, and (ii) $193,000 of consulting, attributable primarily to prior year preparation of our YUTIQ NDA submission.

Sales and Marketing

In anticipation of the commercial launch of DEXYCU and YUTIQ, we continued the build-out of our commercial infrastructure and marketing activities that had commenced in the fourth quarter of fiscal 2018. Sales and marketing expense, which totaled $3.6 million in the three months ended September 30, 2018, consisted primarily of (i) approximately $1.0 million of personnel and related costs, (ii) $922,000 of implementation and startup costs related to our contract sales organization agreement, (iii) $488,000 of professional services primarily related to development of our distribution channel and market access, (iv) $480,000 for the accrual of severance benefits and incremental stock-based compensation for our former General Manager, US, and (v) $474,000 of marketing program and agency costs. We expect increases in sales and marketing costs throughout at least the next few quarters, including additional headcount, costs associated with contract sales organization operations, managed markets and sales operations activities.

General and Administrative

General and administrative expenses increased by $1.6 million, or 62%, to $4.2 million for the three months ended September 30, 2018 from $2.6 million for the same period in the prior year. This increase was attributable primarily to (i) a $562,000 increase in personnel and related expenses stemming from the hiring of our CFO as well as other personnel and includes $270,000 of stock-based compensation, (ii) a $471,000 increase in legal, audit and other professional fees, and (iii) a $276,000 increase in consulting services, primarily for corporate compliance and business development.

Interest (Expense) Income and Other

On March 28, 2018, we borrowed $15.0 million under a term loan facility in connection with the Icon Acquisition. Following consummation of the Second Tranche Financing on June 25, 2018, we borrowed an additional $5.0 million under that term loan facility. For the three months ended September 30, 2018 we incurred $661,000 of interest expense on the term loan and $154,000 of amortization of debt discount.

Interest income from amounts invested in an institutional money market fund increased to $129,000 for the three months ended September 30, 2018 compared to $23,000 in the prior year quarter, due primarily to significantly higher interest-bearing assets and higher money market interest rates.

 

25


Table of Contents

Change in Fair Value of Derivative Liability

The Second Tranche Warrants issued on June 25, 2018 were liability classified and subject to revaluation at each balance sheet date. Immediately prior to the exercise of the Second Tranche Warrants in late September 2018 by the Second Tranche Investors, the derivative liability was remeasured at fair value and resulted in an $18.9 million change in fair value of derivative liability that was recorded as a component of non-operating expense for the three months ended September 30, 2018. Upon consummation of the warrant exercises, the resulting derivative liability balance of $38.7 million was reclassified to equity.

Liquidity and Capital Resources

Our operations for the three months ended September 30, 2018 were financed primarily from existing capital resources of $38.8 million at June 30, 2018, which amount included gross proceeds received in June 2018 of (i) $25.5 million from the sale of Units in the Second Tranche Transaction and (ii) $5.0 million from an additional drawdown of our Loan. In late September 2018, we received additional proceeds of $28.9 million from the exercise of all 20,184,224 Second Tranche Warrants at an exercise price of $1.43 per common share. At September 30, 2018, our principal sources of liquidity were cash and cash equivalents that totaled $55.8 million.

As of September 30, 2018, our debt consists of $20.0 million, which amount represents the amount outstanding under the Loan pursuant to the Credit Agreement. The Loan is due and payable on March 27, 2023 (the “Maturity Date”). The Loan bears interest at a per annum rate of the three-month London Interbank Offered Rate (“LIBOR”), subject to a 1.5% floor, plus 10.50%. The Credit Agreement permits us to pay interest only on the principal amount loaned thereunder for the first eight quarterly payments through February 15, 2020. Following the interest-only period, we will be required to make quarterly payments of interest, plus repayments of the principal amount loaned under the Credit Agreement in an aggregate amount of up to approximately $1.67 million per quarter (the “Quarterly Principal Repayment Cap”). Subject to the Quarterly Principal Repayment Cap, the amount of any quarterly principal payments during any fiscal year is based on (x) a percentage of our year-to-date net revenue through the end of such quarter less (y) any prior quarterly principal and interest payments made during such fiscal year. In addition, we paid an upfront fee of 1.5% of the aggregate principal amount of the Loan. We are also required to pay an exit fee equal to 6% of the aggregate principal amount advanced under the Credit Agreement.

Subject to certain exceptions, we are required to make mandatory prepayments of the Loan with the proceeds of assets sales and insurance proceeds. In addition, we may make a voluntary prepayment of the Loan, in whole, but not in part, at any time on or after the first anniversary of March 28, 2018. All mandatory and voluntary prepayments of the Loan are subject to the payment of prepayment premiums as follows: (i) in the case of mandatory prepayments, if prepayment occurs prior to the first anniversary of March 28, 2018, a customary make-whole amount equal to the amount of interest that would have accrued on the principal amount so prepaid had it remained outstanding through the first anniversary of March 28, 2018, (ii) if prepayment occurs on or after the first anniversary of March 28, 2018 but prior to the second anniversary of March 28, 2018, 6% of the aggregate amount of the principal prepaid and (iii) if prepayment occurs on or after the second anniversary of March 28, 2018 but prior to the third anniversary of March 28, 2018, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid on or after the third anniversary of March 28, 2018.

With the exception of net income for the fiscal year ended June 30, 2015 resulting from our receipt of a $25.0 million ILUVIEN FDA-approval milestone payment from Alimera, we have predominantly incurred operating losses since inception, and at September 30, 2018 we had a total accumulated deficit of $396.9 million. We do not currently have any significant assured sources of future revenue, and our anticipated recurring use of cash to fund operations in combination with no probable source of additional capital raises substantial doubt about our ability to continue as a going concern for one year from the issuance of our financial statements included in this Quarterly Report on Form 10-Q. We have historically financed our operations primarily from the proceeds of sales of our equity securities, debt financing transactions and receipt of license fees and royalty income from our collaboration partners and research and development funding under feasibility study agreements. We believe that our cash and cash equivalents of $55.8 million at September 30, 2018 and expected cash inflows under existing collaboration agreements will enable us to fund our current and planned operations (including continuation of our two Phase 3 clinical trials for YUTIQ and current plans for the U.S. commercial launches of DEXYCU and YUTIQ) into the second quarter of calendar year 2019. In order to extend our ability to fund our operations beyond then, including our planned commercial launches of DEXYCU and YUTIQ, our plans include accessing additional equity financing from the sale of our equity securities, our ATM program or other equity or debt financing transactions and/or, as applicable, reducing or deferring operating expenses. The timing and extent of our implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaboration or other

 

26


Table of Contents

agreements and/or proceeds from any financing transactions There is no assurance that we will receive significant revenues from the planned commercialization of DEXYCU or YUTIQ, or license revenues from ILUVIEN®, or be able to obtain financing from any other sources.

The additional capital we will require will be influenced by many factors, including, but not limited to:

 

   

the success and timing of our direct commercialization efforts with respect to DEXYCU and YUTIQ in the U.S.;

 

   

the success and timing of obtaining commercial supply of DEXYCU and YUTIQ;

 

   

the timing of payment of the $15.0 million development milestone payable to the former Icon securityholders within 30 days after the first commercial sale of DEXYCU;

 

   

whether and to what extent we are required to make additional milestone and earn-out payments to the former Icon securityholders;

 

   

the amount of future revenues we receive with respect to our planned commercialization of DEXYCU and YUTIQ and license revenues from ILUVIEN for DME and, if and when approved in the EMEA, of ILUVIEN for NIPU;

 

   

whether and to what extent we internally fund, whether and when we initiate, and how we conduct other product development programs;

 

   

the amount of Retisert royalties and other payments we receive under collaboration agreements;

 

   

whether and when we are able to enter into strategic arrangements for our products or product candidates and the nature of those arrangements;

 

   

timely and successful development, regulatory approval and commercialization of our products and product candidates;

 

   

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims;

 

   

changes in our operating plan, resulting in increases or decreases in our need for capital; and

 

   

our views on the availability, timing and desirability of raising capital.

We do not know if additional capital will be available when needed or on terms favorable to us or our stockholders. Collaboration, licensing or other agreements may not be available on favorable terms, or at all. We do not know the extent to which we will be able to establish commercial and other capabilities to successfully launch DEXYCU or YUTIQ. Although we expect that our restructured Alimera collaboration agreement will provide a more consistent flow of royalty income, we do not know the extent to which Alimera will achieve increasing revenues from its commercialization of ILUVIEN for DME and, if approved in the EMEA, for NIPU. If we seek to sell equity securities, we do not know whether and to what extent we will be able to do so, or on what terms. Further, the rules and regulations of the Nasdaq Global Market require us to obtain stockholder approval for sales of our equity securities under certain circumstances, which could delay or prevent us from raising additional capital from such sales. Also, the state of the economy and financial and credit markets at the time or times we seek any additional financing may make it more difficult or expensive to obtain. If available, additional equity financing may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and dilute our existing stockholders’ equity, and funding through collaboration agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products. If adequate financing is not available if and when needed, we may delay, reduce the scope of, or eliminate research or development programs, potential independent commercialization of DEXYCU and YUTIQ or other new products, if any, and postpone or cancel the pursuit of product candidates, including pre-clinical and clinical trials and new business opportunities, reduce staff and operating costs, or otherwise significantly curtail our operations to reduce our cash requirements and extend our capital.

 

27


Table of Contents

Our consolidated statements of historical cash flows are summarized as follows (in thousands):

 

     Three Months Ended
September 30,
     Change  
     2018      2017  

Net loss:

   $ (33,126    $ (5,983    $ (27,143

Changes in operating assets and liabilities

     265        (887      1,152  

Other adjustments to reconcile net loss to cash flows from operating activities

     21,095        902        20,193  
  

 

 

    

 

 

    

 

 

 

Net cash used in operating activities

   $ (11,766    $ (5,968    $ (5,798
  

 

 

    

 

 

    

 

 

 

Net cash used in investing activities

   $ (109    $ (64    $ (45
  

 

 

    

 

 

    

 

 

 

Net cash provided by financing activities

   $ 28,863      $ 963      $ 27,900  
  

 

 

    

 

 

    

 

 

 

For the three months ended September 30, 2018, net cash used in operating activities increased by $5.8 million compared to the three months ended September 30, 2017, due predominantly to higher operating cash outflows. Increases in operating cash outflows of approximately $6.0 million consisted primarily of (i) $1.9 million of personnel and related expenses; (ii) $1.8 million of marketing and market access related expenses; (iii) $616,000 related to the scale up of DEXYCU manufacturing; (iv) $583,000 of interest expense related to our term loan with SWK Funding LLC; and (v) $265,000 of legal and audit fees.

Net cash used in investing activities during the three months ended September 30, 2018 and 2017 consisted of $109,000 and $64,000, respectively, of purchases of property and equipment.

Net cash provided by financing activities for the three months ended September 30, 2018 consisted of $28.9 million of proceeds from the September 2018 exercise of the 20,184,224 Second Tranche Warrants. Net cash provided by financing activities for the three months ended September 30, 2017 consisted of $963,000 of proceeds, net of share issue costs, from the sale of 843,784 shares of common stock under our ATM facility.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements as of September 30, 2018 that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to various market risks, which may result in potential losses arising from adverse changes in market rates, such as interest rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes and do not believe we are exposed to material market risk with respect to our cash and cash equivalents.

As of September 30, 2018, we had cash and cash equivalents of $55.8 million. We do not engage in any hedging activities against changes in interest rates. Because of the short-term maturities of our cash and cash equivalents, we do not believe that an immediate 10% increase in interest rates would have a significant impact on the realized value of our investments.

The interest rate on our Loan under the Credit Agreement is variable based on the three-month LIBOR, subject to a 1.5% floor, plus 10.50%. Accordingly, such interest rate is affected by changes in market interest rates. As of September 30, 2018, we had $20.0 million of aggregate principal amount outstanding under the Credit Agreement, and the three-month LIBOR was 2.40%. A hypothetical 1% increase in the three-month LIBOR would result in $200,000 in incremental annual interest expense under the Loan.

 

28


Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2018, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2018, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in Part I, “Item 1A, Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2018, which was filed with the SEC on September 18, 2018 and amended on October 29, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In September 2018, the Second Tranche Investors exercised the Second Tranche Warrants in full at an exercise price of $1.43 per share for gross proceeds of approximately $28.9 million, resulting in the issuance of 20,184,224 shares of Company common stock. The shares of Company common stock issued upon exercise of the Second Tranche Warrants were offered and sold without registration under the Securities Act pursuant to the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder as transactions not involving a public offering.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

 

29


Table of Contents

Item 6. Exhibits

The following exhibits are being filed herewith:

 

  10.1+    Stock Option Award Agreement, dated May 14, 2018, by and between EyePoint Pharmaceuticals, Inc. and Leonard M. Blum.
  10.2+    Stock Option Award Agreement, dated May 14, 2018, by and between EyePoint Pharmaceuticals, Inc. and Leonard M. Blum.
  10.3+    Stock Option Award Agreement, dated August 1, 2018, by and between EyePoint Pharmaceuticals, Inc. and David Price.
  10.4+    Performance Stock Unit Award Agreement, dated August 1, 2018, by and between EyePoint Pharmaceuticals, Inc. and David Price.
  10.5+    Stock Option Award Agreement, dated August 14, 2018, by and between EyePoint Pharmaceuticals, Inc. and John Weet.
  31.1    Certification of Principal Executive Officer required by Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  31.2    Certification of Principal Financial Officer required by Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1    Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  32.2    Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101    The following materials from EyePoint Pharmaceutical’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Loss; (iii) Condensed Consolidated Statement of Stockholders’ Equity; (iv) Condensed Consolidated Statements of Cash Flows; and (v) Notes to Condensed Consolidated Financial Statements

 

+

Indicates management contract or compensatory plan.

 

30


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    EyePoint Pharmaceuticals, Inc.
Date: November 9, 2018     By:   /s/ Nancy Lurker
    Name:   Nancy Lurker
    Title:   President and Chief Executive Officer

 

31

EX-10.1 2 d635570dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

Nonstatutory Stock Option

Executive Officer Inducement Award

1. Grant of Option.

This certificate evidences a nonstatutory stock option (this “Stock Option”) granted by EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on May 14, 2018 (the “Date of Grant”) to Leonard Blum (the “Participant”). This Stock Option is granted to the Participant in connection with his entering into employment with the Company and is regarded by the parties as an inducement material to the Participant’s entering into employment within the meaning of Nasdaq Listing Rule 5635(c). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of 375,000 shares of common stock of the Company (the “Shares”) at $1.95 per Share, which is not less than the fair market value of a Share on the Date of Grant. The latest date on which this Stock Option, or any part thereof, may be exercised is 5:00 P.M. Eastern Time on May 14, 2028 (the “Final Exercise Date”). The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, meaning an option that does not qualify as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). This Stock Option shall be subject to and governed by, and shall be construed and administered in accordance with, the terms and conditions of the Company’s 2016 Long-Term Incentive Plan (as from time to time in effect, the “Plan”), which terms and conditions are incorporated herein by reference. A copy of the Plan has been made available to the Participant. Notwithstanding the foregoing, this Stock Option is not awarded under the Plan and the grant of this Stock Option shall not reduce the number of shares of Stock available for issuance under awards issued pursuant to the Plan.

2. Vesting.

(a) During Employment. This Stock Option will vest and become exercisable with respect to one third (1/3) of the Shares on each of the first, second and third anniversaries of the Grant Date; provided that, and subject to Section 2(c) below, upon a cessation of the Participant’s Employment by reason of an involuntary termination without Cause (as defined in the Employment Agreement between the Company and the Participant dated May 14, 2018 (“Employment Agreement”) (“Cause”)) or a voluntary termination for Good Cause (as defined in the Employment Agreement (“Good Cause”)) any unvested portion of this Stock Option that would have vested as of the first anniversary of the cessation of the Participant’s Employment had the Participant continued in Employment through such first anniversary will vest immediately prior to such cessation of Employment.

 

-1-


(b) Termination of Employment. Notwithstanding the foregoing, and subject to Section 2(c) below, the following rules will apply if a Participant’s Employment ceases regardless of the circumstances: automatically and immediately upon the cessation of Employment, this Stock Option will cease to be exercisable and will terminate, except that:

(I) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for any reason other than for Cause or as a result of Participant’s death and as is then exercisable (after giving effect to any accelerated vesting owing to a cessation of Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause pursuant to Section 2(a) above), will remain exercisable until (i) 5:00 P.M. Eastern Time on the last day of the three-month period commencing on the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate;

(II) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the Participant’s death and as is then exercisable, will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; and

(III) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for Cause will immediately terminate.

(c) Change of Control. Notwithstanding any other provision of this Section 2 to the contrary, if a Change of Control occurs, whether or not the Change of Control also constitutes a Covered Transaction, and within the 24 months thereafter there is a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause, the provisions of this Section 2(c) shall apply:

(I) This Stock Option, if it survives the Change of Control, including any stock option granted in substitution for this Stock Option in connection with the Change of Control, shall automatically vest and become exercisable immediately prior to such cessation of Employment and will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; provided that, in the event of the Participant’s death during such extended exercise period following a Change of Control, any portion of this Stock Option as is held by the Participant immediately prior to the Participant’s death will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate.

(II) Any and all performance or other vesting conditions imposed pursuant to Section 7(a)(5) of the Plan with respect to any stock, cash or other property delivered in exchange for this Stock Option in connection with the Change of Control shall automatically be deemed to have been satisfied immediately prior to such cessation of Employment.

 

-2-


(III) For purposes of this Section 2(c), “Employment” shall be deemed to include employment with any successor to the Company’s business or assets in connection with a Change of Control.

(IV) For purposes of this Stock Option, “Change of Control” shall mean:

(A) the acquisition by any Person (defined as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (“Exchange Act”))) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (a), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company (“Benefit Plan”), or (iii) by an entity pursuant to a transaction that complies with the clauses (i), (ii) and (iii) of subsection (C) below; or

(B) individuals who, as of the Date of Grant, constitute the Board (together with the individuals identified in the proviso to this Section 2(c)(IV)(B), the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company’s stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

(C) consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company, (a “transaction”) in each case unless, following such transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such transaction (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such transaction, of the outstanding common stock of the Company, (ii) no Person (excluding any entity or wholly owned subsidiary of any entity resulting from such transaction or any Benefit Plan of the Company or such entity or wholly owned subsidiary of such entity resulting from such transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such transaction; or

 

-3-


(D) approval by the stockholders of the Company of a liquidation or dissolution of the Company.

(d) Notwithstanding the foregoing provisions of this Section 2, this Stock Option shall not vest or become eligible to vest on any date specified above unless the Participant has continuously been, since the Grant Date until the date immediately prior to such termination of Employment, Employed by the Company, its Affiliates, its subsidiaries, or, following a Change of Control, any successor to the Company’s business or assets in connection with the Change of Control.

3. Exercise of Stock Option.

Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant’s executor, administrator, or legally appointed representative (in the event of the Participant’s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the “Option Holder”), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows: (i) by delivery of cash or check acceptable to the Administrator; or (ii) through a broker-assisted exercise program acceptable to the Administrator; or (iii) by any other means acceptable to the Administrator, or (iv) by any combination of the foregoing means of exercise. In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.

4. Withholding.

Except as otherwise determined by the Administrator, this Stock Option may not be exercised unless the person exercising this Stock Option timely remits to the Company, in cash, all amounts required to be withheld upon exercise (all as determined by the Administrator) or makes other arrangements satisfactory to the Administrator for the payment of such taxes.

5. Nontransferability of Stock Option.

This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant (or in the event of the Participant’s incapacity, the person or persons legally appointed to act on the Participant’s behalf).

 

-4-


6. Provisions of the Plan.

This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant. By accepting this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.

7. Other Agreements.

The Company and Participant agree, in consideration of the grant of this Stock Option, and other good and valuable consideration, the receipt of which is mutually acknowledged, that the provisions of Section 2 shall supersede the provisions of any other agreement between the Company and Participant regarding the vesting and exercise of this Stock Option following a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause.

IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.

 

EyePoint Pharmaceuticals, Inc.
By   /s/ Nancy Lurker
  Nancy Lurker, President & CEO

Dated: May 14, 2018

 

Acknowledged and agreed:
       /s/ Leonard M. Blum
  Leonard M. Blum

Dated: May 14, 2018

 

-5-

EX-10.2 3 d635570dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

Nonstatutory Stock Option

Executive Officer Inducement Award

1. Grant of Option.

This certificate evidences a nonstatutory stock option (this “Stock Option”) granted by EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on May 14, 2018 (the “Date of Grant”) to Leonard Blum (the “Participant”). This Stock Option is granted to the Participant in connection with his entering into employment with the Company and is regarded by the parties as an inducement material to the Participant’s entering into employment within the meaning of Nasdaq Listing Rule 5635(c). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of 65,000 shares of common stock of the Company (the “Shares”) at $1.95 per Share, which is not less than the fair market value of a Share on the Date of Grant. The latest date on which this Stock Option, or any part thereof, may be exercised is 5:00 P.M. Eastern Time on May 14, 2028 (the “Final Exercise Date”). The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, meaning an option that does not qualify as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). This Stock Option shall be subject to and governed by, and shall be construed and administered in accordance with, the terms and conditions of the Company’s 2016 Long-Term Incentive Plan (as from time to time in effect, the “Plan”), which terms and conditions are incorporated herein by reference. A copy of the Plan has been made available to the Participant. Notwithstanding the foregoing, this Stock Option is not awarded under the Plan and the grant of this Stock Option shall not reduce the number of shares of Stock available for issuance under awards issued pursuant to the Plan.

2. Vesting.

(a) During Employment. This Stock Option will vest and become exercisable with respect to 100% of the Shares on the first anniversary of the Grant Date; provided that, and subject to Section 2(c) below, upon a cessation of the Participant’s Employment by reason of an involuntary termination without Cause (as defined in the Employment Agreement between the Company and the Participant dated May 14, 2018 (“Employment Agreement”) (“Cause”)) or a voluntary termination for Good Cause (as defined in the Employment Agreement (“Good Cause”)) any unvested portion of this Stock Option that would have vested as of the first anniversary of the cessation of the Participant’s Employment had the Participant continued in Employment through such first anniversary will vest immediately prior to such cessation of Employment.

 

-1-


(b) Termination of Employment. Notwithstanding the foregoing, and subject to Section 2(c) below, the following rules will apply if a Participant’s Employment ceases regardless of the circumstances: automatically and immediately upon the cessation of Employment, this Stock Option will cease to be exercisable and will terminate, except that:

(I) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for any reason other than for Cause or as a result of Participant’s death and as is then exercisable (after giving effect to any accelerated vesting owing to a cessation of Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause pursuant to Section 2(a) above), will remain exercisable until (i) 5:00 P.M. Eastern Time on the last day of the three-month period commencing on the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate;

(II) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the Participant’s death and as is then exercisable, will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; and

(III) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for Cause will immediately terminate.

(c) Change of Control. Notwithstanding any other provision of this Section 2 to the contrary, if a Change of Control occurs, whether or not the Change of Control also constitutes a Covered Transaction, and within the 24 months thereafter there is a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause, the provisions of this Section 2(c) shall apply:

(I) This Stock Option, if it survives the Change of Control, including any stock option granted in substitution for this Stock Option in connection with the Change of Control, shall automatically vest and become exercisable immediately prior to such cessation of Employment and will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; provided that, in the event of the Participant’s death during such extended exercise period following a Change of Control, any portion of this Stock Option as is held by the Participant immediately prior to the Participant’s death will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate.

(II) Any and all performance or other vesting conditions imposed pursuant to Section 7(a)(5) of the Plan with respect to any stock, cash or other property delivered in exchange for this Stock Option in connection with the Change of Control shall automatically be deemed to have been satisfied immediately prior to such cessation of Employment.

 

-2-


(III) For purposes of this Section 2(c), “Employment” shall be deemed to include employment with any successor to the Company’s business or assets in connection with a Change of Control.

(IV) For purposes of this Stock Option, “Change of Control” shall mean:

(A) the acquisition by any Person (defined as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (“Exchange Act”))) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (a), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company (“Benefit Plan”), or (iii) by an entity pursuant to a transaction that complies with the clauses (i), (ii) and (iii) of subsection (C) below; or

(B) individuals who, as of the Date of Grant, constitute the Board (together with the individuals identified in the proviso to this Section 2(c)(IV)(B), the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company’s stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

(C) consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company, (a “transaction”) in each case unless, following such transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such transaction (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such transaction, of the outstanding common stock of the Company, (ii) no Person (excluding any entity or wholly owned subsidiary of any entity resulting from such transaction or any Benefit Plan of the Company or such entity or wholly owned subsidiary of such entity resulting from such transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such transaction; or

 

-3-


(D) approval by the stockholders of the Company of a liquidation or dissolution of the Company.

(d) Notwithstanding the foregoing provisions of this Section 2, this Stock Option shall not vest or become eligible to vest on any date specified above unless the Participant has continuously been, since the Grant Date until the date immediately prior to such termination of Employment, Employed by the Company, its Affiliates, its subsidiaries, or, following a Change of Control, any successor to the Company’s business or assets in connection with the Change of Control.

3. Exercise of Stock Option.

Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant’s executor, administrator, or legally appointed representative (in the event of the Participant’s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the “Option Holder”), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows: (i) by delivery of cash or check acceptable to the Administrator; or (ii) through a broker-assisted exercise program acceptable to the Administrator; or (iii) by any other means acceptable to the Administrator, or (iv) by any combination of the foregoing means of exercise. In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.

4. Withholding.

Except as otherwise determined by the Administrator, this Stock Option may not be exercised unless the person exercising this Stock Option timely remits to the Company, in cash, all amounts required to be withheld upon exercise (all as determined by the Administrator) or makes other arrangements satisfactory to the Administrator for the payment of such taxes.

5. Nontransferability of Stock Option.

This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant (or in the event of the Participant’s incapacity, the person or persons legally appointed to act on the Participant’s behalf).

 

-4-


6. Provisions of the Plan.

This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant. By accepting this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.

7. Other Agreements.

The Company and Participant agree, in consideration of the grant of this Stock Option, and other good and valuable consideration, the receipt of which is mutually acknowledged, that the provisions of Section 2 shall supersede the provisions of any other agreement between the Company and Participant regarding the vesting and exercise of this Stock Option following a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause.

IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.

 

EyePoint Pharmaceuticals, Inc.
By   /s/ Nancy Lurker
  Nancy Lurker, President & CEO

Dated: May 14, 2018

 

Acknowledged and agreed:
       /s/ Leonard M. Blum
  Leonard M. Blum

Dated: May 14, 2018

 

-5-

EX-10.3 4 d635570dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

Nonstatutory Stock Option

Executive Officer Inducement Award

1. Grant of Option.

This certificate evidences a nonstatutory stock option (this “Stock Option”) granted by EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on August 1, 2018 (the “Date of Grant”) to David Price (the “Participant”). This Stock Option is granted to the Participant in connection with his entering into employment with the Company and is regarded by the parties as an inducement material to the Participant’s entering into employment within the meaning of Nasdaq Listing Rule 5635(c). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of 385,000 shares of common stock of the Company (the “Shares”) at $2.22 per Share, which is not less than the fair market value of a Share on the Date of Grant. The latest date on which this Stock Option, or any part thereof, may be exercised is 5:00 P.M. Eastern Time on August 1, 2028 (the “Final Exercise Date”). The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, meaning an option that does not qualify as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). This Stock Option shall be subject to and governed by, and shall be construed and administered in accordance with, the terms and conditions of the Company’s 2016 Long-Term Incentive Plan (as from time to time in effect, the “Plan”), which terms and conditions are incorporated herein by reference. A copy of the Plan has been made available to the Participant. Notwithstanding the foregoing, this Stock Option is not awarded under the Plan and the grant of this Stock Option shall not reduce the number of shares of Stock available for issuance under awards issued pursuant to the Plan.

2. Vesting.

(a) During Employment. This Stock Option will vest and become exercisable with respect to one third (1/3) of the Shares on each of the first, second and third anniversaries of the Grant Date; provided that, and subject to Section 2(c) below, upon a cessation of the Participant’s Employment by reason of an involuntary termination without Cause (as defined in the Employment Agreement between the Company and the Participant dated August 1, 2018 (“Employment Agreement”) (“Cause”)) or a voluntary termination for Good Cause (as defined in the Employment Agreement (“Good Cause”)) any unvested portion of this Stock Option that would have vested as of the first anniversary of the cessation of the Participant’s Employment had the Participant continued in Employment through such first anniversary will vest immediately prior to such cessation of Employment.

 

-1-


(b) Termination of Employment. Notwithstanding the foregoing, and subject to Section 2(c) below, the following rules will apply if a Participant’s Employment ceases regardless of the circumstances: automatically and immediately upon the cessation of Employment, this Stock Option will cease to be exercisable and will terminate, except that:

(I) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for any reason other than for Cause or as a result of Participant’s death and as is then exercisable (after giving effect to any accelerated vesting owing to a cessation of Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause pursuant to Section 2(a) above), will remain exercisable until (i) 5:00 P.M. Eastern Time on the last day of the three-month period commencing on the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate;

(II) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the Participant’s death and as is then exercisable, will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; and

(III) such portion, if any, of this Stock Option as is held by the Participant immediately prior to the cessation of the Participant’s Employment for Cause will immediately terminate.

(c) Change of Control. Notwithstanding any other provision of this Section 2 to the contrary, if a Change of Control occurs, whether or not the Change of Control also constitutes a Covered Transaction, and within the 24 months thereafter there is a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause, the provisions of this Section 2(c) shall apply:

(I) This Stock Option, if it survives the Change of Control, including any stock option granted in substitution for this Stock Option in connection with the Change of Control, shall automatically vest and become exercisable immediately prior to such cessation of Employment and will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the date of such cessation of Employment or (ii) the Final Exercise Date, if earlier, and will thereupon terminate; provided that, in the event of the Participant’s death during such extended exercise period following a Change of Control, any portion of this Stock Option as is held by the Participant immediately prior to the Participant’s death will remain exercisable until (i) 5:00 P.M. Eastern Time on the first anniversary of the Participant’s death or (ii) the Final Exercise Date, if earlier, and will thereupon terminate.

(II) Any and all performance or other vesting conditions imposed pursuant to Section 7(a)(5) of the Plan with respect to any stock, cash or other property delivered in exchange for this Stock Option in connection with the Change of Control shall automatically be deemed to have been satisfied immediately prior to such cessation of Employment.

 

-2-


(III) For purposes of this Section 2(c), “Employment” shall be deemed to include employment with any successor to the Company’s business or assets in connection with a Change of Control.

(IV) For purposes of this Stock Option, “Change of Control” shall mean:

(A) the acquisition by any Person (defined as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (“Exchange Act”))) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (a), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company (“Benefit Plan”), or (iii) by an entity pursuant to a transaction that complies with the clauses (i), (ii) and (iii) of subsection (C) below; or

(B) individuals who, as of the Date of Grant, constitute the Board (together with the individuals identified in the proviso to this Section 2(c)(IV)(B), the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company’s stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

(C) consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company, (a “transaction”) in each case unless, following such transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such transaction (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such transaction, of the outstanding common stock of the Company, (ii) no Person (excluding any entity or wholly owned subsidiary of any entity resulting from such transaction or any Benefit Plan of the Company or such entity or wholly owned subsidiary of such entity resulting from such transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such transaction; or

 

-3-


(D) approval by the stockholders of the Company of a liquidation or dissolution of the Company.

(d) Notwithstanding the foregoing provisions of this Section 2, this Stock Option shall not vest or become eligible to vest on any date specified above unless the Participant has continuously been, since the Grant Date until the date immediately prior to such termination of Employment, Employed by the Company, its Affiliates, its subsidiaries, or, following a Change of Control, any successor to the Company’s business or assets in connection with the Change of Control.

3. Exercise of Stock Option.

Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant’s executor, administrator, or legally appointed representative (in the event of the Participant’s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the “Option Holder”), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows: (i) by delivery of cash or check acceptable to the Administrator; or (ii) through a broker-assisted exercise program acceptable to the Administrator; or (iii) by any other means acceptable to the Administrator, or (iv) by any combination of the foregoing means of exercise. In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.

4. Withholding.

Except as otherwise determined by the Administrator, this Stock Option may not be exercised unless the person exercising this Stock Option timely remits to the Company, in cash, all amounts required to be withheld upon exercise (all as determined by the Administrator) or makes other arrangements satisfactory to the Administrator for the payment of such taxes.

5. Nontransferability of Stock Option.

This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant (or in the event of the Participant’s incapacity, the person or persons legally appointed to act on the Participant’s behalf).

 

-4-


6. Provisions of the Plan.

This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant. By accepting this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.

7. Other Agreements.

The Company and Participant agree, in consideration of the grant of this Stock Option, and other good and valuable consideration, the receipt of which is mutually acknowledged, that the provisions of Section 2 shall supersede the provisions of any other agreement between the Company and Participant regarding the vesting and exercise of this Stock Option following a cessation of the Participant’s Employment by reason of an involuntary termination without Cause or a voluntary termination for Good Cause.

IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.

 

EyePoint Pharmaceuticals, Inc.
By   /s/ Nancy Lurker
  Nancy Lurker, President & CEO

Dated: August 1, 2018

 

Acknowledged and agreed:
       /s/ David Price
  David Price

Dated: August 1, 2018

 

-5-

EX-10.4 5 d635570dex104.htm EX-10.4 EX-10.4

EXHIBIT 10.4

EYEPOINT PHARMACEUTICALS, INC.

INDUCEMENT AWARD

PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT

COVER SHEET

EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an Award of performance-based Restricted Stock Units to the Participant named below (the “PSUs”). Each PSU represents the right to receive one share of common stock of the Company, par value $0.001 per share (the “Common Stock”), subject to the terms and conditions set forth on this Cover Sheet and in the attached Performance-Based Restricted Stock Unit Agreement (together, the “Agreement”). The PSUs are granted to the Participant in connection with his entering into employment with the Company and are regarded by the parties as an inducement material to the Participant’s entering into employment within the meaning of Nasdaq Listing Rule 5635(c). The PSUs shall be subject to and governed by, and shall be construed and administered in accordance with, the terms and conditions of the Company’s 2016 Long-Term Incentive Plan (as from time to time in effect, the “Plan”), which terms and conditions are incorporated herein by reference. A copy of the Plan has been made available to the Participant. Notwithstanding the foregoing, the PSUs are not awarded under the Plan and the grant of the PSUs shall not reduce the number of shares of stock available for issuance under awards issued pursuant to the Plan.

Participant Name: David Price

Grant Date: August 1, 2018

Number of Shares of Common Stock Underlying the PSUs: 225,000

Vesting Schedule: The PSUs are eligible to become earned and vested as set forth below in this Agreement.

By the Participant’s signature below, the Participant agrees to all of the terms and conditions described in the Agreement and in the Plan. The Participant further acknowledges that the Participant has carefully reviewed the Plan, and agrees that the Plan shall control in the event any provision of this Agreement should appear to be inconsistent with the Plan.

 

Participant:   /s/ David Price     Date:   November 8, 2018
  David Price      
Company:   /s/ Nancy Lurker     Date:   November 8, 2018
  Nancy Lurker      
  President & CEO      

Attachment

This is not a share certificate or a negotiable instrument.


EYEPOINT PHARMACEUTICALS, INC.

INDUCEMENT AWARD

PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT

 

Performance-Based Restricted Stock Units

This Agreement evidences an Award of PSUs in the number set forth on the Cover Sheet of this Agreement and subject to the vesting and other terms and conditions set forth in this Agreement and in the Plan.

 

Vesting

150,000 of the PSUs (the “Revenue PSUs”) shall become earned based upon the Administrator’s determination of the Company’s cumulative product revenues for the period beginning on July 1, 2018 and ending on June 30, 2021 (the “Performance Period”), as follows: (i) fifty percent (50%) of the Revenue PSUs shall become earned if the Company’s cumulative product revenues for the Performance Period are at least seventy-five percent (75%) of the product revenues target for the Performance Period as set forth in the Company’s fiscal year 2018 strategic plan (the “Revenue Target”); (ii) seventy-five percent (75%) of the Revenue PSUs shall become earned if the Company’s cumulative product revenues for the Performance Period are at least ninety percent (90%) of the Revenue Target; and (iii) one-hundred percent (100%) of the Revenue PSUs shall become earned if the Company’s cumulative product revenues for the Performance Period are at least one-hundred percent (100%) of the Revenue Target. If the Company’s cumulative product revenues for the Performance Period are less than seventy-five percent (75%) of the Revenue Target, then none of the Revenue PSUs shall become earned. If the Company’s cumulative product revenues for the Performance Period fall between seventy-five percent (75%) and ninety percent (90%), or between ninety percent (90%) and one-hundred percent (100%), of the Revenue Target, then linear interpolation shall apply in determining the percentage of the Revenue PSUs that become earned. Within forty-five (45) days following the end of the Performance Period, the Administrator shall determine, in its sole discretion, the percentage of Revenue PSUs, if any, that have become earned based upon the achievement of the Revenue Target. Any Revenue PSUs that do not become earned shall be immediately and automatically forfeited by the Participant. The number of Revenue PSUs that become earned, if any, shall vest on the later of (x) the date that the Administrator determines the level of achievement of the Revenue Target and (y) August 1, 2021, subject, in each case, to the Participant’s continued Employment through August 1, 2021. Any Revenue PSUs that vest shall be rounded down to the nearest whole number of units, and any fractional vested Revenue PSUs shall be disregarded.

 

  75,000 of the PSUs (the “Transaction PSUs”) shall become earned based upon the Administrator’s determination of the cumulative net present value (the “NPV”) of any merger or acquisition transactions, asset in-licenses, asset out-licenses, collaborations or other commercial transactions closed by the Company during the period commencing on the Grant Date and ending on


 

August 1, 2021 (collectively, the “Transactions”), as follows: (i) fifty percent (50%) of the Transaction PSUs shall become earned when the cumulative NPV of the Transactions is equal to or greater than $112,500,000; (ii) seventy-five percent (75%) of the Transaction PSUs shall become earned when the cumulative NPV of the Transactions is equal to or greater than $135,000,000; and (iii) one-hundred percent (100%) of the Transaction PSUs shall become earned when the cumulative NPV of the Transactions is equal to or greater than $150,000,000. The cumulative NPV of the Transactions shall be determined by the Administrator, in its sole discretion, within thirty (30) days following the closing date of each Transaction. The number of Transaction PSUs that shall become earned in connection with each Transaction, if any, shall be equal to the cumulative number of Transaction PSUs that become earned as of the closing date of such Transaction, minus the total number of Transaction PSUs that have previously become earned, if any, in connection with prior Transactions. In connection with each Transaction, if the cumulative NPV of the Transactions falls between $112,500,000 and $135,000,000, or between $135,000,000 and $150,000,000, then linear interpolation shall apply in determining the percentage of the Transaction PSUs that become earned. The number of Transaction PSUs that become earned in connection with each Transaction, if any, shall vest on the date that the Administrator determines the cumulative NPV of the Transactions, subject to the Participant’s continued Employment through the closing date of the applicable Transaction. Any Transaction PSUs that vest shall be rounded down to the nearest whole number of units, and any fractional vested Transaction PSUs shall be disregarded. If the cumulative NPV of the Transactions is less than $112,500,000 as of August 1, 2021 (the “End Date”), then none of the Transaction PSUs shall become earned. Any Transaction PSUs that have not become earned as of the End Date shall be immediately and automatically forfeited by the Participant.

 

  The Participant may not vest in more than the number of shares of Common Stock underlying the PSUs, as set forth on the Cover Sheet of this Agreement.

 

Change of Control

In the event that a Change of Control (as defined below) occurs during the Performance Period (with respect to the Revenue PSUs) or prior to the End Date (with respect to the Transaction PSUs), the Administrator shall determine, in its sole discretion, immediately prior to the date of such Change of Control, the number of Revenue PSUs and the number of Transaction PSUs, as applicable, that are earned, if any, in connection with such Change of Control, based upon the Company’s achievement of the applicable performance objectives, determined as of the date of such Change of Control. For purposes of the preceding sentence, the Revenue Target shall be pro-rated by multiplying such amount by a fraction, the numerator of which is the product revenues target set forth in the Company’s fiscal year 2018 strategic plan for the period commencing on July 1, 2018 and ending on the date of the Change of Control, as determined by the Administrator in its sole discretion (using linear interpolation when the Change in Control occurs on a date that


 

falls between two measurement dates in the fiscal year 2018 strategic plan), and the denominator of which is the full Revenue Target. Any Revenue PSUs and/or Transaction PSUs that do not become earned in connection with a Change of Control shall be immediately and automatically forfeited by the Participant. The number of Revenue PSUs and/or Transaction PSUs that become earned in connection with a Change of Control, if any, shall vest on the date of the Change of Control, subject to the Participant’s continued Employment through such date. Any Revenue PSUs and/or Transaction PSUs that vest shall be rounded down to the nearest whole number of units, and any fractional vested Revenue PSUs and/or Transaction PSUs shall be disregarded.

 

Change of Control Definition

For purposes of this Agreement, the term “Change of Control” shall mean:

 

  (A)

the acquisition by any Person (defined as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (“Exchange Act”))) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (A), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company (“Benefit Plan”), or (iii) by an entity pursuant to a transaction that complies with the clauses (i), (ii) and (iii) of subsection (C) below;

 

  (B)

individuals who, as of the Grant Date, constitute the Board (together with the individuals identified in the proviso to this subsection (B), the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Grant Date whose election, or nomination for election by the Company’s stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board;

 

  (C)

consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company (a “transaction”), in each case unless, following such transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such transaction (including, without limitation, an entity which as a result of such


  transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such transaction, of the outstanding common stock of the Company, (ii) no Person (excluding any entity or wholly owned subsidiary of any entity resulting from such transaction or any Benefit Plan of the Company or such entity or wholly owned subsidiary of such entity resulting from such transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such transaction; or

 

  (D)

approval by the stockholders of the Company of a liquidation or dissolution of the Company.

 

Termination of Employment

The Participant shall immediately and automatically forfeit to the Company all of the unvested Revenue PSUs in the event the Participant’s Employment terminates for any reason prior to August 1, 2021. For the avoidance of doubt, if the Participant’s Employment terminates on or following August 1, 2021, but prior to the Administrator’s determination of the level of achievement of the Revenue Target, then the Participant shall remain eligible to vest in any Revenue PSUs that become earned. The Participant shall immediately and automatically forfeit to the Company all of the unvested Transaction PSUs in the event the Participant’s Employment terminates for any reason. For the avoidance of doubt, if the Participant’s Employment terminates on or following the closing date of a Transaction but prior to the Administrator’s determination of the cumulative NPV of the Transactions in connection with such Transaction, then the Participant shall remain eligible to vest in any Transaction PSUs that become earned in connection with such Transaction.

 

Covered Transaction

In the event of a Covered Transaction, the PSUs shall be treated in the manner so provided in Section 7 of the Plan.

 

Leaves of Absence

For purposes of the PSUs, the Participant’s Employment does not terminate when the Participant goes on a bona fide employee leave of absence that the Company approves in writing if the terms of the leave provided for continued service crediting or when continued service crediting is required by applicable law or contract. The Participant’s Employment terminates in any event when the approved leave ends unless the Participant immediately returns to active employment. The Company, in its sole discretion, determines which leave counts for this purpose and when the Participant Employment terminates for all purposes under the Plan.


Dividend Equivalents

Should any cash dividend or other cash distribution be declared and paid with respect to the shares of Common Stock during the period between the Grant Date and the date or dates on which the PSUs are delivered as shares of Common Stock, the Company shall credit to a dividend equivalent bookkeeping account the value of such dividends or distributions that would have been paid if the outstanding PSUs at the time of the declaration of the dividend were outstanding shares of Common Stock. At the same time that the corresponding PSUs are converted to shares of Common Stock and delivered to the Participant, the Company shall pay to the Participant a lump sum cash payment equal to the value of the dividends credited to the dividend equivalent bookkeeping account that correspond to such PSUs that have become vested; provided, however, that any dividend equivalents that were credited to the Participant’s dividend equivalent bookkeeping account that are attributable to PSUs that have been forfeited shall be forfeited and not be payable to the Participant. No interest shall accrue on any dividend equivalents credited to the Participant’s dividend equivalent bookkeeping account.

 

Evidence of Issuance

The issuance of shares of Common Stock with respect to the PSUs shall be evidenced in such a manner as the Administrator, in its discretion, deems appropriate, including, without limitation, book-entry registration or delivery of stock certificates.

 

Delivery

Delivery of the shares of Common Stock underlying the Participant’s vested PSUs shall be made as soon as practicable (but in no event later than thirty (30) days) following the applicable vesting date.

 

Withholding

In the event that the Company determines that it is required to withhold foreign, federal, state or local tax as a result of the vesting of PSUs, the delivery of the shares of Common Stock underlying the PSUs or the payment of dividend equivalents pursuant to this Agreement, the Participant, as a condition to such vesting, delivery of shares of Common Stock or payment of dividend equivalents, as applicable, shall make arrangements satisfactory to the Company to enable it to satisfy all withholding requirements. Satisfactory arrangements shall include share withholding and/or delivery of previously owned shares of Common Stock in an amount equal to the applicable withholding or other taxes due; provided; however, that no shares of Common Stock shall be withheld with a value in excess of the maximum statutory rates for the applicable jurisdictions or such greater amount as would not result in adverse accounting consequences to the Company under FASB ASC Topic 718 (or any successor provision). Notwithstanding the foregoing, the Company may, in its sole discretion, elect to satisfy all applicable withholding requirements by share withholding without the Participant’s consent.

 

Transferability

The PSUs may not be sold, pledged, hypothecated, assigned, margined or otherwise transferred or encumbered by the Participant in any manner, except by will or by the laws of descent and distribution. Any attempted assignment, transfer, pledge, hypothecation or other disposition of the PSUs, or levy of attachment or similar process upon the PSUs not specifically permitted herein, shall be null and void and without effect.


Retention Rights

This Agreement and the PSUs evidenced by this Agreement do not give the Participant the right to be retained by the Company or any Affiliate in any capacity. Unless otherwise specified in any employment or other written agreement between the Participant and the Company or any Affiliate, the Company and any Affiliate reserve the right to terminate the Participant’s Employment at any time and for any reason.

 

Shareholder Rights

Neither the Participant nor the Participant’s estate or heirs have any rights as a shareholder of the Company until the shares of Common Stock have been delivered and either a certificate evidencing the shares of Common Stock has been issued or an appropriate entry has been made on the Company’s books. No adjustments are made for dividends, distributions, or other rights if the applicable record date occurs before a certificate is issued or the appropriate book entry is made, except as set forth above or as described in the Plan.

 

Recovery of Compensation

Notwithstanding anything to the contrary in this Agreement, the Participant acknowledges and agrees that the Administrator shall have the right to cause the Participant to forfeit and disgorge to the Company the PSUs (whether or not vested) and any shares of Common Stock acquired by, or dividend equivalents paid to the Participant pursuant to the PSUs, with interest and other related earnings, as the Administrator in its discretion shall determine, (A) if the Participant violates (i) a non-competition, non-solicitation, confidentiality or other restrictive covenant by which the Participant is bound, or (ii) any Company policy applicable to the Participant that provides for forfeiture or disgorgement with respect to incentive compensation that includes Awards under the Plan, and (B) to the extent required by law or applicable stock exchange listing rules, including, without limitation, Section 10D of the Exchange Act and any related Company policy. The Participant agrees to cooperate fully with the Administrator, and to cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture or disgorgement required hereunder. Neither the Administrator nor the Company nor any other person, other than the Participant and the Participant’s permitted transferees, if any, shall be responsible for any adverse tax or other consequences to the Participant or the Participant’s permitted transferees, if any, that may arise in connection with this paragraph.

 

Applicable Law

The validity and construction of this Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive laws of any other jurisdiction.


The Plan

The text of the Plan is incorporated into this Agreement.

 

  Certain capitalized terms used in this Agreement are defined in the Plan, and have the meaning set forth in the Plan.

 

  This Agreement and the Plan constitute the entire understanding between the Participant and the Company regarding the PSUs. Any prior agreements, commitments, or negotiations concerning the PSUs are superseded; except that any other written confidentiality, non-competition, non-solicitation, and/or severance agreement, or any other written agreement between the Participant and the Company or any Affiliate, as applicable, shall supersede this Agreement with respect to its subject matter.

 

Data Privacy

To facilitate the administration of this Award, the Company may process personal data about the Participant. This data includes, without limitation, information provided in this Agreement and any changes to such information, other appropriate personal and financial data about the Participant, including the Participant’s contact information, payroll information and any other information that the Company deems appropriate to facilitate the administration of this Award.

 

  By accepting the PSUs, the Participant gives explicit consent to the Company to process any such personal data.

 

Code Section 409A

The grant of the PSUs under this Agreement is intended to comply with Section 409A of the Code (“Section 409A”) to the extent subject thereto, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance with Section 409A. Notwithstanding anything to the contrary in this Agreement, the Company is not making any representation hereunder as to the particular tax treatment of the PSUs.

 

  To the extent that the PSUs constitute “deferred compensation” under Section 409A, a termination of Employment occurs only upon an event that would be a “separation from service” within the meaning of Section 409A. If, at the time of the Participant’s separation from service, (i) the Participant is a “specified employee” within the meaning of Section 409A, and (ii) the Company makes a good faith determination that an amount payable on account of the Participant’s separation from service constitutes deferred compensation (within the meaning of Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Section 409A to avoid taxes or penalties under Section 409A (the “Delay Period”), then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it in a lump sum on the first business day after the Delay Period (or upon the Participant’s death, if earlier), without interest. Each installment of PSUs that vest under this Agreement (if there is more than one installment) shall be considered one of a series of separate payments for purposes of Section 409A.


Disclaimer of Rights

The grant of PSUs under this Agreement shall in no way be interpreted to require the Company to transfer any amounts to a third-party trustee or otherwise hold any amounts in trust or escrow for payment to the Participant. The Participant shall have no rights under this Agreement other than those of a general unsecured creditor of the Company. PSUs represent unfunded and unsecured obligations of the Company, subject to the terms and conditions of this Agreement.

 

Notice Delivery

By accepting the PSUs, the Participant agrees that notices may be given to the Participant in writing either at the Participant’s home or mailing address as shown in the records of the Company or any Affiliate or by electronic transmission (including e-mail or reference to a website or other URL) sent to the Participant through the normal process employed by the Company or any Affiliate, as applicable, for communicating electronically with its employees.

By signing this Agreement, the Participant agrees to all of the terms and conditions described above and in the Plan.

EX-10.5 6 d635570dex105.htm EX-10.5 EX-10.5

Exhibit 10.5

Nonstatutory Stock Option

Inducement Award

1. Grant of Option.

This certificate evidences a nonstatutory stock option (this “Stock Option”) granted by EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on August 14, 2018 (the “Date of Grant”) to John Weet (the “Participant”). This Stock Option is granted to the Participant in connection with his entering into employment with the Company and is regarded by the parties as an inducement material to the Participant’s entering into employment within the meaning of Nasdaq Listing Rule 5635(c). Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of 100,000 shares of common stock of the Company (the “Shares”) at $2.10 per Share, which is not less than the fair market value of a Share on the Date of Grant. The latest date on which this Stock Option, or any part thereof, may be exercised is 5:00 P.M. Eastern Time on August 14, 2028 (the “Final Exercise Date”). The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, meaning an option that does not qualify as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). This Stock Option shall be subject to and governed by, and shall be construed and administered in accordance with, the terms and conditions of the Company’s 2016 Long-Term Incentive Plan (as from time to time in effect, the “Plan”), which terms and conditions are incorporated herein by reference. A copy of the Plan has been made available to the Participant. Notwithstanding the foregoing, this Stock Option is not awarded under the Plan and the grant of this Stock Option shall not reduce the number of shares of Stock available for issuance under awards issued pursuant to the Plan.

2. Vesting.

(a) During Employment. This Stock Option will vest and become exercisable with respect to one third (1/3) of the Shares on each of the first, second and third anniversaries of the Grant Date.

(b) Termination of Employment. Notwithstanding the foregoing, upon termination of the Participant’s Employment, any portion of this Stock Option that is not then exercisable will immediately expire and the remainder of this Stock Option will remain exercisable for three months; provided, that any portion of this Stock Option held by the Participant immediately prior to the Participant’s death, to the extent then exercisable, will remain exercisable for one year following the Participant’s death; further provided, that if termination of the Participant’s Employment resulted from reasons that in the determination of the Administrator cast such discredit on the Participant as to justify immediate forfeiture of this Stock Option, this Stock Option shall expire in its entirety immediately upon termination of the Participant’s Employment and no portion of this Stock Option shall thereafter remain exercisable; and further provided, that in no event shall any portion of this Stock Option be exercisable after the Final Exercise Date.

 

-1-


(c) Notwithstanding the foregoing provisions of this Section 2, this Stock Option shall not vest or become eligible to vest on any date specified above unless the Participant has continuously been, since the Grant Date until the date immediately prior to such termination of Employment, Employed by the Company, its Affiliates or its subsidiaries.

3. Exercise of Stock Option.

Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant’s executor, administrator, or legally appointed representative (in the event of the Participant’s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the “Option Holder”), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan. Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows: (i) by delivery of cash or check acceptable to the Administrator; or (ii) through a broker-assisted exercise program acceptable to the Administrator; or (iii) by any other means acceptable to the Administrator, or (iv) by any combination of the foregoing means of exercise. In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.

4. Withholding.

Except as otherwise determined by the Administrator, this Stock Option may not be exercised unless the person exercising this Stock Option timely remits to the Company, in cash, all amounts required to be withheld upon exercise (all as determined by the Administrator) or makes other arrangements satisfactory to the Administrator for the payment of such taxes.

5. Nontransferability of Stock Option.

This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant (or in the event of the Participant’s incapacity, the person or persons legally appointed to act on the Participant’s behalf).

6. Provisions of the Plan.

This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant. By accepting this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.

 

-2-


IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.

 

EyePoint Pharmaceuticals, Inc.
By   /s/ Nancy Lurker
  Nancy Lurker

Dated: August 14, 2018

 

Acknowledged and agreed:
By:   /s/ John Weet
  John Weet

Dated: August 14, 2018

 

-3-

EX-31.1 7 d635570dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.

CERTIFICATIONS

I, Nancy Lurker, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of EyePoint Pharmaceuticals, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2018

/s/ Nancy Lurker

Name:   Nancy Lurker
Title:   President and Chief Executive Officer
(Principal Executive Officer)
EX-31.2 8 d635570dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.

CERTIFICATIONS

I, David Price, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of EyePoint Pharmaceuticals, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2018

/s/ David Price

Name:   David Price
Title:   Chief Financial Officer
  (Principal Financial Officer)
EX-32.1 9 d635570dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Quarterly Report of EyePoint Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nancy Lurker, President and Chief Executive Officer of the Company, certify that to the best of my knowledge:

 

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2018

/s/ Nancy Lurker

Name:   Nancy Lurker
Title:   President and Chief Executive Officer
  (Principal Executive Officer)
EX-32.2 10 d635570dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Quarterly Report of EyePoint Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Price, Chief Financial Officer of the Company, certify that to the best of my knowledge:

 

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2018

/s/ David Price

Name:   David Price
Title:   Chief Financial Officer
  (Principal Financial Officer)
EX-101.INS 11 eypt-20180930.xml XBRL INSTANCE DOCUMENT 3000000 94855705 95000000 15000000 2000000 2500000 1800000 353000 1.10 20000000 8 15000000 2100000 299000 1.10 48334 2.50 17048000 623605 35246000 35610000 13336000 323284000 833000 39356999 39000 -310820000 1.265 18200000 1.93 5000000 97000 652000 3723000 39909000 353000 926000 374766000 2940000 838000 71670000 1.23 38776000 38926000 150000000 74512048 486812 0.001 74512048 74000 19780000 36964000 68322000 31358000 21663000 59983000 71670000 17309000 38000 0 1231000 253000 0.001 5000000 0 780000 0 150000 -363991000 11687000 254000 742000 15000000 1763000 1.58 898129 241668 1.95 35001 1290000 3.06 0 0 19780000 19780000 19780000 28826000 28826000 0 0 0 0 0 0 28826000 28826000 19780000 19780000 P6M 2.08 0.8540 0.0210 6460244 2.79 306000 19800000 374766000 838000 74512048 74000 -363991000 20184224 0.00 11983000 0 9001000 0 0 1.24 324927000 837000 40200783 40000 -316803000 3343000 57642000 489000 722000 443671000 4075000 838000 88855000 1.23 55764000 55914000 150000000 94696272 486812 0.001 94696272 95000 218000 0 5200000 37579000 68322000 30743000 22418000 41150000 88855000 17463000 46000 0 1269000 320000 0.001 5000000 0 1389000 0 150000 -396899000 47705000 0 0 332000 1039000 15000000 1204000 1.58 895829 241668 1.95 35418 308000 615000 3.11 1525000 2.96 975000 0 0 0 25955000 25955000 0 0 25955000 25955000 P5Y P5Y 150000 P5Y 1497886 1747000 3151142 3.34 6459469 2.76 6203000 670750 0 0 225000 0 443671000 0 838000 94696272 0 95000 218000 -396899000 1.43 225000 2.22 P3Y 385000 2.10 P3Y 100000 48332 2018-03-28 127000 0.16 0.12 15000000 32000000 32000000 P13Y 200000000 0.20 0.015 2 0.06 0.01 409091 P7Y 1.10 409091 Quarterly 1670000 2018-05-15 2018-03-28 0.015 2023-03-27 10000000 0.06 0.1050 Three-month LIBOR rate(subject to a 1.5% floor)plus 10.50%. 0.015 0.06 8606324 9500000 0.50 0.50 0.50 0.50 25000000 10000000 1381 25500000 20184224 77721 P7Y 1.93 77721 202000 218000 0.08 0.06 75000000 0.50 5000000 0.50 0.20 0.34 20000000 0.030 28900000 100000 100000 981000 739000 31973000 737000 500000 1600000 681000 6898655 681000 182000 -5065000 -5979000 39000 -0.15 4000 0 2572000 0 -129000 -40000 -972000 0 0 -64000 963000 -5968000 -5983000 4000 23000 4000 6391000 -6006000 64000 963000 0 -5983000 3819000 385000 681000 963000 0 39430000 -4000 0 623605 2.50 5740155 948500 0 210000 0 377000 304000 0 245000 245000 140000 50000 90000 50000 81000 843784 1000000 681000 0 0 962000 0 0 4000 0 0 0 0 1000 843784 0 -5983000 0 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>6. Accrued Expenses</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Accrued expenses consisted of the following at September&#xA0;30, 2018 and June&#xA0;30, 2018 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Clinical trial costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">742</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Personnel costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,763</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">722</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,343</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,723</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 1397000 10369196 false 1397000 615000 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>3. Acquisition of Icon Bioscience, Inc.</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> On March&#xA0;28, 2018, the Company and its newly-created wholly-owned subsidiary, Oculus Merger Sub, Inc., acquired Icon, a specialty biopharmaceutical company, through a reverse triangular merger (the &#x201C;Icon Acquisition&#x201D;) pursuant to an Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;) between the Company, Icon, and Shareholder Representative Services LLC (&#x201C;SRS&#x201D;), solely in its capacity as representative of Icon&#x2019;s securityholders. The Icon Acquisition was accounted for as an asset acquisition because substantially all of the fair value of the gross assets acquired were deemed to be concentrated in a group of similar identifiable assets related to Icon&#x2019;s lead product, DEXYCU. A portion of the Icon Acquisition was funded by an equity financing and a debt financing, both of which closed concurrently with the Icon Acquisition (see Notes 7 and 8).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Pursuant to the Merger Agreement, the Company made a closing payment of $15.0&#xA0;million to SRS, net of an estimated $127,000 working capital adjustment, and is obligated to pay certain post-closing contingent cash payments upon the achievement of specified milestones and based upon certain net sales and partnering revenue standards, in each case subject to the terms and conditions set forth in the Merger Agreement. These include but are not limited to (i)&#xA0;a <font style="white-space:nowrap">one-time</font> development milestone of $15.0&#xA0;million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0&#xA0;million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare&#xA0;&amp; Medicaid Services (&#x201C;CMS&#x201D;) reimbursement conditions set forth in the Merger Agreement, (iii)&#xA0;quarterly <font style="white-space:nowrap">earn-out</font> payments equal to 12% on net sales of DEXYCU in a given year, which <font style="white-space:nowrap">earn-out</font> payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual DEXYCU consideration exceeds $200.0&#xA0;million in such year, (iv)&#xA0;quarterly <font style="white-space:nowrap">earn-out</font> payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v)&#xA0;single-digit percentage quarterly <font style="white-space:nowrap">earn-out</font> payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The purchase price on the date of the Icon Acquisition was $32.0&#xA0;million, comprising the closing consideration of $15.0&#xA0;million, including the assumption of an estimated $127,000 of net current liabilities of Icon, the contingent development milestone payment of $15.0&#xA0;million and transaction costs of approximately $2.0&#xA0;million. Given the stage of development of DEXYCU, the Company determined these payments did not represent research and development costs. The contingent consideration in the form of sales milestones will be capitalized as additional intangible assets when any such consideration becomes probable and can be reasonably estimated. Sales-based royalty payments will be expensed as incurred.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The $32.0&#xA0;million purchase price was allocated to a single finite-lived intangible asset with an expected amortization life of approximately 13 years. The intangible asset is being amortized on a straight-line basis over that period. The acquisition did not have a net tax impact due to a full valuation allowance against the acquired net deferred tax assets.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>4. License and Collaboration Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Alimera</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Under a collaboration agreement with Alimera, as amended in March 2008 (the &#x201C;Prior Alimera Agreement&#x201D;), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN for DME, and Alimera assumed all financial responsibility for the development of the licensed products. In addition, the Company was entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">quarter-by-quarter</font></font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">country-by-country</font></font>&#xA0;basis. Alimera was entitled to recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company&#x2019;s net profit share to 16% in each country until those net losses were recouped. In the event that Alimera sublicensed commercialization in any country, the Company was entitled to 20% of royalties and 33% of&#xA0;<font style="WHITE-SPACE: nowrap">non-royalty</font>&#xA0;consideration received by Alimera, less certain permitted deductions. The Company was also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On July&#xA0;10, 2017, the Company entered into a further amended and restated collaboration agreement (the &#x201C;Amended Alimera Agreement&#x201D;), pursuant to which the Company (i)&#xA0;licensed its three-year NIPU product candidate (called YUTIQ in the U.S. and planned to be called ILUVIEN in Europe, the Middle East and Africa (&#x201C;EMEA&#x201D;)) to Alimera for the EMEA and (ii)&#xA0;converted the net profit share arrangement for each licensed product (including ILUVIEN) under the Prior Alimera Agreement to a sales-based royalty on a calendar quarter basis commencing July&#xA0;1, 2017, with payments from Alimera due 60 days following the end of each quarter.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Sales-based royalties start at the rate of 2%. Commencing January&#xA0;1, 2019, the sales-based royalty will increase to 6% on aggregate calendar year net sales up to $75&#xA0;million and 8% in excess of $75&#xA0;million. Alimera&#x2019;s share of contingently recoverable accumulated ILUVIEN commercialization losses under the Prior Alimera Agreement, capped at $25&#xA0;million, are to be reduced as follows: (i) $10.0&#xA0;million was cancelled in lieu of an upfront license fee on the effective date of the Amended Alimera Agreement; (ii)&#xA0;for calendar years 2019 and 2020, 50% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments otherwise due from Alimera; (iii)&#xA0;on January&#xA0;1, 2020, another $5&#xA0;million will be cancelled, provided, however, that such date of cancellation may be extended under certain circumstances related to Alimera&#x2019;s regulatory approval process for the ILUVIEN three-year NIPU product candidate, with such extension, if any, subject to mutual agreement by the parties; and (iv)&#xA0;commencing in calendar year 2021, 20% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments due from Alimera until such time as the balance of the original $25&#xA0;million of recoverable commercialization losses has been fully recouped.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Following the completion of the Amended Alimera Agreement, the Company withdrew its previously filed EU marketing approval application and its EU orphan drug designation for YUTIQ, and Alimera was responsible for filing a Type II variation for ILUVIEN for the treatment of NIPU. In January 2018, Alimera received validation of a Type II variation submitted in December 2017 in all seventeen European countries in which it previously received regulatory approval for ILUVIEN for DME. If the variation is approved, Alimera plans to commercialize the indication for NIPU under its ILUVIEN trademark.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Revenue under the Prior Alimera Agreement and/or the Amended Alimera Agreement totaled $249,000 and $90,000 for the three months ended September&#xA0;30, 2018 and 2017, respectively. In addition to patent fee reimbursements in both periods, revenue included (i) $215,000 of accrued sales-based royalty income for the three months ended September&#xA0;30, 2018 under the Amended Alimera Agreement and (ii) $50,000 of net profits received in the three months ended September&#xA0;30, 2017 attributable to the fourth quarter of fiscal 2017 (recorded as collaborative research and development revenue under the Prior Alimera Agreement).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Prior to the July&#xA0;1, 2018 adoption of ASC 606, the Company had recorded royalties earned from Alimera one quarter in arrears. Under ASC 606, the Company is required to accrue royalty income based on an estimate of royalties earned in each fiscal quarter, with a true-up to actual in the following quarter. As a result, $218,000 of royalties earned for the quarter ended June&#xA0;30, 2018 that would have been recorded as royalty income in the three months ended September&#xA0;30, 2018 have been accounted for as a cumulative effect adjustment to beginning accumulated deficit at July&#xA0;1, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Bausch&#xA0;&amp; Lomb</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Pursuant to a licensing and development agreement, as amended, Bausch&#xA0;&amp; Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Royalty income totaled $215,000 and $245,000 for the three months ended September&#xA0;30, 2018 and 2017, respectively. Accounts receivable from Bausch&#xA0;&amp; Lomb totaled $225,000 at September&#xA0;30, 2018 and $306,000 at June&#xA0;30, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>OncoSil Medical</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly owned subsidiary of OncoSil Medical Ltd (&#x201C;OncoSil&#x201D;) for the development of BrachySil, the Company&#x2019;s BioSilicon product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and certain milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year, the most recent of which was received in December 2017. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any licensed patent maintenance costs, sales-based royalties and&#xA0;<font style="WHITE-SPACE: nowrap">sub-licensee</font>&#xA0;sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. As of September&#xA0;30, 2018, OncoSil has not received regulatory approval in any jurisdiction, although an application for CE Mark approval in Europe is pending. There was no revenue related to the OncoSil agreement in either of the three-month periods ended September&#xA0;30, 2018 and 2017. As of September&#xA0;30, 2018, no deferred revenue was recorded for this agreement.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Evaluation Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized by the Company as revenue over the term of the feasibility study agreement. Revenues under evaluation agreements totaled $15,000 and $50,000 for the three months ended September&#xA0;30, 2018 and 2017, respectively. At September&#xA0;30, 2018 no deferred revenue was recorded for these agreements.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>12. Commitments and Contingencies</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Operating Leases</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On May&#xA0;17, 2018, the Company entered into a Second Amendment (the &#x201C;Second Amendment&#x201D;) to its lease in Watertown, Massachusetts. The original <font style="WHITE-SPACE: nowrap">5-year</font> lease for approximately 13,650 square feet of combined office and laboratory space (the &#x201C;Existing Space&#x201D;) of the building located at 480 Pleasant Street, Watertown, MA 02472 (the &#x201C;Premises&#x201D;) and was set to expire in April 2019. Under the Second Amendment, the Company leased an additional 6,590 square feet of rentable area (the &#x201C;Additional Space&#x201D;, and together with the Existing Space, the &#x201C;Total Space&#x201D;) on the Premises, with a commencement date of September&#xA0;10, 2018 (the &#x201C;Additional Space Effective Time&#x201D;). The landlord agreed to provide the Company a construction allowance of up to $670,750 to be applied toward the aggregate work to be conducted on the Total Space. The Second Amendment extended the term of the lease, which will now expire on May&#xA0;31, 2025; provided, however, that the base rent for the Total Space will be abated during the first four months following the Additional Space Effective Time. The Company also has an option to extend the term of the lease for one additional five-year period. The Company previously provided a cash-collateralized $150,000 irrevocable standby letter of credit as security for the Company&#x2019;s obligations under the lease, which was extended for a period of four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Commencing July&#xA0;1, 2017, the Company leased approximately 3,000 square feet of office space in Liberty Corner, New Jersey under a lease term extending through June 2022, with two five-year renewal options at 95% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional 1,381 square feet of adjoining space from Caladrius Biosciences, Inc. (&#x201C;Caladrius&#x201D;) through May 2022. The Chief Executive Officer of Caladrius is a director of the Company.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Legal Proceedings</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company&#x2019;s financial position, results of operations or cash flows.</p> </div> 16988000 -33126000 --06-30 43000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>9. Share-Based Payment Awards</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Equity Incentive Plans</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The 2016 Long-Term Incentive Plan (the &#x201C;2016 Plan&#x201D;), approved by the Company&#x2019;s stockholders on December&#xA0;12, 2016 (the &#x201C;Adoption Date&#x201D;), provides for the issuance of up to 3,000,000 shares of the Company&#x2019;s common stock reserved for issuance under the 2016 Plan plus any additional shares of the Company&#x2019;s common stock that were available for grant under the 2008 Incentive Plan (the &#x201C;2008 Plan&#x201D;) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At September&#xA0;30, 2018, a total of 1,497,886 shares were available for new awards.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Stock Options</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table provides a reconciliation of stock option activity under the Company&#x2019;s equity incentive plans for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> Options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,460,244</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">166,575</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(10,600</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.76</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(156,750</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.85</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,459,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.76</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.26</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercisable at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,151,142</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.34</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the three months ended September&#xA0;30, 2018, the Company granted 115,000 options to employees with ratable annual vesting over 3 years, 1,667 options to a&#xA0;<font style="WHITE-SPACE: nowrap">non-executive</font>&#xA0;director with&#xA0;<font style="WHITE-SPACE: nowrap">1-year</font>&#xA0;cliff vesting and 49,908 options to an external consultant with&#xA0;<font style="WHITE-SPACE: nowrap">1-year</font>&#xA0;cliff vesting. All option grants have a&#xA0;<font style="WHITE-SPACE: nowrap">10-year</font>&#xA0;term. The weighted-average grant date fair value of these options was $1.31 per share. In determining the grant date fair value of option awards under the 2016 Plan during the three months ended September&#xA0;30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">5.50 - 6.00</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">59% - 60%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.78%&#xA0;-2.90%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.0%</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Options to purchase a total of 401,558 shares of the Company&#x2019;s common stock vested during the three months ended September&#xA0;30, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Time-Vested Restricted Stock Units</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Time-vested restricted stock unit awards (&#x201C;RSUs&#x201D;) issued to date under the 2016 Plan generally vest on a ratable annual basis over 3 years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Company&#x2019;s common stock on the date of grant.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table provides a reconciliation of RSU activity under the 2016 Plan for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Restricted<br /> Stock&#xA0;Units</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Grant<br /> Date Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Nonvested at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">898,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,300</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.81</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Nonvested at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">895,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At September&#xA0;30, 2018, the weighted average remaining vesting term of the RSUs was 1.09 years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Performance-Based Stock Units</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Performance Stock Units (&#x201C;PSUs&#x201D;) were previously awarded to certain employees. The performance conditions associated with the PSU awards are as follows: (a)&#xA0;for one third of the PSUs, upon an FDA acceptance of the Company&#x2019;s NDA submission of YUTIQ for review on or before March&#xA0;31, 2018 and (b)&#xA0;for&#xA0;<font style="WHITE-SPACE: nowrap">two-thirds</font>&#xA0;of the PSUs, upon an FDA approval of YUTIQ on or before March&#xA0;31, 2019. For each performance criteria that is achieved, 50% of the PSUs that are associated with that performance condition vest at the achievement date and 50% vest on the first anniversary of such date, in each case subject to continued employment through such date. As a result of the achievement of the first performance condition on March&#xA0;19, 2018, 48,332 PSUs vested at that date and the other 48,334 PSUs became subject to a service-based condition with a vesting date of March&#xA0;19, 2019. On October&#xA0;12, 2018, the second performance condition associated with the PSUs was achieved and, accordingly, cumulative stock-based compensation from the PSU award date through September&#xA0;30, 2018 was recorded for that portion of the PSUs during the three months ended September&#xA0;30, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> There were 241,668 PSUs outstanding at each of September&#xA0;30, 2018 and June&#xA0;30, 2018. The weighted average remaining vesting term of the time-based RSUs associated with achievement of the first performance condition was approximately 5.6 months at September&#xA0;30, 2018.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Deferred Stock Units</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table provides a reconciliation of deferred stock units (&#x201C;DSUs&#x201D;) for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Deferred<br /> Stock&#xA0;Units</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Grant&#xA0;Date<br /> Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,001</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.32</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,418</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Each DSU vests one year from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company&#x2019;s common stock upon the earliest to occur of (i)&#xA0;each director&#x2019;s termination of service on the Company&#x2019;s Board of Directors and (ii)&#xA0;the occurrence of a change of control as defined in the award agreement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At September&#xA0;30, 2018, the weighted average remaining vesting term of the DSUs was approximately 8.8 months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Market-Based Restricted Stock Units</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At September&#xA0;30, 2018 and June&#xA0;30, 2018, there were 500,000 market-based RSUs (&#x201C;market-based RSUs&#x201D;) outstanding that were issued on September&#xA0;15, 2016 as an inducement award to the Company&#x2019;s President and CEO Subject to a service condition through September&#xA0;15, 2019, the number of shares underlying the market-based RSUs that will vest will be based upon a relative percentile rank of the&#xA0;<font style="WHITE-SPACE: nowrap">3-year</font>&#xA0;change in the closing price of the Company&#x2019;s common stock compared to that of the companies that make up the Nasdaq Biotechnology Index. The grant date fair value of the market-based RSUs of $1.45 per share was determined using a Monte Carlo valuation model at the date of grant.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b><i>Other Inducement Grants</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In connection with the August&#xA0;1, 2018 hire of the Company&#x2019;s Chief Financial Officer, the Company granted as inducement awards (i) 385,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.22 per share; and (ii) 225,000 PSUs. The PSUs are subject to proportional vesting based on cumulative measurement for the&#xA0;<font style="WHITE-SPACE: nowrap">3-year</font>&#xA0;period ending June&#xA0;30, 2021, with&#xA0;<font style="WHITE-SPACE: nowrap">two-thirds</font>&#xA0;of the award based upon defined amounts of the Company&#x2019;s product revenues and&#xA0;<font style="WHITE-SPACE: nowrap">one-third</font>&#xA0;based upon the net present value of each applicable business development transaction measured as of the date that each such transaction is consummated by the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In connection with the August&#xA0;14, 2018 hire of the Company&#x2019;s Senior Vice President of Regulatory and Quality, the Company granted as an inducement award 100,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.10 per share.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In determining the grant date fair value of inducement option awards during the three months ended September&#xA0;30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">6.00</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">59% - 60%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.81%&#xA0;-&#xA0;2.92%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.0%</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The inducement option grants have a&#xA0;<font style="WHITE-SPACE: nowrap">10-year</font>&#xA0;term and, although not awarded under the 2016 Plan, are subject to and governed by the terms and conditions of the 2016 Plan. The weighted average grant date fair value of the inducement grants was $1.27.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table provides a reconciliation of the Company&#x2019;s inducement stock option awards for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,290,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.06</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">485,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,525,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.96</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.60</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercisable at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">615,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.11</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Stock-Based Compensation Expense</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company&#x2019;s consolidated statements of comprehensive loss included total compensation expense from stock-based payment awards for the three months ended September&#xA0;30, 2018 and 2017, as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br /> Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Compensation expense included in:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">486</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">304</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">648</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,397</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">681</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In connection with termination benefits provided to the Company&#x2019;s former Executive Vice President and General Manager, US, the vesting of certain options was accelerated in accordance with the terms of the options, with an exercise period through December&#xA0;26, 2018. All remaining&#xA0;<font style="WHITE-SPACE: nowrap">non-vested</font>&#xA0;options were forfeited. The option modifications and forfeitures were accounted for in the quarter ended September&#xA0;30, 2018, the net effect of which resulted in a $171,000 increase of stock-based compensation expense included in sales and marketing for the three months ended September&#xA0;30, 2018 in the table above.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At September&#xA0;30, 2018, there was approximately $5.2&#xA0;million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan and the inducement awards that is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.</p> </div> Q1 2019 10-Q -0.44 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>13. Net Loss per Share</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive. Potentially dilutive shares were not included in the calculation of diluted net loss per share for each of the three months ended September&#xA0;30, 2018 and 2017 as their inclusion would be anti-dilutive.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Options outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,984,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,740,155</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Warrants outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,395,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">948,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Performance stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">466,668</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">210,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,418</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,369,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,898,655</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.21 0001314102 0 P1Y7M6D EyePoint Pharmaceuticals, Inc. true <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>10. Fair Value Measurements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following tables summarize the Company&#x2019;s assets and liabilities carried at fair value measured on a recurring basis at September&#xA0;30, 2018 and June&#xA0;30, 2018 by valuation hierarchy (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September 30, 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> carrying&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active&#xA0;markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>June 30, 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>carrying&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active&#xA0;markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Derivative liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk have historically consisted principally of cash and cash equivalents. At September&#xA0;30, 2018 and June&#xA0;30, 2018, substantially all of the Company&#x2019;s interest-bearing cash equivalent balances were concentrated in one U.S. Government institutional money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. These deposits may be redeemed upon demand and, therefore, generally have minimal risk. The Company&#x2019;s cash equivalents are classified within Level&#xA0;1 on the basis of valuations using quoted market prices.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Upon the closing of the Second Tranche Transaction on June&#xA0;25, 2018, the Company issued the Second Tranche Warrants, which were determined to be liability classified, which required that the liability be measured at fair value each period with changes in fair value being recorded as a component of net loss in the consolidated statement of comprehensive loss. This valuation was determined to be a level 3 valuation because it included unobservable inputs. The Second Tranche Warrants were valued using a Monte Carlo simulation valuation model. This model incorporated several inputs, including the closing price of the Company&#x2019;s common stock on the date of valuation, the historical share price volatility over the expected term and the risk-free interest rate. The resulting derivative liability at June&#xA0;30, 2018 was $19.8&#xA0;million. Significant assumptions used to <font style="WHITE-SPACE: nowrap">re-measure</font> this liability at June&#xA0;30, 2018 included volatility of 85.40%, risk free interest rate of 2.10%, a term of 6 months and the valuation date stock price of $2.08.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Second Tranche Investors delivered exercise notices covering all of the Second Tranche Warrants during the period from September 25 - 28, 2018 (see Note 8). The Company revalued the Second Tranche Warrants liability immediately prior to the respective exercise notice dates of the Second Tranche Investors, measured as the excess of the closing share price on the exercise notice date over the actual warrant exercise price of $1.43 per share times the number of shares purchased. The resulting liability balance was then reclassified to equity.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table sets forth a summary of changes in the fair value of the Company&#x2019;s derivative liability for which fair value is determined by Level&#xA0;3 inputs (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Second&#xA0;Tranche<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Change in fair value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,886</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification to equity</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,666</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 2018-09-30 false Non-accelerated Filer <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table sets forth a summary of changes in the fair value of the Company&#x2019;s derivative liability for which fair value is determined by Level&#xA0;3 inputs (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Second&#xA0;Tranche<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Change in fair value</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,886</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Reclassification to equity</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(38,666</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0 -18886000 0 4161000 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>11. Income Taxes</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management&#x2019;s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company did not record any income tax expense or benefit for the three months ended September&#xA0;30, 2018 and 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For the three months ended September&#xA0;30, 2018 and 2017, the Company had no significant unrecognized tax benefits. At September&#xA0;30, 2018 and June&#xA0;30, 2018, the Company had no accrued penalties or interest related to uncertain tax positions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On December&#xA0;22, 2017, the Tax Cuts and Jobs Act (the &#x201C;Tax Act&#x201D;) was enacted which, amongst other corporate and individual tax law changes, lowered the federal corporate income tax rate from 34% to 21% effective January&#xA0;1, 2018. Because the Company provides a full valuation allowance for all of its net deferred tax assets, there is no effect of the Tax Act on the Company&#x2019;s consolidated financial statements as of and for the three months ended September&#xA0;30, 2018.</p> </div> 529000 0 756000 815000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>5. Intangible Assets</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The reconciliation of intangible assets for the three months ended September&#xA0;30, 2018 and for the year ended June&#xA0;30, 2018 was as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three Months<br /> Ended<br /> September&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year&#xA0;Ended<br /> June&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Patented technologies</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross carrying amount at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,610</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of Icon Bioscience Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">739</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross carrying amount at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated amortization at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,964</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(35,246</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Amortization expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(615</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(737</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated amortization at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(37,579</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,964</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net book value at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,743</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,358</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $615,000 and $182,000 for the three months ended September&#xA0;30, 2018 and 2017, respectively.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In connection with the Icon Acquisition (see Note 3), the initial purchase price of $32.0&#xA0;million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of 12.5 years at the rate of approximately $2.5&#xA0;million per year.</p> </div> 583000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>7. Term Loan Agreement</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On March&#xA0;28, 2018 (the &#x201C;Closing Date&#x201D;), the Company entered into a Credit Agreement (the &#x201C;Credit Agreement&#x201D;) among the Company, as borrower, SWK Funding LLC, as agent (the &#x201C;Agent&#x201D;), and the lenders party thereto from time to time (the &#x201C;Lenders&#x201D;), providing for a senior secured term loan of up to $20&#xA0;million (the &#x201C;Loan&#x201D;). On the Closing Date, $15&#xA0;million of the Loan was advanced (the &#x201C;Initial Advance&#x201D;). The remaining $5&#xA0;million of the Loan was advanced on June&#xA0;26, 2018 following satisfaction of the Minimum Capital Raise (as defined in the Credit Agreement) (the &#x201C;Additional Advance&#x201D;). The Loan may be increased by $10&#xA0;million upon the request of the Company, subject to the Agent obtaining additional loan commitments and satisfaction of certain conditions in the Credit Agreement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Loan is due and payable on March&#xA0;27, 2023 (the &#x201C;Maturity Date&#x201D;). The Loan bears interest at a per annum rate of the three-month LIBOR rate (subject to a 1.5% floor) plus 10.50%. The Credit Agreement permits the Company to pay interest only on the principal amount for the first eight payments (payments are due on a quarterly basis commencing May&#xA0;15, 2018). Following the interest-only period, the Company will be required to make quarterly payments of interest, plus repayments of the principal in an aggregate amount of up to $1.67&#xA0;million per quarter (the &#x201C;Quarterly Principal Repayment Cap&#x201D;). Subject to the Quarterly Principal Repayment Cap, the amount of any quarterly principal payments during any fiscal year of the Company is based on (x)&#xA0;a percentage of the <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">year-to-date</font></font> net revenue of the Company through the end of such quarter less (y)&#xA0;any prior quarterly principal and interest payments made during such fiscal year. In addition, the Company paid an upfront fee of 1.5% of the aggregate principal amount of the Loan. The Company is required to pay an exit fee equal to 6% of the aggregate principal amount advanced under the Credit Agreement (the &#x201C;Exit Fee&#x201D;), which amount is included in other long-term liabilities in the accompanying condensed consolidated balance sheet.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the Credit Agreement), all or any amounts outstanding with respect to the Loan may become due and payable upon request of the Agent or majority Lenders. Additionally, subject to certain exceptions, the Company is required to make mandatory prepayments of the Loan with the proceeds of assets sales and insurance proceeds. The Company may make a voluntary prepayment of the Loan, in whole, but not in part, at any time on or after the first anniversary of the Closing Date. All mandatory and voluntary prepayments of the Loan are subject to the payment of prepayment premiums as follows: (i)&#xA0;in the case of mandatory prepayments, if prepayment occurs prior to the first anniversary of the Closing Date, a customary make-whole amount equal to the amount of interest that would have accrued on the principal amount so prepaid had it remained outstanding through the first anniversary of the Closing Date, (ii)&#xA0;if prepayment occurs on or after the first anniversary of the Closing Date, but prior to the second anniversary of the Closing Date, 6% of the aggregate amount of the principal prepaid and (iii)&#xA0;if prepayment occurs on or after the second anniversary of the Closing Date, but prior to the third anniversary of the Closing Date, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid on or after the third anniversary of the Closing Date.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In connection with the Loan, the Company issued a warrant (the &#x201C;SWK Warrant&#x201D;) to the Agent to purchase (a) 409,091 shares of Company common stock (the &#x201C;Initial Advance Warrant Shares&#x201D;) at an exercise price equal to $1.10 and (b) 77,721 shares of Company common stock (the &#x201C;Additional Advance Warrant Shares&#x201D;) at an exercise price of $1.93 per share. The SWK Warrant is exercisable (i)&#xA0;with respect to the Initial Advance Warrant Shares, any time on or after the Closing Date until the close of business on the <font style="WHITE-SPACE: nowrap">7-year</font> anniversary of the Initial Advance and (ii)&#xA0;with respect to the Additional Advance Warrant Shares, any time on or after the closing of the Additional Advance until the close of business on the <font style="WHITE-SPACE: nowrap">7-year</font> anniversary of the Additional Advance. The Agent may exercise the SWK Warrant on a cashless basis at any time. In the event the Agent exercises the SWK Warrant on a cashless basis the Company will not receive any proceeds.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The total debt discount related to the Initial Advance was $2.1&#xA0;million and was comprised of (1) $1.8&#xA0;million which included the 1.5% upfront fee, the Exit Fee and legal and other transaction costs, which were ratably allocated to each of the two tranches of the Loan based upon the total principal amount available to the Company under each tranche and (2) $353,000 related to the aggregate fair value of the Initial Advance Warrant Shares and the Additional Advance Warrant Shares. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest method.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The total debt issue costs related to the Additional Advance was $299,000 and was comprised of the allocated portions of the 1.5% upfront fee and the Exit Fee. This amount was recorded as a prepaid expense to be amortized ratably from the Closing Date through December&#xA0;31, 2018. Through the date of the Additional Advance, $97,000 was amortized and the remaining balance of $202,000 was reclassified to debt discount. Together with the 6% Exit Fee on the Additional Advance and other transaction costs, total debt discount of $652,000 associated with the Additional Advance is being amortized over the remaining life of the Additional Advance portion of the Loan using the effective interest method.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>1. Operations and Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the &#x201C;Company&#x201D;) as of September&#xA0;30, 2018 and for the three months ended September&#xA0;30, 2018 and 2017 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the &#x201C;SEC&#x201D;). These financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and footnotes included in its Annual Report on Form&#xA0;<font style="WHITE-SPACE: nowrap">10-K</font>&#xA0;for the fiscal year ended June&#xA0;30, 2018 (&#x201C;fiscal 2018&#x201D;). In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June&#xA0;30, 2018, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company&#x2019;s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (&#x201C;U.S.&#x201D;) generally accepted accounting principles (&#x201C;GAAP&#x201D;) requires management to make assumptions and estimates that affect, among other things, (i)&#xA0;reported amounts of assets and liabilities; (ii)&#xA0;disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii)&#xA0;reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended September&#xA0;30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Following U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) approval of DEXYCU&#x2122; and YUTIQ&#x2122;, the Company is targeting the direct U.S. commercial launch of YUTIQ in the first quarter of calendar 2019 and DEXYCU in the first half of calendar 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> DEXYCU&#x2122; (dexamethasone intraocular suspension) 9%, approved by the FDA in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes the Company&#x2019;s proprietary Verisome<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;drug-delivery platform, which allows for a single injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and the Company expects to launch DEXYCU in the U.S. in the first half of 2019 with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (&#x201C;Icon&#x201D;) in March 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> YUTIQ&#x2122;, a&#xA0;<font style="WHITE-SPACE: nowrap">non-erodible</font>&#xA0;fluocinolone acetonide insert for the treatment of chronic&#xA0;<font style="WHITE-SPACE: nowrap">non-infectious</font>&#xA0;posterior uveitis affecting the posterior segment of the eye (chronic &#x201C;NIPU&#x201D;), was approved by the FDA on October&#xA0;12, 2018. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis (zero order release) for approximately three years. YUTIQ is based on the Company&#x2019;s proprietary Durasert&#x2122; sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. NIPU is the third leading cause of blindness in the U.S. and is estimated to affect between 55,000 to 120,000 people. The Company expects to launch YUTIQ in the U.S. in the first quarter of calendar 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> ILUVIEN<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;for diabetic macular edema (&#x201C;DME&#x201D;), the Company&#x2019;s lead licensed product, was also developed from the Durasert technology platform and is sold directly in the U.S. and several European Union (&#x201C;EU&#x201D;) countries by Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;). Retisert<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, one of the Company&#x2019;s earlier generation products, was approved in 2005 by the FDA for the treatment of chronic NIPU and is sold in the U.S. by Bausch&#xA0;&amp; Lomb Incorporated (&#x201C;Bausch&#xA0;&amp; Lomb&#x201D;). The Company&#x2019;s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company&#x2019;s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has financed its operations primarily from sales of equity securities, issuance of debt and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company&#x2019;s anticipated recurring use of cash to fund operations in combination with no probable source of additional capital raises substantial doubt about its ability to continue as a going concern for one year from the issuance of its financial statements. The Company received proceeds of $28.9&#xA0;million in late September 2018 from the exercise of investor warrants (the &#x201C;Second Tranche Warrants) (see Note 8) and had total cash and cash equivalents of $55.8&#xA0;million at September&#xA0;30, 2018. The Company believes that its cash and cash equivalents of $55.8&#xA0;million at September&#xA0;30, 2018, and expected proceeds from existing collaboration agreements, will enable the Company to maintain its current and planned operations (including continuation of its two Phase 3 clinical trials for YUTIQ and plans for the U.S. commercial launch of both DEXYCU and YUTIQ) into the second quarter of calendar year 2019. In order to extend the Company&#x2019;s ability to fund its operations beyond then, management&#x2019;s plans include obtaining additional equity financing and/or additional debt financing and/or, as applicable, reducing or deferring operating expenses. The timing and extent of the Company&#x2019;s implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaborations or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant revenues from its planned commercialization of DEXYCU or YUTIQ, or from its product license revenues under existing collaboration agreements or be able to obtain financing from any other sources.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Recently Adopted and Recently Issued Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company&#x2019;s financial position, results of operations and cash flows or do not apply to the Company&#x2019;s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company adopted Accounting Standards Codification (&#x201C;ASC&#x201D;) 606,&#xA0;<i>Revenue from Contracts with Customers</i>, with a date of initial application of July&#xA0;1, 2018. As a result, the Company has updated its accounting policy for revenue recognition to reflect the new standard (see Note 2). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company&#x2019;s services and will provide financial statement readers with enhanced disclosures. The Company applied ASC 606 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard resulted in a $218,000 reduction to the opening balance of accumulated deficit at July&#xA0;1, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In February 2016, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;2016-02,</font>&#xA0;<i>Leases</i>. The new standard establishes a&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font>&#xA0;(&#x201C;ROU&#x201D;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December&#xA0;15, 2018, including interim periods within those fiscal years. Based on the change in the Company&#x2019;s fiscal year (see Note 14), ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02</font>&#xA0;will become effective on January&#xA0;1, 2019. A modified retrospective transition approach is required for lessee capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In June 2018, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-07,</font>&#xA0;<i>Improvements to Nonemployee Share-Based Payment Accounting</i>. The standard aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. The ASU is effective for fiscal years beginning after December&#xA0;15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but not before an entity adopts the new revenue guidance. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-07,</font>&#xA0;which was early adopted on July&#xA0;1, 2018, did not have a significant impact on the Company&#x2019;s financial statements.</p> </div> -109000 28863000 -11766000 -33126000 0 129000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of RSU activity under the 2016 Plan for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Restricted<br /> Stock&#xA0;Units</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Grant<br /> Date Fair<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Nonvested at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">898,129</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,300</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.81</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Nonvested at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">895,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0 14040000 -13554000 109000 0 28863000 -33126000 6233000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Options outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,984,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,740,155</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Warrants outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Restricted stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,395,829</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">948,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Performance stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">466,668</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">210,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Deferred stock units outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,418</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,369,196</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,898,655</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following tables summarize the Company&#x2019;s assets and liabilities carried at fair value measured on a recurring basis at September&#xA0;30, 2018 and June&#xA0;30, 2018 by valuation hierarchy (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September 30, 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> carrying&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active&#xA0;markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,955</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>June 30, 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b><br /> <b>carrying&#xA0;value</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices&#xA0;in<br /> active&#xA0;markets<br /> (Level 1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable&#xA0;inputs<br /> (Level 2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable&#xA0;inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cash equivalents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,826</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Derivative liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The reconciliation of intangible assets for the three months ended September&#xA0;30, 2018 and for the year ended June&#xA0;30, 2018 was as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three Months<br /> Ended<br /> September&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year&#xA0;Ended<br /> June&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Patented technologies</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross carrying amount at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,610</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Acquisition of Icon Bioscience Inc.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,973</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">739</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Gross carrying amount at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,322</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated amortization at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,964</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(35,246</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Amortization expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(615</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(981</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency translation adjustments</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(737</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated amortization at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(37,579</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(36,964</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net book value at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,743</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,358</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Revenue Recognition</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#xA0;identify the contract(s) with a customer; (ii)&#xA0;identify the performance obligations in the contract; (iii)&#xA0;determine the transaction price; (iv)&#xA0;allocate the transaction price to the performance obligations in the contract; and (v)&#xA0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Collaborative research and development revenue</i></b> &#x2014; The Company analyzes each element of its collaborative arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of <font style="white-space:nowrap">non-refundable</font> <font style="white-space:nowrap">up-front</font> license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-55-65.</font></font></font> For those milestone payments which are contingent on the occurrence of particular future events, the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-32-18,</font></font></font> the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#x2019;s contracts contained a significant financing component as of September&#xA0;30, 2018.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Reimbursement of costs</i></b> &#x2014; The Company may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. The Company acts primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. The Company records the expenses incurred and reimbursed on a gross basis.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Royalties</i></b> &#x2014; The Company recognizes revenue from license arrangements with its commercial partners&#x2019; net sales of products. Such revenues are included as royalty income. In accordance with ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-55-65,</font></font></font> royalties are recognized when the subsequent sale of the commercial partner&#x2019;s products occurs. The Company&#x2019;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a <font style="white-space:nowrap">true-up</font> when it receives royalty reports from its commercial partners. Historically, these <font style="white-space:nowrap">true-up</font> adjustments have been immaterial.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Feasibility Studies</i></b> &#x2014; The Company recognizes revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the feasibility study agreement.</p> </div> 486000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Accrued expenses consisted of the following at September&#xA0;30, 2018 and June&#xA0;30, 2018 (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2018</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Clinical trial costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,039</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">742</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Personnel costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,204</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,763</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">722</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">926</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">46</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,343</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,723</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 1397000 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>2. Summary of Significant Accounting Policies</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Revenue Recognition</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#xA0;identify the contract(s) with a customer; (ii)&#xA0;identify the performance obligations in the contract; (iii)&#xA0;determine the transaction price; (iv)&#xA0;allocate the transaction price to the performance obligations in the contract; and (v)&#xA0;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Collaborative research and development revenue</i></b> &#x2014; The Company analyzes each element of its collaborative arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of <font style="white-space:nowrap">non-refundable</font> <font style="white-space:nowrap">up-front</font> license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-55-65.</font></font></font> For those milestone payments which are contingent on the occurrence of particular future events, the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-32-18,</font></font></font> the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#x2019;s contracts contained a significant financing component as of September&#xA0;30, 2018.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Reimbursement of costs</i></b> &#x2014; The Company may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. The Company acts primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. The Company records the expenses incurred and reimbursed on a gross basis.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Royalties</i></b> &#x2014; The Company recognizes revenue from license arrangements with its commercial partners&#x2019; net sales of products. Such revenues are included as royalty income. In accordance with ASC <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">606-10-55-65,</font></font></font> royalties are recognized when the subsequent sale of the commercial partner&#x2019;s products occurs. The Company&#x2019;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a <font style="white-space:nowrap">true-up</font> when it receives royalty reports from its commercial partners. Historically, these <font style="white-space:nowrap">true-up</font> adjustments have been immaterial.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Feasibility Studies</i></b> &#x2014; The Company recognizes revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the feasibility study agreement.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Please refer to Note 4 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company&#x2019;s consolidated statements of comprehensive loss included total compensation expense from stock-based payment awards for the three months ended September&#xA0;30, 2018 and 2017, as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br /> Ended<br /> September&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Compensation expense included in:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">486</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">304</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">263</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">648</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">377</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,397</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">681</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 3646000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> In determining the grant date fair value of option awards under the 2016 Plan during the three months ended September&#xA0;30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">5.50 - 6.00</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">59% - 60%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.78%&#xA0;-2.90%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.0%</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of warrants to purchase shares of the Company&#x2019;s common stock for the three months ended September&#xA0;30, 2018 and 2017:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Three Months Ended September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.23</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">623,605</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(623,605</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance and exercisable at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.23</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> EYPT <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>14. Subsequent Event</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On November&#xA0;1, 2018, the Board of Directors approved a change in the Company&#x2019;s fiscal year from June&#xA0;30 to December&#xA0;31, effective immediately. The Company will file a transition report on Form <font style="WHITE-SPACE: nowrap">10-KT</font> for the six months ending December&#xA0;31, 2018 with the U.S. Securities and Exchange Commission in connection with its newly adopted fiscal year.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>8. Stockholders&#x2019; Equity</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>2018 Equity Financing</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On the Closing Date, the Company entered into a Securities Purchase Agreement (the &#x201C;First Tranche Securities Purchase Agreement&#x201D;) with EW Healthcare Partners, L.P. and EW Healthcare&#xA0;<font style="WHITE-SPACE: nowrap">Partners-A,</font>&#xA0;L.P. (collectively, the &#x201C;First Tranche Investors&#x201D;), pursuant to which the Company offered and sold to the First Tranche Investors an aggregate of 8,606,324 shares of the Company&#x2019;s common stock at a purchase price of $1.10 per share (the &#x201C;First Tranche Purchase Price&#x201D;) for aggregate gross proceeds of approximately $9.5&#xA0;million (the &#x201C;First Tranche Transaction&#x201D;).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On the Closing Date, the Company entered into a Second Securities Purchase Agreement (the &#x201C;Second Tranche Securities Purchase Agreement&#x201D; and together with the First Tranche Securities Purchase Agreement, the &#x201C;Securities Purchase Agreements&#x201D;) with the First Tranche Investors and certain other accredited investors (collectively, the &#x201C;Second Tranche Investors&#x201D;). Following approval of the Company&#x2019;s stockholders on June&#xA0;22, 2018, the Company sold to the Second Tranche Investors an aggregate of 20,184,224 Units at a purchase price of $1.265 per Unit for gross proceeds of approximately $25.5&#xA0;million. Each Unit consisted of (a)&#xA0;one share of the Company&#x2019;s common stock and (b)&#xA0;one warrant to purchase a share of the Company&#x2019;s common stock (the &#x201C;Second Tranche Transaction&#x201D; and together with the First Tranche Transaction, the &#x201C;Equity Transactions&#x201D;).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The warrants issued in the Second Tranche Transaction (each a &#x201C;Second Tranche Warrant,&#x201D; and collectively, the &#x201C;Second Tranche Warrants&#x201D;) were exercisable any time until on or prior to the close of business on the 15th business day following the date on which the holders of the Second Tranche Warrants received written notice from the Company that CMS had announced that a new&#xA0;<font style="WHITE-SPACE: nowrap">C-Code</font>&#xA0;had been established for DEXYCU. CMS approved transitional pass-through status and reimbursement through a&#xA0;<font style="WHITE-SPACE: nowrap">C-code</font>&#xA0;with an effective date of October&#xA0;1, 2018. Following written notice of such approval to the holders of the Second Tranche Warrants on September&#xA0;7, 2018, the Second Tranche Warrants were exercised in September 2018 at a purchase price of $1.43 per share for proceeds of approximately $28.9&#xA0;million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company determined that the Second Tranche Warrants were considered puttable warrants that represented an obligation indexed to a repurchase of the Company&#x2019;s shares and would require a transfer of assets that require classification as liabilities. The initial valuation of the Second Tranche Warrants on June&#xA0;25, 2018 of $18.2&#xA0;million was&#xA0;<font style="WHITE-SPACE: nowrap">re-measured</font>&#xA0;at June&#xA0;30, 2018, resulting in a change in fair value of derivative liability of approximately $1.6&#xA0;million and a derivative liability balance of $19.8&#xA0;million at June&#xA0;30, 2018. The Second Tranche Warrants were revalued immediately prior to exercise and resulted in a change in fair value of approximately $18.9&#xA0;million. The change in fair value was determined as the excess of the closing share price of the Company&#x2019;s common stock on the respective dates of exercise notice submitted by each of the Second Tranche Investors over the $1.43 per share exercise price. Upon exercise of the Second Tranche Warrants, the resulting derivative liability balance of approximately $38.7&#xA0;million was reclassified to equity.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>ATM Facility</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In February 2017, the Company entered into an ATM program pursuant to which, under its Form&#xA0;<font style="WHITE-SPACE: nowrap">S-3</font>&#xA0;shelf registration statement, the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $20.0&#xA0;million. The Company will pay the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> During the three months ended September&#xA0;30, 2017, the Company sold 843,784 shares of its Common Stock under the ATM program at a weighted average price of $1.24 per share for gross proceeds of approximately $1.0&#xA0;million. Share issue costs, including sales agent commissions, totaled $81,000 for the three months ended September&#xA0;30, 2017. The Company did not sell any shares of its common stock pursuant to the ATM program during the three months ended September&#xA0;30, 2018. At September&#xA0;30, 2018, approximately $3.8&#xA0;million of aggregate proceeds remains available to be utilized under the current ATM program.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Warrants to Purchase Common Shares</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The following table provides a reconciliation of warrants to purchase shares of the Company&#x2019;s common stock for the three months ended September&#xA0;30, 2018 and 2017:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> &#xA0;</p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>Three Months Ended September 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Warrants</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at beginning of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.23</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">623,605</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(623,605</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.50</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance and exercisable at end of period</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">486,812</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.23</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In connection with the Loan (see Note 7), the Company issued a warrant to purchase (i) 409,091 shares of Company common stock on March&#xA0;28, 2018 at an exercise price of $1.10 per share with a seven-year term and (ii) 77,721 shares of Company common stock on June&#xA0;26, 2018 at an exercise price of $1.93 per share with a seven-year term. At September&#xA0;30, 2018 the weighted average remaining life of the warrants was 6.54 years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> At June&#xA0;30, 2018 a total of 20,184,224 Second Tranche Warrants were outstanding with a variable exercise price and, accordingly, were excluded from the above table. These warrants were exercised in full in late September 2018.</p> </div> 75170000 28863000 0 38000 154000 0 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of deferred stock units (&#x201C;DSUs&#x201D;) for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Number&#xA0;of<br /> Deferred<br /> Stock&#xA0;Units</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Grant&#xA0;Date<br /> Fair&#xA0;Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,001</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.32</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">35,418</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.00 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of the Company&#x2019;s inducement stock option awards for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,290,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.06</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">485,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.95</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,525,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.96</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.60</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercisable at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">615,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.11</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">308</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0 38666000 7984469 1395829 486812 466668 35418 One third P5Y7M6D Two-thirds 2300 P3Y 1.81 P1Y1M2D 401558 1.45 500000 417 2.32 P8M24D P10Y P6Y 0.60 0.000 0.59 0.0281 1.27 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In determining the grant date fair value of inducement option awards during the three months ended September&#xA0;30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Option life (in years)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">6.00</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock volatility</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">59% - 60%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk-free interest rate</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.81%&#xA0;-&#xA0;2.92%</font></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expected dividends</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" align="center">0.0%</td> </tr> </table> </div> 0.0292 P7Y7M6D P5Y6M29D 250000 485000 1.95 2.20 These include but are not limited to (i) a one-time development milestone of $15.0 million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0 million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare & Medicaid Services (“CMS”) reimbursement conditions set forth in the Merger Agreement, (iii) quarterly earn-out payments equal to 12% on net sales of DEXYCU in a given year, which earn-out payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual DEXYCU consideration exceeds $200.0 million in such year, (iv) quarterly earn-out payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v) single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition. P6Y6M14D -18886000 -38666000 648000 486000 263000 171000 2022-06-30 2017-07-01 2 3000 0.95 2025-05-31 2018-09-10 6590 2019-04-30 13650 P10Y 0.60 0.000 0.59 0.0278 1.31 0.0290 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The following table provides a reconciliation of stock option activity under the Company&#x2019;s equity incentive plans for the three months ended September&#xA0;30, 2018:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> Options</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br /> Intrinsic<br /> Value</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center">(in years)</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2" align="center"> (in&#xA0;thousands)</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at July 1, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,460,244</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">166,575</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.31</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Forfeited</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(10,600</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.76</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(156,750</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.85</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Outstanding at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,459,469</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.76</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.26</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,203</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Exercisable at September 30, 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,151,142</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.34</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.20</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,747</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P6Y P5Y6M P1Y 49908 P3Y 115000 P1Y 1667 156750 P7Y3M3D 2.85 P5Y2M12D 10600 166575 2.76 2.31 430000 215000 17 56000 15000 0.02 218000 215000 249000 2012-12 0.08 0.20 0.04 0.20 0.20 0.33 0.16 0.20 0 3800000 18900000 38700000 1397000 0 28842000 0 38666000 0 0 0 0 0 0 0 21000 20184224 0 0 0 -33126000 0 0 0 The PSUs are subject to proportional vesting based on cumulative measurement for the 3-year period ending June 30, 2021, with two-thirds of the award based upon defined amounts of the Company's product revenues and one-third upon based on the net present value of each applicable business development transaction measured as of the date that each such transaction is consummated by the Company. 0001314102 us-gaap:ChiefFinancialOfficerMember 2018-07-01 2018-09-30 0001314102 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001314102 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheWarrantsMember 2018-07-01 2018-09-30 0001314102 eypt:AtTheMarketOfferingMember 2018-07-01 2018-09-30 0001314102 eypt:PriorAlimeraAgreementMember 2018-07-01 2018-09-30 0001314102 eypt:OncoSilMedicalUKLimitedMember 2018-07-01 2018-09-30 0001314102 eypt:PriorAlimeraAgreementAndOrAmendedAlimeraAgreementMember 2018-07-01 2018-09-30 0001314102 eypt:AmendedAlimeraAgreementMember 2018-07-01 2018-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember eypt:FeasibilityStudyAgreementMember 2018-07-01 2018-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2018-07-01 2018-09-30 0001314102 eypt:ILUVIENMember srt:EuropeMember 2018-07-01 2018-09-30 0001314102 us-gaap:RoyaltyMember eypt:BauschAndLombMember 2018-07-01 2018-09-30 0001314102 us-gaap:RoyaltyMember 2018-07-01 2018-09-30 0001314102 eypt:EquityIncentivePlansMember 2018-07-01 2018-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember eypt:NonExecutiveDirectorsMember 2018-07-01 2018-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember eypt:EmployeesMember 2018-07-01 2018-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember eypt:ExternalConsultantMember 2018-07-01 2018-09-30 0001314102 srt:MinimumMember eypt:TwoThousandSixteenIncentivePlanMember 2018-07-01 2018-09-30 0001314102 srt:MaximumMember eypt:TwoThousandSixteenIncentivePlanMember 2018-07-01 2018-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2018-07-01 2018-09-30 0001314102 stpr:MA eypt:OriginalLeaseMember 2018-07-01 2018-09-30 0001314102 stpr:MA eypt:SecondAmendmentLeaseMember 2018-07-01 2018-09-30 0001314102 stpr:NJ eypt:LibertyCornerOfficeSpaceMember 2018-07-01 2018-09-30 0001314102 eypt:ExecutiveVicePresidentAndGeneralManagerMember 2018-07-01 2018-09-30 0001314102 eypt:SalesAndMarketingMember 2018-07-01 2018-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001314102 us-gaap:FairValueInputsLevel3Member eypt:SecondTrancheWarrantsMember 2018-07-01 2018-09-30 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember 2018-07-01 2018-09-30 0001314102 eypt:IconBioscienceIncMember 2018-07-01 2018-09-30 0001314102 eypt:OtherInducementGrantsMember eypt:TwoThousandSixteenIncentivePlanMember 2018-07-01 2018-09-30 0001314102 eypt:OtherInducementGrantsMember 2018-07-01 2018-09-30 0001314102 eypt:DeferredStockUnitsMember 2018-07-01 2018-09-30 0001314102 eypt:MarketBasedRestrictedStockUnitsMember 2018-07-01 2018-09-30 0001314102 us-gaap:StockCompensationPlanMember 2018-07-01 2018-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenIncentivePlanMember 2018-07-01 2018-09-30 0001314102 eypt:PerformanceConditionTwoMember eypt:PerformanceStockUnitsMember 2018-07-01 2018-09-30 0001314102 eypt:PerformanceConditionOneMember eypt:PerformanceStockUnitsMember 2018-07-01 2018-09-30 0001314102 eypt:DeferredStockUnitsMember 2018-07-01 2018-09-30 0001314102 eypt:PerformanceStockUnitsMember 2018-07-01 2018-09-30 0001314102 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001314102 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001314102 2018-07-01 2018-09-30 0001314102 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0001314102 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-07-01 2017-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0001314102 eypt:AtTheMarketOfferingMember 2017-07-01 2017-09-30 0001314102 eypt:PriorAlimeraAgreementMember 2017-07-01 2017-09-30 0001314102 eypt:PriorAlimeraAgreementAndOrAmendedAlimeraAgreementMember 2017-07-01 2017-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember eypt:FeasibilityStudyAgreementMember 2017-07-01 2017-09-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember 2017-07-01 2017-09-30 0001314102 us-gaap:RoyaltyMember eypt:BauschAndLombMember 2017-07-01 2017-09-30 0001314102 us-gaap:RoyaltyMember 2017-07-01 2017-09-30 0001314102 eypt:SalesAndMarketingMember 2017-07-01 2017-09-30 0001314102 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001314102 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0001314102 eypt:DeferredStockUnitsMember 2017-07-01 2017-09-30 0001314102 eypt:PerformanceStockUnitsMember 2017-07-01 2017-09-30 0001314102 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0001314102 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001314102 2017-07-01 2017-09-30 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheWarrantsMember 2018-04-01 2018-06-30 0001314102 eypt:MarketBasedRestrictedStockUnitsMember 2017-07-01 2018-06-30 0001314102 2017-07-01 2018-06-30 0001314102 eypt:CollaborativeResearchAndDevelopmentMember eypt:OncoSilMedicalUKLimitedMember 2017-12-01 2017-12-31 0001314102 eypt:OncoSilMedicalUKLimitedMember 2013-03-01 2013-03-31 0001314102 eypt:SecondTrancheWarrantsMember 2018-09-01 2018-09-30 0001314102 eypt:AtTheMarketOfferingMember 2017-02-01 2017-02-28 0001314102 2017-07-01 2017-12-31 0001314102 us-gaap:ScenarioForecastMember eypt:AmendedAlimeraAgreementMember 2021-01-01 2021-01-01 0001314102 us-gaap:ScenarioForecastMember eypt:AmendedAlimeraAgreementMember 2020-01-01 2020-01-01 0001314102 us-gaap:ScenarioForecastMember eypt:AmendedAlimeraAgreementMember 2019-01-01 2019-01-01 0001314102 srt:MinimumMember us-gaap:ScenarioForecastMember eypt:AmendedAlimeraAgreementMember 2019-01-01 2019-01-01 0001314102 srt:MaximumMember us-gaap:ScenarioForecastMember eypt:AmendedAlimeraAgreementMember 2019-01-01 2019-01-01 0001314102 us-gaap:AccountingStandardsUpdate201409Member 2018-07-01 2018-07-01 0001314102 eypt:SeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-06-26 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:AdditionalAdvanceMember 2018-06-26 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember 2018-06-26 2018-06-26 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheTransactionMember 2018-06-22 2018-06-22 0001314102 eypt:SecondSecuritiesPurchaseAgreementMember 2018-06-22 2018-06-22 0001314102 eypt:CaladriusMember 2018-06-11 2018-06-11 0001314102 eypt:AmendedAlimeraAgreementMember 2017-07-10 2017-07-10 0001314102 eypt:PerformanceConditionTwoMember eypt:PerformanceStockUnitsMember us-gaap:ScenarioForecastMember 2020-03-31 2020-03-31 0001314102 eypt:PerformanceConditionTwoMember eypt:PerformanceStockUnitsMember us-gaap:ScenarioForecastMember 2019-03-31 2019-03-31 0001314102 eypt:PerformanceConditionOneMember eypt:PerformanceStockUnitsMember us-gaap:ScenarioForecastMember 2019-03-31 2019-03-31 0001314102 eypt:PerformanceConditionOneMember eypt:PerformanceStockUnitsMember 2018-03-31 2018-03-31 0001314102 eypt:FirstTrancheSecuritiesPurchaseAgreementMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:InitialAdvanceMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:InitialAdvanceMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:PrepaymentAfterSecondAnniversaryAndOnOrPriorToThirdAnniversaryMember eypt:SWKFundingLLCMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:PrepaymentAfterFirstAnniversaryAndOnOrPriorToSecondAnniversaryMember eypt:SWKFundingLLCMember 2018-03-28 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember 2018-03-28 2018-03-28 0001314102 us-gaap:NonUsMember eypt:IconBioscienceIncMember 2018-03-28 2018-03-28 0001314102 srt:MinimumMember eypt:IconBioscienceIncMember 2018-03-28 2018-03-28 0001314102 eypt:IconBioscienceIncMember eypt:DEXYCUMember 2018-03-28 2018-03-28 0001314102 eypt:IconBioscienceIncMember 2018-03-28 2018-03-28 0001314102 eypt:PerformanceConditionOneMember eypt:PerformanceStockUnitsMember 2018-03-19 2018-03-19 0001314102 eypt:SeniorVicePresidentMember 2018-08-14 2018-08-14 0001314102 us-gaap:ChiefFinancialOfficerMember 2018-08-01 2018-08-01 0001314102 eypt:OtherInducementGrantsMember us-gaap:ChiefFinancialOfficerMember 2018-08-01 2018-08-01 0001314102 eypt:SecondTrancheWarrantsMember 2018-09-30 0001314102 us-gaap:RetainedEarningsMember 2018-09-30 0001314102 us-gaap:CommonStockMember 2018-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001314102 eypt:BauschAndLombMember 2018-09-30 0001314102 eypt:FeasibilityStudyAgreementMember 2018-09-30 0001314102 eypt:OncoSilMedicalUKLimitedMember 2018-09-30 0001314102 srt:MaximumMember stpr:MA 2018-09-30 0001314102 eypt:EquityIncentivePlansMember 2018-09-30 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2018-09-30 0001314102 stpr:MA eypt:OriginalLeaseMember 2018-09-30 0001314102 stpr:MA eypt:SecondAmendmentLeaseMember 2018-09-30 0001314102 stpr:NJ eypt:LibertyCornerOfficeSpaceMember 2018-09-30 0001314102 us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001314102 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001314102 us-gaap:FairValueInputsLevel3Member eypt:SecondTrancheWarrantsMember 2018-09-30 0001314102 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0001314102 eypt:OtherInducementGrantsMember eypt:TwoThousandSixteenIncentivePlanMember 2018-09-30 0001314102 eypt:DeferredStockUnitsMember 2018-09-30 0001314102 eypt:PerformanceStockUnitsMember 2018-09-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenIncentivePlanMember 2018-09-30 0001314102 2018-09-30 0001314102 us-gaap:RetainedEarningsMember 2017-09-30 0001314102 us-gaap:CommonStockMember 2017-09-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001314102 eypt:AtTheMarketOfferingMember 2017-09-30 0001314102 2017-09-30 0001314102 eypt:SecondTrancheWarrantsMember 2018-06-30 0001314102 us-gaap:RetainedEarningsMember 2018-06-30 0001314102 us-gaap:CommonStockMember 2018-06-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheWarrantsMember 2018-06-30 0001314102 eypt:BauschAndLombMember 2018-06-30 0001314102 eypt:EquityIncentivePlansMember 2018-06-30 0001314102 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-06-30 0001314102 us-gaap:MeasurementInputPriceVolatilityMember 2018-06-30 0001314102 us-gaap:MeasurementInputSharePriceMember 2018-06-30 0001314102 us-gaap:MeasurementInputExpectedTermMember 2018-06-30 0001314102 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001314102 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001314102 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001314102 us-gaap:FairValueInputsLevel3Member eypt:SecondTrancheWarrantsMember 2018-06-30 0001314102 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001314102 eypt:OtherInducementGrantsMember eypt:TwoThousandSixteenIncentivePlanMember 2018-06-30 0001314102 eypt:DeferredStockUnitsMember 2018-06-30 0001314102 eypt:PerformanceStockUnitsMember 2018-06-30 0001314102 us-gaap:RestrictedStockUnitsRSUMember eypt:TwoThousandSixteenIncentivePlanMember 2018-06-30 0001314102 2018-06-30 0001314102 eypt:SeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-06-26 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:AdditionalAdvanceMember 2018-06-26 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheWarrantsMember 2018-06-25 0001314102 eypt:TwoThousandAndEighteenEquityFinancingMember eypt:SecondTrancheTransactionMember 2018-06-22 0001314102 us-gaap:RetainedEarningsMember 2017-06-30 0001314102 us-gaap:CommonStockMember 2017-06-30 0001314102 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0001314102 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001314102 2017-06-30 0001314102 eypt:PerformanceConditionOneMember eypt:PerformanceStockUnitsMember us-gaap:ScenarioForecastMember 2019-03-31 0001314102 eypt:FirstTrancheSecuritiesPurchaseAgreementMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:AdditionalAdvanceMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:InitialAdvanceMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember eypt:SWKFundingLLCMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember us-gaap:WarrantMember eypt:InitialAdvanceMember 2018-03-28 0001314102 eypt:SeniorSecuredTermLoanMember 2018-03-28 0001314102 eypt:IconBioscienceIncMember eypt:DEXYCUMember 2018-03-28 0001314102 eypt:IconBioscienceIncMember 2018-03-28 0001314102 2018-11-05 0001314102 eypt:TwoThousandSixteenIncentivePlanMember 2016-12-12 shares iso4217:USD iso4217:USD shares eypt:Payments pure eypt:Tranches utr:sqft eypt:Renewal_Options eypt:Country EX-101.SCH 12 eypt-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Operations and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Acquisition of Icon Bioscience, Inc. link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Term Loan Agreement link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Share-Based Payment Awards link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Share-Based Payment Awards (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Operations and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Acquisition of Icon Bioscience, Inc - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Term Loan Agreement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Stockholders' Equity - 2018 Equity Financing - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Stockholders' Equity - ATM Facility & Share Offering - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Share-Based Payment Awards - Stock Options - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Share-Based Payment Awards - Performance-Based Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Share-Based Payment Awards - Summary of Deferred Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Share-Based Payment Awards - Market-Based Restricted Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Share-Based Payment Awards - Other Inducement Grants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Share-Based Payment Awards - Key Assumptions Used to Apply Option Pricing Model For Options Granted (2016 Long Term Incentive Plan) (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Share-Based Payment Awards - Summary of Other Inducement Award Grants (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Share-Based Payment Award - Stock-Based Compensation Expense - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of the Company's Derivative Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 13 eypt-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 14 eypt-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 15 eypt-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 16 eypt-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
3 Months Ended
Sep. 30, 2018
Nov. 05, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Trading Symbol EYPT  
Entity Registrant Name EyePoint Pharmaceuticals, Inc.  
Entity Central Index Key 0001314102  
Current Fiscal Year End Date --06-30  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   94,855,705
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Jun. 30, 2018
Current assets:    
Cash and cash equivalents $ 55,764 $ 38,776
Accounts and other receivables 489 353
Prepaid expenses and other current assets 1,389 780
Total current assets 57,642 39,909
Property and equipment, net 320 253
Intangible assets, net 30,743 31,358
Restricted cash 150 150
Total assets 88,855 71,670
Current liabilities:    
Accounts payable 4,075 2,940
Accrued expenses 3,343 3,723
Accrued development milestone 15,000 15,000
Total current liabilities 22,418 21,663
Long-term debt 17,463 17,309
Derivative liability 0 19,780
Other long-term liabilities 1,269 1,231
Total liabilities 41,150 59,983
Stockholders' equity:    
Preferred stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $.001 par value, 150,000,000 shares authorized, 94,696,272 and 74,512,048 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively 95 74
Additional paid-in capital 443,671 374,766
Accumulated deficit (396,899) (363,991)
Accumulated other comprehensive income 838 838
Total stockholders' equity 47,705 11,687
Total liabilities and stockholders' equity $ 88,855 $ 71,670
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Jun. 30, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 94,696,272 74,512,048
Common stock, shares outstanding 94,696,272 74,512,048
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Revenues:    
Total revenues $ 486 $ 385
Operating expenses:    
Research and development 6,233 3,819
Sales and marketing 3,646 0
General and administrative 4,161 2,572
Total operating expenses 14,040 6,391
Operating loss (13,554) (6,006)
Interest and other income, net 129 23
Interest expense (815) 0
Change in fair value of derivative liability (18,886) 0
Net loss $ (33,126) $ (5,983)
Net loss per common share:    
Basic and diluted $ (0.44) $ (0.15)
Weighted average common shares:    
Basic and diluted 75,170 39,430
Net loss $ (33,126) $ (5,983)
Other comprehensive income:    
Foreign currency translation adjustments 0 4
Other comprehensive income 0 4
Comprehensive loss (33,126) (5,979)
Collaborative Research and Development [Member]    
Revenues:    
Total revenues 56 140
Royalty Income [Member]    
Revenues:    
Total revenues $ 430 $ 245
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Balance at Jun. 30, 2017 $ 13,336 $ 39 $ 323,284 $ (310,820) $ 833
Balance, shares at Jun. 30, 2017   39,356,999      
Net loss (5,983) $ 0 0 (5,983) 0
Other comprehensive income 4 0 0 0 4
Issuance of stock, net of issue costs 963 $ 1 962 0 0
Issuance of stock, shares   843,784      
Stock-based compensation 681 $ 0 681 0 0
Balance at Sep. 30, 2017 9,001 $ 40 324,927 (316,803) 837
Balance, shares at Sep. 30, 2017   40,200,783      
Balance at Jun. 30, 2018 $ 11,687 $ 74 374,766 (363,991) 838
Balance, shares at Jun. 30, 2018 74,512,048 74,512,048      
Net loss $ (33,126) $ 0 0 (33,126) 0
Exercise of warrants 28,863 $ 21 28,842 0 0
Other comprehensive income 0        
Exercise of warrants , shares   20,184,224      
Settlement of derivative liability $ 38,666 $ 0 $ 38,666 $ 0 $ 0
Settlement of derivative liability, shares 0 0 0 0 0
Stock-based compensation $ 1,397 $ 0 $ 1,397 $ 0 $ 0
Balance at Sep. 30, 2018 $ 47,705 $ 95 443,671 (396,899) 838
Balance, shares at Sep. 30, 2018 94,696,272 94,696,272      
Cumulative effect adjustment for adoption of new accounting principle $ 218 $ 0 $ 0 $ 218 $ 0
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Cash flows from operating activities:      
Net loss $ (33,126) $ (5,983)  
Adjustments to reconcile net loss to cash flows used in operating activities:      
Amortization of intangible assets 615 182 $ 981
Depreciation of property and equipment 43 39  
Amortization of debt discount 154 0  
Stock-based compensation expense 1,397 681  
Change in fair value of derivative liability 18,886 0  
Changes in operating assets and liabilities:      
Accounts receivable and other current assets (529) 129  
Accounts payable and accrued expenses 756 (972)  
Deferred revenue 0 (40)  
Deferred rent 38 (4)  
Net cash used in operating activities (11,766) (5,968)  
Cash flows from investing activities:      
Purchases of property and equipment (109) (64)  
Net cash used in investing activities (109) (64)  
Cash flows from financing activities:      
Proceeds from exercise of warrants 28,863 0  
Proceeds from issuance of stock, net of issuance costs 0 963  
Net cash provided by financing activities 28,863 963  
Effect of foreign exchange rate changes on cash and cash equivalents 0 4  
Net increase (decrease) in cash, cash equivalents and restricted cash 16,988 (5,065)  
Cash, cash equivalents and restricted cash at beginning of period 38,926 17,048 17,048
Cash, cash equivalents and restricted cash at end of period 55,914 11,983 $ 38,926
Supplemental cash flow information:      
Cash interest paid $ 583 $ 0  
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Operations and Basis of Presentation
3 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Operations and Basis of Presentation

1. Operations and Basis of Presentation

The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (collectively, the “Company”) as of September 30, 2018 and for the three months ended September 30, 2018 and 2017 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2018 (“fiscal 2018”). In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2018, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.

The Company is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Following U.S. Food and Drug Administration (“FDA”) approval of DEXYCU™ and YUTIQ™, the Company is targeting the direct U.S. commercial launch of YUTIQ in the first quarter of calendar 2019 and DEXYCU in the first half of calendar 2019.

DEXYCU™ (dexamethasone intraocular suspension) 9%, approved by the FDA in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes the Company’s proprietary Verisome® drug-delivery platform, which allows for a single injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and the Company expects to launch DEXYCU in the U.S. in the first half of 2019 with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (“Icon”) in March 2018.

YUTIQ™, a non-erodible fluocinolone acetonide insert for the treatment of chronic non-infectious posterior uveitis affecting the posterior segment of the eye (chronic “NIPU”), was approved by the FDA on October 12, 2018. Injected into the eye in an office visit, YUTIQ is a micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis (zero order release) for approximately three years. YUTIQ is based on the Company’s proprietary Durasert™ sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. NIPU is the third leading cause of blindness in the U.S. and is estimated to affect between 55,000 to 120,000 people. The Company expects to launch YUTIQ in the U.S. in the first quarter of calendar 2019.

ILUVIEN® for diabetic macular edema (“DME”), the Company’s lead licensed product, was also developed from the Durasert technology platform and is sold directly in the U.S. and several European Union (“EU”) countries by Alimera Sciences, Inc. (“Alimera”). Retisert®, one of the Company’s earlier generation products, was approved in 2005 by the FDA for the treatment of chronic NIPU and is sold in the U.S. by Bausch & Lomb Incorporated (“Bausch & Lomb”). The Company’s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company’s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.

The Company has financed its operations primarily from sales of equity securities, issuance of debt and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company’s anticipated recurring use of cash to fund operations in combination with no probable source of additional capital raises substantial doubt about its ability to continue as a going concern for one year from the issuance of its financial statements. The Company received proceeds of $28.9 million in late September 2018 from the exercise of investor warrants (the “Second Tranche Warrants) (see Note 8) and had total cash and cash equivalents of $55.8 million at September 30, 2018. The Company believes that its cash and cash equivalents of $55.8 million at September 30, 2018, and expected proceeds from existing collaboration agreements, will enable the Company to maintain its current and planned operations (including continuation of its two Phase 3 clinical trials for YUTIQ and plans for the U.S. commercial launch of both DEXYCU and YUTIQ) into the second quarter of calendar year 2019. In order to extend the Company’s ability to fund its operations beyond then, management’s plans include obtaining additional equity financing and/or additional debt financing and/or, as applicable, reducing or deferring operating expenses. The timing and extent of the Company’s implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaborations or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant revenues from its planned commercialization of DEXYCU or YUTIQ, or from its product license revenues under existing collaboration agreements or be able to obtain financing from any other sources.

Recently Adopted and Recently Issued Accounting Pronouncements

New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted accounting pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.

The Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, with a date of initial application of July 1, 2018. As a result, the Company has updated its accounting policy for revenue recognition to reflect the new standard (see Note 2). The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company’s services and will provide financial statement readers with enhanced disclosures. The Company applied ASC 606 using the modified retrospective method. The cumulative effect of initially applying the new revenue standard resulted in a $218,000 reduction to the opening balance of accumulated deficit at July 1, 2018.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Based on the change in the Company’s fiscal year (see Note 14), ASU 2016-02 will become effective on January 1, 2019. A modified retrospective transition approach is required for lessee capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. The standard aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the new guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but not before an entity adopts the new revenue guidance. ASU 2018-07, which was early adopted on July 1, 2018, did not have a significant impact on the Company’s financial statements.

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
3 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

Collaborative research and development revenue — The Company analyzes each element of its collaborative arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of September 30, 2018.

Reimbursement of costs — The Company may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. The Company acts primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. The Company records the expenses incurred and reimbursed on a gross basis.

Royalties — The Company recognizes revenue from license arrangements with its commercial partners’ net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. The Company’s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial.

Feasibility Studies — The Company recognizes revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the feasibility study agreement.

Please refer to Note 4 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition of Icon Bioscience, Inc.
3 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Acquisition of Icon Bioscience, Inc.

3. Acquisition of Icon Bioscience, Inc.

On March 28, 2018, the Company and its newly-created wholly-owned subsidiary, Oculus Merger Sub, Inc., acquired Icon, a specialty biopharmaceutical company, through a reverse triangular merger (the “Icon Acquisition”) pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) between the Company, Icon, and Shareholder Representative Services LLC (“SRS”), solely in its capacity as representative of Icon’s securityholders. The Icon Acquisition was accounted for as an asset acquisition because substantially all of the fair value of the gross assets acquired were deemed to be concentrated in a group of similar identifiable assets related to Icon’s lead product, DEXYCU. A portion of the Icon Acquisition was funded by an equity financing and a debt financing, both of which closed concurrently with the Icon Acquisition (see Notes 7 and 8).

Pursuant to the Merger Agreement, the Company made a closing payment of $15.0 million to SRS, net of an estimated $127,000 working capital adjustment, and is obligated to pay certain post-closing contingent cash payments upon the achievement of specified milestones and based upon certain net sales and partnering revenue standards, in each case subject to the terms and conditions set forth in the Merger Agreement. These include but are not limited to (i) a one-time development milestone of $15.0 million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0 million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare & Medicaid Services (“CMS”) reimbursement conditions set forth in the Merger Agreement, (iii) quarterly earn-out payments equal to 12% on net sales of DEXYCU in a given year, which earn-out payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual DEXYCU consideration exceeds $200.0 million in such year, (iv) quarterly earn-out payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v) single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition.

The purchase price on the date of the Icon Acquisition was $32.0 million, comprising the closing consideration of $15.0 million, including the assumption of an estimated $127,000 of net current liabilities of Icon, the contingent development milestone payment of $15.0 million and transaction costs of approximately $2.0 million. Given the stage of development of DEXYCU, the Company determined these payments did not represent research and development costs. The contingent consideration in the form of sales milestones will be capitalized as additional intangible assets when any such consideration becomes probable and can be reasonably estimated. Sales-based royalty payments will be expensed as incurred.

The $32.0 million purchase price was allocated to a single finite-lived intangible asset with an expected amortization life of approximately 13 years. The intangible asset is being amortized on a straight-line basis over that period. The acquisition did not have a net tax impact due to a full valuation allowance against the acquired net deferred tax assets.

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
License and Collaboration Agreements
3 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License and Collaboration Agreements

4. License and Collaboration Agreements

Alimera

Under a collaboration agreement with Alimera, as amended in March 2008 (the “Prior Alimera Agreement”), the Company licensed to Alimera the rights to develop, market and sell certain product candidates, including ILUVIEN for DME, and Alimera assumed all financial responsibility for the development of the licensed products. In addition, the Company was entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera, measured on a quarter-by-quarter and country-by-country basis. Alimera was entitled to recover 20% of previously incurred and unapplied net losses (as defined) for commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company’s net profit share to 16% in each country until those net losses were recouped. In the event that Alimera sublicensed commercialization in any country, the Company was entitled to 20% of royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company was also entitled to reimbursement of certain patent maintenance costs with respect to the patents licensed to Alimera.

On July 10, 2017, the Company entered into a further amended and restated collaboration agreement (the “Amended Alimera Agreement”), pursuant to which the Company (i) licensed its three-year NIPU product candidate (called YUTIQ in the U.S. and planned to be called ILUVIEN in Europe, the Middle East and Africa (“EMEA”)) to Alimera for the EMEA and (ii) converted the net profit share arrangement for each licensed product (including ILUVIEN) under the Prior Alimera Agreement to a sales-based royalty on a calendar quarter basis commencing July 1, 2017, with payments from Alimera due 60 days following the end of each quarter.

 

Sales-based royalties start at the rate of 2%. Commencing January 1, 2019, the sales-based royalty will increase to 6% on aggregate calendar year net sales up to $75 million and 8% in excess of $75 million. Alimera’s share of contingently recoverable accumulated ILUVIEN commercialization losses under the Prior Alimera Agreement, capped at $25 million, are to be reduced as follows: (i) $10.0 million was cancelled in lieu of an upfront license fee on the effective date of the Amended Alimera Agreement; (ii) for calendar years 2019 and 2020, 50% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments otherwise due from Alimera; (iii) on January 1, 2020, another $5 million will be cancelled, provided, however, that such date of cancellation may be extended under certain circumstances related to Alimera’s regulatory approval process for the ILUVIEN three-year NIPU product candidate, with such extension, if any, subject to mutual agreement by the parties; and (iv) commencing in calendar year 2021, 20% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments due from Alimera until such time as the balance of the original $25 million of recoverable commercialization losses has been fully recouped.

Following the completion of the Amended Alimera Agreement, the Company withdrew its previously filed EU marketing approval application and its EU orphan drug designation for YUTIQ, and Alimera was responsible for filing a Type II variation for ILUVIEN for the treatment of NIPU. In January 2018, Alimera received validation of a Type II variation submitted in December 2017 in all seventeen European countries in which it previously received regulatory approval for ILUVIEN for DME. If the variation is approved, Alimera plans to commercialize the indication for NIPU under its ILUVIEN trademark.

Revenue under the Prior Alimera Agreement and/or the Amended Alimera Agreement totaled $249,000 and $90,000 for the three months ended September 30, 2018 and 2017, respectively. In addition to patent fee reimbursements in both periods, revenue included (i) $215,000 of accrued sales-based royalty income for the three months ended September 30, 2018 under the Amended Alimera Agreement and (ii) $50,000 of net profits received in the three months ended September 30, 2017 attributable to the fourth quarter of fiscal 2017 (recorded as collaborative research and development revenue under the Prior Alimera Agreement).

Prior to the July 1, 2018 adoption of ASC 606, the Company had recorded royalties earned from Alimera one quarter in arrears. Under ASC 606, the Company is required to accrue royalty income based on an estimate of royalties earned in each fiscal quarter, with a true-up to actual in the following quarter. As a result, $218,000 of royalties earned for the quarter ended June 30, 2018 that would have been recorded as royalty income in the three months ended September 30, 2018 have been accounted for as a cumulative effect adjustment to beginning accumulated deficit at July 1, 2018.

Bausch & Lomb

Pursuant to a licensing and development agreement, as amended, Bausch & Lomb has a worldwide exclusive license to make and sell Retisert in return for royalties based on sales. Royalty income totaled $215,000 and $245,000 for the three months ended September 30, 2018 and 2017, respectively. Accounts receivable from Bausch & Lomb totaled $225,000 at September 30, 2018 and $306,000 at June 30, 2018.

OncoSil Medical

The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly owned subsidiary of OncoSil Medical Ltd (“OncoSil”) for the development of BrachySil, the Company’s BioSilicon product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and certain milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year, the most recent of which was received in December 2017. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any licensed patent maintenance costs, sales-based royalties and sub-licensee sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. As of September 30, 2018, OncoSil has not received regulatory approval in any jurisdiction, although an application for CE Mark approval in Europe is pending. There was no revenue related to the OncoSil agreement in either of the three-month periods ended September 30, 2018 and 2017. As of September 30, 2018, no deferred revenue was recorded for this agreement.

 

Evaluation Agreements

The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third party drug candidates in the treatment of various diseases. Consideration received is generally recognized by the Company as revenue over the term of the feasibility study agreement. Revenues under evaluation agreements totaled $15,000 and $50,000 for the three months ended September 30, 2018 and 2017, respectively. At September 30, 2018 no deferred revenue was recorded for these agreements.

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets
3 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

5. Intangible Assets

The reconciliation of intangible assets for the three months ended September 30, 2018 and for the year ended June 30, 2018 was as follows (in thousands):

 

     Three Months
Ended
September 30,
2018
     Year Ended
June 30,
2018
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 68,322      $ 35,610  

Acquisition of Icon Bioscience Inc.

     —          31,973  

Foreign currency translation adjustments

     —          739  
  

 

 

    

 

 

 

Gross carrying amount at end of period

     68,322        68,322  
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

     (36,964      (35,246

Amortization expense

     (615      (981

Foreign currency translation adjustments

     —          (737
  

 

 

    

 

 

 

Accumulated amortization at end of period

     (37,579      (36,964
  

 

 

    

 

 

 

Net book value at end of period

   $ 30,743      $ 31,358  
  

 

 

    

 

 

 

The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization of intangible assets totaled $615,000 and $182,000 for the three months ended September 30, 2018 and 2017, respectively.

In connection with the Icon Acquisition (see Note 3), the initial purchase price of $32.0 million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of 12.5 years at the rate of approximately $2.5 million per year.

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses
3 Months Ended
Sep. 30, 2018
Payables and Accruals [Abstract]  
Accrued Expenses

6. Accrued Expenses

Accrued expenses consisted of the following at September 30, 2018 and June 30, 2018 (in thousands):

 

     September 30,
2018
     June 30,
2018
 

Clinical trial costs

   $ 1,039      $ 742  

Personnel costs

     1,204        1,763  

Professional fees

     722        926  

Interest

     332        254  

Other

     46        38  
  

 

 

    

 

 

 
   $ 3,343      $ 3,723  
  

 

 

    

 

 

 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Term Loan Agreement
3 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Term Loan Agreement

7. Term Loan Agreement

On March 28, 2018 (the “Closing Date”), the Company entered into a Credit Agreement (the “Credit Agreement”) among the Company, as borrower, SWK Funding LLC, as agent (the “Agent”), and the lenders party thereto from time to time (the “Lenders”), providing for a senior secured term loan of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was advanced (the “Initial Advance”). The remaining $5 million of the Loan was advanced on June 26, 2018 following satisfaction of the Minimum Capital Raise (as defined in the Credit Agreement) (the “Additional Advance”). The Loan may be increased by $10 million upon the request of the Company, subject to the Agent obtaining additional loan commitments and satisfaction of certain conditions in the Credit Agreement.

The Loan is due and payable on March 27, 2023 (the “Maturity Date”). The Loan bears interest at a per annum rate of the three-month LIBOR rate (subject to a 1.5% floor) plus 10.50%. The Credit Agreement permits the Company to pay interest only on the principal amount for the first eight payments (payments are due on a quarterly basis commencing May 15, 2018). Following the interest-only period, the Company will be required to make quarterly payments of interest, plus repayments of the principal in an aggregate amount of up to $1.67 million per quarter (the “Quarterly Principal Repayment Cap”). Subject to the Quarterly Principal Repayment Cap, the amount of any quarterly principal payments during any fiscal year of the Company is based on (x) a percentage of the year-to-date net revenue of the Company through the end of such quarter less (y) any prior quarterly principal and interest payments made during such fiscal year. In addition, the Company paid an upfront fee of 1.5% of the aggregate principal amount of the Loan. The Company is required to pay an exit fee equal to 6% of the aggregate principal amount advanced under the Credit Agreement (the “Exit Fee”), which amount is included in other long-term liabilities in the accompanying condensed consolidated balance sheet.

Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the Credit Agreement), all or any amounts outstanding with respect to the Loan may become due and payable upon request of the Agent or majority Lenders. Additionally, subject to certain exceptions, the Company is required to make mandatory prepayments of the Loan with the proceeds of assets sales and insurance proceeds. The Company may make a voluntary prepayment of the Loan, in whole, but not in part, at any time on or after the first anniversary of the Closing Date. All mandatory and voluntary prepayments of the Loan are subject to the payment of prepayment premiums as follows: (i) in the case of mandatory prepayments, if prepayment occurs prior to the first anniversary of the Closing Date, a customary make-whole amount equal to the amount of interest that would have accrued on the principal amount so prepaid had it remained outstanding through the first anniversary of the Closing Date, (ii) if prepayment occurs on or after the first anniversary of the Closing Date, but prior to the second anniversary of the Closing Date, 6% of the aggregate amount of the principal prepaid and (iii) if prepayment occurs on or after the second anniversary of the Closing Date, but prior to the third anniversary of the Closing Date, an amount equal to 1% of the principal prepaid. No prepayment premium is due on any principal prepaid on or after the third anniversary of the Closing Date.

In connection with the Loan, the Company issued a warrant (the “SWK Warrant”) to the Agent to purchase (a) 409,091 shares of Company common stock (the “Initial Advance Warrant Shares”) at an exercise price equal to $1.10 and (b) 77,721 shares of Company common stock (the “Additional Advance Warrant Shares”) at an exercise price of $1.93 per share. The SWK Warrant is exercisable (i) with respect to the Initial Advance Warrant Shares, any time on or after the Closing Date until the close of business on the 7-year anniversary of the Initial Advance and (ii) with respect to the Additional Advance Warrant Shares, any time on or after the closing of the Additional Advance until the close of business on the 7-year anniversary of the Additional Advance. The Agent may exercise the SWK Warrant on a cashless basis at any time. In the event the Agent exercises the SWK Warrant on a cashless basis the Company will not receive any proceeds.

The total debt discount related to the Initial Advance was $2.1 million and was comprised of (1) $1.8 million which included the 1.5% upfront fee, the Exit Fee and legal and other transaction costs, which were ratably allocated to each of the two tranches of the Loan based upon the total principal amount available to the Company under each tranche and (2) $353,000 related to the aggregate fair value of the Initial Advance Warrant Shares and the Additional Advance Warrant Shares. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest method.

The total debt issue costs related to the Additional Advance was $299,000 and was comprised of the allocated portions of the 1.5% upfront fee and the Exit Fee. This amount was recorded as a prepaid expense to be amortized ratably from the Closing Date through December 31, 2018. Through the date of the Additional Advance, $97,000 was amortized and the remaining balance of $202,000 was reclassified to debt discount. Together with the 6% Exit Fee on the Additional Advance and other transaction costs, total debt discount of $652,000 associated with the Additional Advance is being amortized over the remaining life of the Additional Advance portion of the Loan using the effective interest method.

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
3 Months Ended
Sep. 30, 2018
Federal Home Loan Banks [Abstract]  
Stockholders' Equity

8. Stockholders’ Equity

2018 Equity Financing

On the Closing Date, the Company entered into a Securities Purchase Agreement (the “First Tranche Securities Purchase Agreement”) with EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. (collectively, the “First Tranche Investors”), pursuant to which the Company offered and sold to the First Tranche Investors an aggregate of 8,606,324 shares of the Company’s common stock at a purchase price of $1.10 per share (the “First Tranche Purchase Price”) for aggregate gross proceeds of approximately $9.5 million (the “First Tranche Transaction”).

On the Closing Date, the Company entered into a Second Securities Purchase Agreement (the “Second Tranche Securities Purchase Agreement” and together with the First Tranche Securities Purchase Agreement, the “Securities Purchase Agreements”) with the First Tranche Investors and certain other accredited investors (collectively, the “Second Tranche Investors”). Following approval of the Company’s stockholders on June 22, 2018, the Company sold to the Second Tranche Investors an aggregate of 20,184,224 Units at a purchase price of $1.265 per Unit for gross proceeds of approximately $25.5 million. Each Unit consisted of (a) one share of the Company’s common stock and (b) one warrant to purchase a share of the Company’s common stock (the “Second Tranche Transaction” and together with the First Tranche Transaction, the “Equity Transactions”).

The warrants issued in the Second Tranche Transaction (each a “Second Tranche Warrant,” and collectively, the “Second Tranche Warrants”) were exercisable any time until on or prior to the close of business on the 15th business day following the date on which the holders of the Second Tranche Warrants received written notice from the Company that CMS had announced that a new C-Code had been established for DEXYCU. CMS approved transitional pass-through status and reimbursement through a C-code with an effective date of October 1, 2018. Following written notice of such approval to the holders of the Second Tranche Warrants on September 7, 2018, the Second Tranche Warrants were exercised in September 2018 at a purchase price of $1.43 per share for proceeds of approximately $28.9 million.

The Company determined that the Second Tranche Warrants were considered puttable warrants that represented an obligation indexed to a repurchase of the Company’s shares and would require a transfer of assets that require classification as liabilities. The initial valuation of the Second Tranche Warrants on June 25, 2018 of $18.2 million was re-measured at June 30, 2018, resulting in a change in fair value of derivative liability of approximately $1.6 million and a derivative liability balance of $19.8 million at June 30, 2018. The Second Tranche Warrants were revalued immediately prior to exercise and resulted in a change in fair value of approximately $18.9 million. The change in fair value was determined as the excess of the closing share price of the Company’s common stock on the respective dates of exercise notice submitted by each of the Second Tranche Investors over the $1.43 per share exercise price. Upon exercise of the Second Tranche Warrants, the resulting derivative liability balance of approximately $38.7 million was reclassified to equity.

ATM Facility

In February 2017, the Company entered into an ATM program pursuant to which, under its Form S-3 shelf registration statement, the Company may, at its option, offer and sell shares of its common stock from time to time for an aggregate offering price of up to $20.0 million. The Company will pay the sales agent a commission of up to 3.0% of the gross proceeds from the sale of such shares.

During the three months ended September 30, 2017, the Company sold 843,784 shares of its Common Stock under the ATM program at a weighted average price of $1.24 per share for gross proceeds of approximately $1.0 million. Share issue costs, including sales agent commissions, totaled $81,000 for the three months ended September 30, 2017. The Company did not sell any shares of its common stock pursuant to the ATM program during the three months ended September 30, 2018. At September 30, 2018, approximately $3.8 million of aggregate proceeds remains available to be utilized under the current ATM program.

 

Warrants to Purchase Common Shares

The following table provides a reconciliation of warrants to purchase shares of the Company’s common stock for the three months ended September 30, 2018 and 2017:

 

     Three Months Ended September 30,  
     2018      2017  
     Number of
Warrants
     Weighted
Average
Exercise
Price
     Number of
Warrants
     Weighted
Average
Exercise
Price
 

Balance at beginning of period

     486,812      $ 1.23        623,605      $ 2.50  

Expired

     —          —          (623,605      2.50  
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance and exercisable at end of period

     486,812      $ 1.23        —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

In connection with the Loan (see Note 7), the Company issued a warrant to purchase (i) 409,091 shares of Company common stock on March 28, 2018 at an exercise price of $1.10 per share with a seven-year term and (ii) 77,721 shares of Company common stock on June 26, 2018 at an exercise price of $1.93 per share with a seven-year term. At September 30, 2018 the weighted average remaining life of the warrants was 6.54 years.

At June 30, 2018 a total of 20,184,224 Second Tranche Warrants were outstanding with a variable exercise price and, accordingly, were excluded from the above table. These warrants were exercised in full in late September 2018.

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards
3 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Payment Awards

9. Share-Based Payment Awards

Equity Incentive Plans

The 2016 Long-Term Incentive Plan (the “2016 Plan”), approved by the Company’s stockholders on December 12, 2016 (the “Adoption Date”), provides for the issuance of up to 3,000,000 shares of the Company’s common stock reserved for issuance under the 2016 Plan plus any additional shares of the Company’s common stock that were available for grant under the 2008 Incentive Plan (the “2008 Plan”) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At September 30, 2018, a total of 1,497,886 shares were available for new awards.

Stock Options

The following table provides a reconciliation of stock option activity under the Company’s equity incentive plans for the three months ended September 30, 2018:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     6,460,244      $ 2.79        

Granted

     166,575        2.31        

Forfeited

     (10,600      2.76        

Expired

     (156,750      2.85        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     6,459,469      $ 2.76        7.26      $ 6,203  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     3,151,142      $ 3.34        5.20      $ 1,747  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

During the three months ended September 30, 2018, the Company granted 115,000 options to employees with ratable annual vesting over 3 years, 1,667 options to a non-executive director with 1-year cliff vesting and 49,908 options to an external consultant with 1-year cliff vesting. All option grants have a 10-year term. The weighted-average grant date fair value of these options was $1.31 per share. In determining the grant date fair value of option awards under the 2016 Plan during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   5.50 - 6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.78% -2.90%

Expected dividends

   0.0%

Options to purchase a total of 401,558 shares of the Company’s common stock vested during the three months ended September 30, 2018.

Time-Vested Restricted Stock Units

Time-vested restricted stock unit awards (“RSUs”) issued to date under the 2016 Plan generally vest on a ratable annual basis over 3 years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Company’s common stock on the date of grant.

The following table provides a reconciliation of RSU activity under the 2016 Plan for the three months ended September 30, 2018:

 

     Number of
Restricted
Stock Units
     Weighted
Average
Grant
Date Fair
Value
 

Nonvested at July 1, 2018

     898,129      $ 1.58  

Forfeited

     (2,300      1.81  
  

 

 

    

 

 

 

Nonvested at September 30, 2018

     895,829      $ 1.58  
  

 

 

    

 

 

 

At September 30, 2018, the weighted average remaining vesting term of the RSUs was 1.09 years.

Performance-Based Stock Units

Performance Stock Units (“PSUs”) were previously awarded to certain employees. The performance conditions associated with the PSU awards are as follows: (a) for one third of the PSUs, upon an FDA acceptance of the Company’s NDA submission of YUTIQ for review on or before March 31, 2018 and (b) for two-thirds of the PSUs, upon an FDA approval of YUTIQ on or before March 31, 2019. For each performance criteria that is achieved, 50% of the PSUs that are associated with that performance condition vest at the achievement date and 50% vest on the first anniversary of such date, in each case subject to continued employment through such date. As a result of the achievement of the first performance condition on March 19, 2018, 48,332 PSUs vested at that date and the other 48,334 PSUs became subject to a service-based condition with a vesting date of March 19, 2019. On October 12, 2018, the second performance condition associated with the PSUs was achieved and, accordingly, cumulative stock-based compensation from the PSU award date through September 30, 2018 was recorded for that portion of the PSUs during the three months ended September 30, 2018.

There were 241,668 PSUs outstanding at each of September 30, 2018 and June 30, 2018. The weighted average remaining vesting term of the time-based RSUs associated with achievement of the first performance condition was approximately 5.6 months at September 30, 2018.

 

Deferred Stock Units

The following table provides a reconciliation of deferred stock units (“DSUs”) for the three months ended September 30, 2018:

 

     Number of
Deferred
Stock Units
     Weighted
Average
Grant Date
Fair Value
 

Outstanding at July 1, 2018

     35,001      $ 1.95  

Granted

     417        2.32  
  

 

 

    

 

 

 

Outstanding at September 30, 2018

     35,418      $ 1.95  
  

 

 

    

 

 

 

Each DSU vests one year from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company’s common stock upon the earliest to occur of (i) each director’s termination of service on the Company’s Board of Directors and (ii) the occurrence of a change of control as defined in the award agreement.

At September 30, 2018, the weighted average remaining vesting term of the DSUs was approximately 8.8 months.

Market-Based Restricted Stock Units

At September 30, 2018 and June 30, 2018, there were 500,000 market-based RSUs (“market-based RSUs”) outstanding that were issued on September 15, 2016 as an inducement award to the Company’s President and CEO Subject to a service condition through September 15, 2019, the number of shares underlying the market-based RSUs that will vest will be based upon a relative percentile rank of the 3-year change in the closing price of the Company’s common stock compared to that of the companies that make up the Nasdaq Biotechnology Index. The grant date fair value of the market-based RSUs of $1.45 per share was determined using a Monte Carlo valuation model at the date of grant.

Other Inducement Grants

In connection with the August 1, 2018 hire of the Company’s Chief Financial Officer, the Company granted as inducement awards (i) 385,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.22 per share; and (ii) 225,000 PSUs. The PSUs are subject to proportional vesting based on cumulative measurement for the 3-year period ending June 30, 2021, with two-thirds of the award based upon defined amounts of the Company’s product revenues and one-third based upon the net present value of each applicable business development transaction measured as of the date that each such transaction is consummated by the Company.

In connection with the August 14, 2018 hire of the Company’s Senior Vice President of Regulatory and Quality, the Company granted as an inducement award 100,000 options to purchase Company common stock with ratable annual vesting over 3 years and an exercise price of $2.10 per share.

In determining the grant date fair value of inducement option awards during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.81% - 2.92%

Expected dividends

   0.0%

The inducement option grants have a 10-year term and, although not awarded under the 2016 Plan, are subject to and governed by the terms and conditions of the 2016 Plan. The weighted average grant date fair value of the inducement grants was $1.27.

 

The following table provides a reconciliation of the Company’s inducement stock option awards for the three months ended September 30, 2018:

 

     Number of
options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     1,290,000      $ 3.06        

Granted

     485,000        2.20        

Forfeited

     (250,000      1.95        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     1,525,000      $ 2.96        7.60      $ 975  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     615,000      $ 3.11        5.58      $ 308  
  

 

 

    

 

 

    

 

 

    

 

 

 

Stock-Based Compensation Expense

The Company’s consolidated statements of comprehensive loss included total compensation expense from stock-based payment awards for the three months ended September 30, 2018 and 2017, as follows (in thousands):

 

     Three Months
Ended
September 30,
 
     2018      2017  

Compensation expense included in:

     

Research and development

   $ 486      $ 304  

Sales and marketing

     263        —    

General and administrative

     648        377  
  

 

 

    

 

 

 
   $ 1,397      $ 681  
  

 

 

    

 

 

 

In connection with termination benefits provided to the Company’s former Executive Vice President and General Manager, US, the vesting of certain options was accelerated in accordance with the terms of the options, with an exercise period through December 26, 2018. All remaining non-vested options were forfeited. The option modifications and forfeitures were accounted for in the quarter ended September 30, 2018, the net effect of which resulted in a $171,000 increase of stock-based compensation expense included in sales and marketing for the three months ended September 30, 2018 in the table above.

At September 30, 2018, there was approximately $5.2 million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan and the inducement awards that is expected to be recognized as expense over a weighted-average period of approximately 1.6 years.

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
3 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements

10. Fair Value Measurements

The following tables summarize the Company’s assets and liabilities carried at fair value measured on a recurring basis at September 30, 2018 and June 30, 2018 by valuation hierarchy (in thousands):

 

     September 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
     June 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Derivative liabilities

   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 

Financial instruments that potentially subject the Company to concentrations of credit risk have historically consisted principally of cash and cash equivalents. At September 30, 2018 and June 30, 2018, substantially all of the Company’s interest-bearing cash equivalent balances were concentrated in one U.S. Government institutional money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. These deposits may be redeemed upon demand and, therefore, generally have minimal risk. The Company’s cash equivalents are classified within Level 1 on the basis of valuations using quoted market prices.

Upon the closing of the Second Tranche Transaction on June 25, 2018, the Company issued the Second Tranche Warrants, which were determined to be liability classified, which required that the liability be measured at fair value each period with changes in fair value being recorded as a component of net loss in the consolidated statement of comprehensive loss. This valuation was determined to be a level 3 valuation because it included unobservable inputs. The Second Tranche Warrants were valued using a Monte Carlo simulation valuation model. This model incorporated several inputs, including the closing price of the Company’s common stock on the date of valuation, the historical share price volatility over the expected term and the risk-free interest rate. The resulting derivative liability at June 30, 2018 was $19.8 million. Significant assumptions used to re-measure this liability at June 30, 2018 included volatility of 85.40%, risk free interest rate of 2.10%, a term of 6 months and the valuation date stock price of $2.08.

The Second Tranche Investors delivered exercise notices covering all of the Second Tranche Warrants during the period from September 25 - 28, 2018 (see Note 8). The Company revalued the Second Tranche Warrants liability immediately prior to the respective exercise notice dates of the Second Tranche Investors, measured as the excess of the closing share price on the exercise notice date over the actual warrant exercise price of $1.43 per share times the number of shares purchased. The resulting liability balance was then reclassified to equity.

 

The following table sets forth a summary of changes in the fair value of the Company’s derivative liability for which fair value is determined by Level 3 inputs (in thousands):

 

     Second Tranche
Warrants
 

Balance at June 30, 2018

   $ 19,780  

Change in fair value

     18,886  

Reclassification to equity

     (38,666
  

 

 

 

Balance at September 30, 2018

   $ —    
  

 

 

 
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
3 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes

11. Income Taxes

The Company recognizes deferred tax assets and liabilities for estimated future tax consequences of events that have been recognized in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established if, based on management’s review of both positive and negative evidence, it is more likely than not that all or a portion of the deferred tax assets will not be realized. Because of its historical losses from operations, the Company established a valuation allowance for the net deferred tax assets. The Company did not record any income tax expense or benefit for the three months ended September 30, 2018 and 2017.

For the three months ended September 30, 2018 and 2017, the Company had no significant unrecognized tax benefits. At September 30, 2018 and June 30, 2018, the Company had no accrued penalties or interest related to uncertain tax positions.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted which, amongst other corporate and individual tax law changes, lowered the federal corporate income tax rate from 34% to 21% effective January 1, 2018. Because the Company provides a full valuation allowance for all of its net deferred tax assets, there is no effect of the Tax Act on the Company’s consolidated financial statements as of and for the three months ended September 30, 2018.

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
3 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

12. Commitments and Contingencies

Operating Leases

On May 17, 2018, the Company entered into a Second Amendment (the “Second Amendment”) to its lease in Watertown, Massachusetts. The original 5-year lease for approximately 13,650 square feet of combined office and laboratory space (the “Existing Space”) of the building located at 480 Pleasant Street, Watertown, MA 02472 (the “Premises”) and was set to expire in April 2019. Under the Second Amendment, the Company leased an additional 6,590 square feet of rentable area (the “Additional Space”, and together with the Existing Space, the “Total Space”) on the Premises, with a commencement date of September 10, 2018 (the “Additional Space Effective Time”). The landlord agreed to provide the Company a construction allowance of up to $670,750 to be applied toward the aggregate work to be conducted on the Total Space. The Second Amendment extended the term of the lease, which will now expire on May 31, 2025; provided, however, that the base rent for the Total Space will be abated during the first four months following the Additional Space Effective Time. The Company also has an option to extend the term of the lease for one additional five-year period. The Company previously provided a cash-collateralized $150,000 irrevocable standby letter of credit as security for the Company’s obligations under the lease, which was extended for a period of four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises.

Commencing July 1, 2017, the Company leased approximately 3,000 square feet of office space in Liberty Corner, New Jersey under a lease term extending through June 2022, with two five-year renewal options at 95% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional 1,381 square feet of adjoining space from Caladrius Biosciences, Inc. (“Caladrius”) through May 2022. The Chief Executive Officer of Caladrius is a director of the Company.

 

Legal Proceedings

The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company’s financial position, results of operations or cash flows.

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share
3 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Net Loss per Share

13. Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the basic weighted average number of common shares outstanding the total number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive. Potentially dilutive shares were not included in the calculation of diluted net loss per share for each of the three months ended September 30, 2018 and 2017 as their inclusion would be anti-dilutive.

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended
September 30,
 
     2018      2017  

Options outstanding

     7,984,469        5,740,155  

Warrants outstanding

     486,812        —    

Restricted stock units outstanding

     1,395,829        948,500  

Performance stock units outstanding

     466,668        210,000  

Deferred stock units outstanding

     35,418        —    
  

 

 

    

 

 

 
     10,369,196        6,898,655  
  

 

 

    

 

 

 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Event
3 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
Subsequent Event

14. Subsequent Event

On November 1, 2018, the Board of Directors approved a change in the Company’s fiscal year from June 30 to December 31, effective immediately. The Company will file a transition report on Form 10-KT for the six months ending December 31, 2018 with the U.S. Securities and Exchange Commission in connection with its newly adopted fiscal year.

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Revenue Recognition

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

Collaborative research and development revenue — The Company analyzes each element of its collaborative arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of these future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of September 30, 2018.

Reimbursement of costs — The Company may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. The Company acts primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. The Company records the expenses incurred and reimbursed on a gross basis.

Royalties — The Company recognizes revenue from license arrangements with its commercial partners’ net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner’s products occurs. The Company’s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60 days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company accrues royalty revenue each quarter and subsequently determines a true-up when it receives royalty reports from its commercial partners. Historically, these true-up adjustments have been immaterial.

Feasibility Studies — The Company recognizes revenue over the term of the feasibility study agreement. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the feasibility study agreement.

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets (Tables)
3 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Reconciliation of Intangible Assets

The reconciliation of intangible assets for the three months ended September 30, 2018 and for the year ended June 30, 2018 was as follows (in thousands):

 

     Three Months
Ended
September 30,
2018
     Year Ended
June 30,
2018
 

Patented technologies

     

Gross carrying amount at beginning of period

   $ 68,322      $ 35,610  

Acquisition of Icon Bioscience Inc.

     —          31,973  

Foreign currency translation adjustments

     —          739  
  

 

 

    

 

 

 

Gross carrying amount at end of period

     68,322        68,322  
  

 

 

    

 

 

 

Accumulated amortization at beginning of period

     (36,964      (35,246

Amortization expense

     (615      (981

Foreign currency translation adjustments

     —          (737
  

 

 

    

 

 

 

Accumulated amortization at end of period

     (37,579      (36,964
  

 

 

    

 

 

 

Net book value at end of period

   $ 30,743      $ 31,358  
  

 

 

    

 

 

 
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses (Tables)
3 Months Ended
Sep. 30, 2018
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following at September 30, 2018 and June 30, 2018 (in thousands):

 

     September 30,
2018
     June 30,
2018
 

Clinical trial costs

   $ 1,039      $ 742  

Personnel costs

     1,204        1,763  

Professional fees

     722        926  

Interest

     332        254  

Other

     46        38  
  

 

 

    

 

 

 
   $ 3,343      $ 3,723  
  

 

 

    

 

 

 
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
3 Months Ended
Sep. 30, 2018
Federal Home Loan Banks [Abstract]  
Summary of Reconciliation of Warrants to Purchase Common Stock

The following table provides a reconciliation of warrants to purchase shares of the Company’s common stock for the three months ended September 30, 2018 and 2017:

 

     Three Months Ended September 30,  
     2018      2017  
     Number of
Warrants
     Weighted
Average
Exercise
Price
     Number of
Warrants
     Weighted
Average
Exercise
Price
 

Balance at beginning of period

     486,812      $ 1.23        623,605      $ 2.50  

Expired

     —          —          (623,605      2.50  
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance and exercisable at end of period

     486,812      $ 1.23        —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards (Tables)
3 Months Ended
Sep. 30, 2018
Stock Option Activity Under Plan

The following table provides a reconciliation of the Company’s inducement stock option awards for the three months ended September 30, 2018:

 

     Number of
options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     1,290,000      $ 3.06        

Granted

     485,000        2.20        

Forfeited

     (250,000      1.95        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     1,525,000      $ 2.96        7.60      $ 975  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     615,000      $ 3.11        5.58      $ 308  
  

 

 

    

 

 

    

 

 

    

 

 

 
Schedule of Key Assumptions Used

In determining the grant date fair value of option awards under the 2016 Plan during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   5.50 - 6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.78% -2.90%

Expected dividends

   0.0%
Summary of Restricted Stock Unit Activity

The following table provides a reconciliation of RSU activity under the 2016 Plan for the three months ended September 30, 2018:

 

     Number of
Restricted
Stock Units
     Weighted
Average
Grant
Date Fair
Value
 

Nonvested at July 1, 2018

     898,129      $ 1.58  

Forfeited

     (2,300      1.81  
  

 

 

    

 

 

 

Nonvested at September 30, 2018

     895,829      $ 1.58  
  

 

 

    

 

 

 
Summary of Deferred Stock Unit Activity

The following table provides a reconciliation of deferred stock units (“DSUs”) for the three months ended September 30, 2018:

 

     Number of
Deferred
Stock Units
     Weighted
Average
Grant Date
Fair Value
 

Outstanding at July 1, 2018

     35,001      $ 1.95  

Granted

     417        2.32  
  

 

 

    

 

 

 

Outstanding at September 30, 2018

     35,418      $ 1.95  
  

 

 

    

 

 

 
Compensation Expense from Stock-Based Payment Awards

The Company’s consolidated statements of comprehensive loss included total compensation expense from stock-based payment awards for the three months ended September 30, 2018 and 2017, as follows (in thousands):

 

     Three Months
Ended
September 30,
 
     2018      2017  

Compensation expense included in:

     

Research and development

   $ 486      $ 304  

Sales and marketing

     263        —    

General and administrative

     648        377  
  

 

 

    

 

 

 
   $ 1,397      $ 681  
  

 

 

    

 

 

 
2016 Long Term Incentive Plan [Member]  
Stock Option Activity Under Plan

The following table provides a reconciliation of stock option activity under the Company’s equity incentive plans for the three months ended September 30, 2018:

 

     Number of
Options
     Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Life
     Aggregate
Intrinsic
Value
 
                   (in years)      (in thousands)  

Outstanding at July 1, 2018

     6,460,244      $ 2.79        

Granted

     166,575        2.31        

Forfeited

     (10,600      2.76        

Expired

     (156,750      2.85        
  

 

 

    

 

 

       

Outstanding at September 30, 2018

     6,459,469      $ 2.76        7.26      $ 6,203  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable at September 30, 2018

     3,151,142      $ 3.34        5.20      $ 1,747  
  

 

 

    

 

 

    

 

 

    

 

 

 
Other Inducement Grants [Member]  
Schedule of Key Assumptions Used

In determining the grant date fair value of inducement option awards during the three months ended September 30, 2018, the Company applied the Black-Scholes option pricing model based on the following key assumptions:

 

Option life (in years)

   6.00

Stock volatility

   59% - 60%

Risk-free interest rate

   2.81% - 2.92%

Expected dividends

   0.0%
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
3 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Assets and Liabilities Carried at Fair Value Measured on Recurring Basis

The following tables summarize the Company’s assets and liabilities carried at fair value measured on a recurring basis at September 30, 2018 and June 30, 2018 by valuation hierarchy (in thousands):

 

     September 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 25,955      $ 25,955      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
     June 30, 2018  
     Total
carrying value
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable inputs
(Level 3)
 

Assets:

           

Cash equivalents

   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 28,826      $ 28,826      $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Derivative liabilities

   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 19,780      $ —        $ —        $ 19,780  
  

 

 

    

 

 

    

 

 

    

 

 

 
Summary of Changes in the Fair Value of the Company's Derivative Liability

The following table sets forth a summary of changes in the fair value of the Company’s derivative liability for which fair value is determined by Level 3 inputs (in thousands):

 

     Second Tranche
Warrants
 

Balance at June 30, 2018

   $ 19,780  

Change in fair value

     18,886  

Reclassification to equity

     (38,666
  

 

 

 

Balance at September 30, 2018

   $ —    
  

 

 

 
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share (Tables)
3 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares

Potential common stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:

 

     Three Months Ended
September 30,
 
     2018      2017  

Options outstanding

     7,984,469        5,740,155  

Warrants outstanding

     486,812        —    

Restricted stock units outstanding

     1,395,829        948,500  

Performance stock units outstanding

     466,668        210,000  

Deferred stock units outstanding

     35,418        —    
  

 

 

    

 

 

 
     10,369,196        6,898,655  
  

 

 

    

 

 

 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Operations and Basis of Presentation - Additional Information (Detail) - USD ($)
3 Months Ended
Jul. 01, 2018
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Operations [Line Items]        
Cash and cash equivalents   $ 55,764,000   $ 38,776,000
Proceeds from exercise of investor warrants   $ 28,863,000 $ 0  
Accounting Standards Update 2014-09 [Member]        
Operations [Line Items]        
Decrease in beginning accumulated deficit resulting from the adoption of ASC 606 $ 218,000      
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition of Icon Bioscience, Inc - Additional Information (Detail) - Icon Bioscience Inc [Member] - USD ($)
3 Months Ended
Mar. 28, 2018
Sep. 30, 2018
Business Acquisition [Line Items]    
Acquisition date Mar. 28, 2018  
Consideration payment at closing $ 15,000,000  
Estimated working capital adjustment at closing (127,000)  
Development milestone payment due upon first commercial sales of DEXYCU 15,000,000  
Maximum of potential sales milestone payments $ 95,000,000  
Quarterly percentage earn-out on product net sales 12.00%  
Increased percentage earn-out on product net sales if net sales and partnering revenue exceed $200 million in a given year 16.00%  
Contingent cash payments, description   These include but are not limited to (i) a one-time development milestone of $15.0 million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0 million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare & Medicaid Services (“CMS”) reimbursement conditions set forth in the Merger Agreement, (iii) quarterly earn-out payments equal to 12% on net sales of DEXYCU in a given year, which earn-out payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual DEXYCU consideration exceeds $200.0 million in such year, (iv) quarterly earn-out payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v) single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition.
Purchase price of acquisition $ 32,000,000  
Transaction costs 2,000,000  
DEXYCU [Member]    
Business Acquisition [Line Items]    
Purchase price of acquisition $ 32,000,000  
Finite-lived intangible asset expected amortization life 13 years  
Minimum [Member]    
Business Acquisition [Line Items]    
Threshold level of annual aggregate consideration above which the 16% royalty on net sales applies in any given year $ 200,000,000  
Non-US [Member]    
Business Acquisition [Line Items]    
Percentage of partnering income received to be paid quarterly as earn-out consideration 20.00%  
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
License and Collaboration Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended
Jan. 01, 2021
Jan. 01, 2020
USD ($)
Jan. 01, 2019
USD ($)
Jul. 10, 2017
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2013
USD ($)
Sep. 30, 2018
USD ($)
Country
Sep. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Agreements And Contracts [Line Items]                  
Revenue             $ 486,000 $ 385,000  
Accounts receivable             489,000   $ 353,000
Collaborative Research and Development [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Revenue             $ 56,000 140,000  
ILUVIEN [Member] | Europe [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Number of countries in which lead licensed product received regulatory approval | Country             17    
Royalty Income [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Revenue             $ 430,000 245,000  
OncoSil Medical UK Limited [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Percentage of non-royalty consideration received from sublicense             20.00%    
Royalty percentage earned from sales of product             8.00%    
License agreement commencement date             2012-12    
Receipt of upfront license fee           $ 100,000      
Deferred revenue             $ 0    
OncoSil Medical UK Limited [Member] | Collaborative Research and Development [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Revenue         $ 100,000        
Prior Alimera Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Percentage of company's share of net profits             20.00%    
Pre-profitability net losses percentage             20.00%    
Maximum percentage offset of current period net profits against previously incurred and unapplied pre-profitability quarterly net losses             4.00%    
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses             16.00%    
Percentage of royalties received from sublicense             20.00%    
Percentage of non-royalty consideration received from sublicense             33.00%    
Amount received, profit share from sale of licensed products               50,000  
Amended Alimera Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Royalty percentage earned from sales of product             2.00%    
Contingently recoverable accumulated commercialization losses       $ 25,000,000          
Partial cancellation of contingently recoverable accumulated commercialization losses in lieu of upfront license fee       $ 10,000,000          
Accrued sales-based royalty income             $ 215,000    
Proceeds received from earned sales-based royalties             218,000    
Amended Alimera Agreement [Member] | Scenario, Forecast [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Calendar year net sales threshold for increase in royalty rate     $ 75,000,000            
Royalty percentage offset for amounts earned above 2% to be applied against balance of accumulated commercialization losses 20.00% 50.00% 50.00%            
Additional cancellation of contingently recoverable commercialization losses   $ 5,000,000              
Amended Alimera Agreement [Member] | Scenario, Forecast [Member] | Minimum [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Royalty percentage earned from sales of product     6.00%            
Amended Alimera Agreement [Member] | Scenario, Forecast [Member] | Maximum [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Royalty percentage earned from sales of product     8.00%            
Bausch and Lomb [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Accounts receivable             225,000   $ 306,000
Bausch and Lomb [Member] | Royalty Income [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Revenue             215,000 245,000  
Feasibility Study Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Deferred revenue             0    
Feasibility Study Agreement [Member] | Collaborative Research and Development [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Revenue             15,000 50,000  
Prior Alimera Agreement and/or Amended Alimera Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Total revenues earned from Alimera             $ 249,000 $ 90,000  
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Reconciliation of Intangible Assets (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]      
Gross carrying amount at beginning of period $ 68,322 $ 35,610 $ 35,610
Acquisition of Icon Bioscience Inc. 0   31,973
Foreign currency translation adjustments 0   739
Gross carrying amount at end of period 68,322   68,322
Accumulated amortization at beginning of period (36,964) (35,246) (35,246)
Amortization expense (615) $ (182) (981)
Foreign currency translation adjustments 0   (737)
Accumulated amortization at end of period (37,579)   (36,964)
Net book value at end of period $ 30,743   $ 31,358
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 28, 2018
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]        
Amortization expense   $ 615 $ 182 $ 981
DEXYCU [Member] | Icon Bioscience Inc [Member]        
Finite-Lived Intangible Assets [Line Items]        
Initial purchase price $ 32,000      
Annual amortization expense $ 2,500      
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Sep. 30, 2018
Jun. 30, 2018
Payables and Accruals [Abstract]    
Clinical trial costs $ 1,039 $ 742
Personnel costs 1,204 1,763
Professional fees 722 926
Interest 332 254
Other 46 38
Accrued expenses $ 3,343 $ 3,723
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Term Loan Agreement - Additional Information (Detail)
Jun. 26, 2018
USD ($)
$ / shares
shares
Mar. 28, 2018
USD ($)
Payments
Tranches
$ / shares
shares
Sep. 30, 2018
$ / shares
Jun. 30, 2018
$ / shares
Sep. 30, 2017
$ / shares
Jun. 30, 2017
$ / shares
Term Loan Agreement [Line Items]            
Exercise price of issued warrants | $ / shares     $ 1.23 $ 1.23 $ 0.00 $ 2.50
Senior Secured Term Loan [Member]            
Term Loan Agreement [Line Items]            
Upfront loan origination fee percentage   1.50%        
Debt issue costs   $ 1,800,000        
Cost allocated tranches, number | Tranches   2        
Aggregate Fairvalue of warrants   $ 353,000        
Senior Secured Term Loan [Member] | Initial Advance [Member]            
Term Loan Agreement [Line Items]            
Exit fee percentage   6.00%        
Debt discount   $ 2,100,000        
Senior Secured Term Loan [Member] | Additional Advance [Member]            
Term Loan Agreement [Line Items]            
Debt issue costs   $ 299,000        
Debt discount $ 652,000          
Amortized cost 97,000          
Debt issuance costs remaining balance reclassified to debt discount $ 202,000          
Senior Secured Term Loan [Member] | Warrants [Member]            
Term Loan Agreement [Line Items]            
Warrants exercise period 7 years 7 years        
Senior Secured Term Loan [Member] | Warrants [Member] | Initial Advance [Member]            
Term Loan Agreement [Line Items]            
Warrants issued in connection with loan | shares   409,091        
Exercise price of issued warrants | $ / shares   $ 1.10        
Senior Secured Term Loan [Member] | Warrants [Member] | Additional Advance [Member]            
Term Loan Agreement [Line Items]            
Warrants issued in connection with loan | shares 77,721          
Exercise price of issued warrants | $ / shares $ 1.93          
Senior Secured Term Loan [Member] | SWK Funding LLC [Member]            
Term Loan Agreement [Line Items]            
Agreement date   Mar. 28, 2018        
Senior secured term loan   $ 20,000,000        
Senior secured term loan, initial advance   15,000,000        
Senior secured term loan, additional advance that followed satisfaction of applicable conditions $ 5,000,000          
Potential future increase in the credit facility, subject to certain condition   $ 10,000,000        
Maturity date   Mar. 27, 2023        
Number of interest | Payments   8        
Loan repayment basis   Quarterly        
Date of first interest only payment   May 15, 2018        
Maximum amount of quarterly repayment of loan principal   $ 1,670,000        
Upfront loan origination fee percentage   1.50%        
Exit fee percentage   6.00%        
Senior Secured Term Loan [Member] | SWK Funding LLC [Member] | London Interbank Offered Rate (LIBOR) [Member]            
Term Loan Agreement [Line Items]            
Interest rate   Three-month LIBOR rate(subject to a 1.5% floor)plus 10.50%.        
LIBOR rate floor   1.50%        
Interest rate (subject to floor rate)   10.50%        
Senior Secured Term Loan [Member] | SWK Funding LLC [Member] | Prepayment After First Anniversary And On Or Prior To Second Anniversary [Member]            
Term Loan Agreement [Line Items]            
Principal prepayment premium percentage   6.00%        
Senior Secured Term Loan [Member] | SWK Funding LLC [Member] | Prepayment After Second Anniversary And On Or Prior To Third Anniversary [Member]            
Term Loan Agreement [Line Items]            
Principal prepayment premium percentage   1.00%        
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - 2018 Equity Financing - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jun. 22, 2018
Mar. 28, 2018
Sep. 30, 2018
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 25, 2018
Jun. 30, 2017
Class of Stock [Line Items]                
Exercise price of Second Tranche Warrants     $ 1.23 $ 1.23 $ 1.23 $ 0.00   $ 2.50
Change in fair value of derivative liability       $ (18,886)   $ 0    
Second Tranche Warrants [Member]                
Class of Stock [Line Items]                
Exercise price of Second Tranche Warrants     $ 1.43 $ 1.43        
Gross proceeds from exercise of warrants     $ 28,900          
First Tranche Securities Purchase Agreement [Member]                
Class of Stock [Line Items]                
Common stock issued to investors   8,606,324            
Common stock price per share   $ 1.10            
Gross proceeds from issuance of common stock   $ 9,500            
Second Securities Purchase Agreement [Member]                
Class of Stock [Line Items]                
Gross proceeds to be received from issuance of common shares, subject to stockholder approval $ 25,500              
2018 Equity Financing [Member] | Second Tranche Transaction [Member]                
Class of Stock [Line Items]                
Common stock issued to investors 20,184,224              
Common stock price per share $ 1.265              
2018 Equity Financing [Member] | Second Tranche Warrants [Member]                
Class of Stock [Line Items]                
Reclassification of the derivative liability balance to equity upon the exercise of the Second Tranche Warrants       $ 38,700        
Change in fair value of derivative liability       $ 18,900 $ 1,600      
Derivative liability balance         $ 19,800   $ 18,200  
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - ATM Facility & Share Offering - Additional Information (Detail) - At-the-Market Offering [Member] - USD ($)
1 Months Ended 3 Months Ended
Feb. 28, 2017
Sep. 30, 2018
Sep. 30, 2017
Class of Stock [Line Items]      
Common stock shares maximum aggregate offering price $ 20,000,000    
Stock issuances, sales agent commission maximum percentage 3.00%    
Common stock issued to investors   0 843,784
Weighted average common stock price per share     $ 1.24
Gross proceeds from issuance of common stock     $ 1,000,000
Share issuance costs     $ 81,000
Aggregate proceeds available from future issuances of common stock under the current ATM program   $ 3,800,000  
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail) - $ / shares
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Common Stock Warrants [Abstract]    
Number of Warrants, Outstanding and exercisable, Beginning balance 486,812 623,605
Number of Warrants, Expired 0 (623,605)
Number of Warrants, Outstanding and exercisable, Ending balance 486,812 0
Weighted Average Exercise Price, Outstanding and exercisable, Beginning balance $ 1.23 $ 2.50
Weighted Average Exercise Price, Expired 0.00 2.50
Weighted Average Exercise Price, Outstanding and exercisable, Ending balance $ 1.23 $ 0.00
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail) - $ / shares
3 Months Ended
Jun. 26, 2018
Mar. 28, 2018
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Class of Stock [Line Items]            
Warrants, outstanding     486,812 486,812 0 623,605
Second Tranche Warrants [Member]            
Class of Stock [Line Items]            
Warrants, outstanding       20,184,224    
Senior Secured Term Loan [Member] | Warrants [Member]            
Class of Stock [Line Items]            
Warrants issued in connection with term loan facility 77,721 409,091        
Exercise price of issued warrants $ 1.93 $ 1.10        
Warrants exercise period 7 years 7 years        
Weighted average remaining life of warrants     6 years 6 months 14 days      
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail) - 2016 Long Term Incentive Plan [Member] - shares
Sep. 30, 2018
Dec. 12, 2016
Class of Stock [Line Items]    
Number of common stock, authorized for issuance   3,000,000
Shares available for grant under the Long Term Incentive Plan, including forfeited and terminated awards transferred from the 2008 Incentive Plan 1,497,886  
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail) - Equity Incentive Plans [Member]
$ / shares in Units, $ in Thousands
3 Months Ended
Sep. 30, 2018
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Aggregate Intrinsic Value, Outstanding at September 30, 2018 | $ $ 6,203
Aggregate Intrinsic Value, Exercisable at September 30, 2018 | $ $ 1,747
Weighted Average Remaining Contractual Life, Outstanding at September 30, 2018 7 years 3 months 3 days
Weighted Average Remaining Contractual Life, Exercisable at September 30, 2018 5 years 2 months 12 days
Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares $ 2.79
Weighted Average Exercise Price, Granted | $ / shares 2.31
Weighted Average Exercise Price, Forfeited | $ / shares 2.76
Weighted Average Exercise Price, Expired | $ / shares 2.85
Weighted Average Exercise Price Outstanding, Ending balance | $ / shares 2.76
Weighted Average Exercise Price, Exercisable at September 30,2018 | $ / shares $ 3.34
Number of Options Outstanding, Beginning balance | shares 6,460,244
Number of Options, Granted | shares 166,575
Number of Options, Forfeited | shares (10,600)
Number of Options, Exercised | shares (156,750)
Number of Options Outstanding, Ending balance | shares 6,459,469
Number of Options, Exercisable at September 30 , 2018 | shares 3,151,142
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Stock Options - Additional Information (Detail)
3 Months Ended
Sep. 30, 2018
$ / shares
shares
Stock Compensation Plan [Member]  
Class of Stock [Line Items]  
Common stock vested during the period 401,558
2016 Long Term Incentive Plan [Member]  
Class of Stock [Line Items]  
Contractual life of option grants 10 years
Weighted-average grant date fair value per share | $ / shares $ 1.31
Employees [Member] | 2016 Long Term Incentive Plan [Member]  
Class of Stock [Line Items]  
Options granted 115,000
Vesting period of equity awards 3 years
Non-executive Directors [Member] | 2016 Long Term Incentive Plan [Member]  
Class of Stock [Line Items]  
Options granted 1,667
Vesting period of equity awards 1 year
External consultant [Member] | 2016 Long Term Incentive Plan [Member]  
Class of Stock [Line Items]  
Options granted 49,908
Vesting period of equity awards 1 year
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail) - 2016 Long Term Incentive Plan [Member]
3 Months Ended
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock volatility, minimum 59.00%
Stock volatility, maximum 60.00%
Risk-free interest rate, minimum 2.78%
Risk-free interest rate, maximum 2.90%
Expected dividends 0.00%
Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Option life (in years) 5 years 6 months
Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Option life (in years) 6 years
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail) - 2016 Long Term Incentive Plan [Member] - RSU [Member]
3 Months Ended
Sep. 30, 2018
Class of Stock [Line Items]  
Vesting period of equity awards 3 years
Weighted average remaining vesting term 1 year 1 month 2 days
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail) - 2016 Long Term Incentive Plan [Member] - RSU [Member]
3 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Stock Units Outstanding, Beginning Balance | shares 898,129
Number of Stock Units, Forfeited | shares (2,300)
Number of Stock Units Outstanding, Ending Balance | shares 895,829
Weighted Average Grant Date Fair Value Nonvested, Beginning balance | $ / shares $ 1.58
Weighted Average Grant Date Fair value, Forfeited | $ / shares 1.81
Weighted Average Grant Date Fair Value Nonvested, Ending balance | $ / shares $ 1.58
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Performance-Based Stock Units - Additional Information (Detail) - Performance Stock Units [Member] - shares
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2018
Mar. 19, 2018
Sep. 30, 2018
Jun. 30, 2018
Class of Stock [Line Items]            
Number of Stock Units Outstanding         241,668 241,668
Performance Condition One [Member]            
Class of Stock [Line Items]            
Stock units vesting, percentage     50.00%      
Portion of stock units subject to an FDA acceptance of the Company's NDA submission of YUTIQ for review on or before March 31, 2018         One third  
Number of Performance-Based Stock Units, vested       48,332    
Weighted average remaining vesting term         5 years 7 months 6 days  
Performance Condition Two [Member]            
Class of Stock [Line Items]            
Portion of stock units subject to an FDA approval of YUTIQ on or before March 31, 2019         Two-thirds  
Scenario, Forecast [Member] | Performance Condition One [Member]            
Class of Stock [Line Items]            
Stock units vesting, percentage   50.00%        
Number of performance-based stock units subject to service-based vesting of one year from performance condition achievement date   48,334        
Scenario, Forecast [Member] | Performance Condition Two [Member]            
Class of Stock [Line Items]            
Stock units vesting, percentage 50.00% 50.00%        
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Summary of Deferred Stock Unit Activity (Detail) - Deferred Stock Units [Member]
3 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Stock Units Outstanding, Beginning Balance | shares 35,001
Number of stock units, granted | shares 417
Number of Stock Units Outstanding, Ending Balance | shares 35,418
Weighted Average Grant Date Fair Value Nonvested, Beginning balance | $ / shares $ 1.95
Weighted average grant date fair value, granted | $ / shares 2.32
Weighted Average Grant Date Fair Value Nonvested, Ending balance | $ / shares $ 1.95
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)
3 Months Ended
Sep. 30, 2018
Deferred Stock Units [Member]  
Class of Stock [Line Items]  
Weighted average remaining vesting term 8 months 24 days
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Market-Based Restricted Stock Units - Additional Information (Detail) - Market-based RSUs [Member] - $ / shares
3 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Class of Stock [Line Items]    
Restricted stock units outstanding 500,000 500,000
Grant date fair value per share $ 1.45  
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Other Inducement Grants - Additional Information (Detail) - $ / shares
3 Months Ended
Aug. 14, 2018
Aug. 01, 2018
Sep. 30, 2018
Chief Financial Officer [Member]      
Class of Stock [Line Items]      
Options granted   385,000  
Vesting period of equity awards   3 years  
Exercise price of option   $ 2.22  
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award     The PSUs are subject to proportional vesting based on cumulative measurement for the 3-year period ending June 30, 2021, with two-thirds of the award based upon defined amounts of the Company's product revenues and one-third upon based on the net present value of each applicable business development transaction measured as of the date that each such transaction is consummated by the Company.
Senior Vice President [Member]      
Class of Stock [Line Items]      
Options granted 100,000    
Vesting period of equity awards 3 years    
Exercise price of option $ 2.10    
Other Inducement Grants [Member]      
Class of Stock [Line Items]      
Contractual life of option grants     10 years
Weighted average grant date fair value of the inducement grants     $ 1.27
Other Inducement Grants [Member] | Chief Financial Officer [Member]      
Class of Stock [Line Items]      
Number of performance stock units, granted   225,000  
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Key Assumptions Used to Apply Option Pricing Model For Options Granted (2016 Long Term Incentive Plan) (Detail) - Other Inducement Grants [Member]
3 Months Ended
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Option life (in years) 6 years
Stock volatility, minimum 59.00%
Stock volatility, maximum 60.00%
Risk-free interest rate, minimum 2.81%
Risk-free interest rate, maximum 2.92%
Expected dividends 0.00%
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Summary of Other Inducement Award Grants (Detail) - 2016 Long Term Incentive Plan [Member] - Other Inducement Grants [Member]
$ / shares in Units, $ in Thousands
3 Months Ended
Sep. 30, 2018
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Options Outstanding, Beginning balance | shares 1,290,000
Number of Options, Granted | shares 485,000
Number of Options, Forfeited | shares (250,000)
Number of Options Outstanding, Ending balance | shares 1,525,000
Number of Options, Exercisable at September 30 , 2018 | shares 615,000
Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares $ 3.06
Weighted Average Exercise Price, Granted | $ / shares 2.20
Weighted Average Exercise Price, Forfeited | $ / shares 1.95
Weighted Average Exercise Price Outstanding, Ending balance | $ / shares 2.96
Weighted Average Exercise Price, Exercisable at September 30,2018 | $ / shares $ 3.11
Weighted Average Remaining Contractual Life, Outstanding at September 30, 2018 7 years 7 months 6 days
Weighted Average Remaining Contractual Life, Exercisable at September 30, 2018 5 years 6 months 29 days
Aggregate Intrinsic Value, Outstanding at September 30, 2018 | $ $ 975
Aggregate Intrinsic Value, Exercisable at September 30, 2018 | $ $ 308
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense $ 1,397 $ 681
Research and Development Expense [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense 486 304
Sales And Marketing [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense 263 0
General and Administrative Expense [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Stock-based compensation expense $ 648 $ 377
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payment Award - Stock-Based Compensation Expense - Additional Information (Detail)
3 Months Ended
Sep. 30, 2018
USD ($)
Class of Stock [Line Items]  
Unrecognized compensation expense $ 5,200,000
Unrecognized compensation expense weighted average period 1 year 7 months 6 days
Executive Vice President And General Manager [Member]  
Class of Stock [Line Items]  
Amount of stock-based compensation included in sales and marketing attributable to accelerated vesting of certain stock options, net of non-vested option forfeitures $ 171,000
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Sep. 30, 2018
Jun. 30, 2018
Assets:    
Cash equivalents $ 25,955 $ 28,826
Total cash equivalents 25,955 28,826
Liabilities:    
Derivative liabilities   19,780
Total derivative liabilities   19,780
Quoted Prices in Active Markets (Level 1) [Member]    
Assets:    
Cash equivalents 25,955 28,826
Total cash equivalents 25,955 28,826
Liabilities:    
Derivative liabilities   0
Total derivative liabilities   0
Significant Other Observable Inputs (Level 2) [Member]    
Assets:    
Cash equivalents 0 0
Total cash equivalents 0 0
Liabilities:    
Derivative liabilities   0
Total derivative liabilities   0
Significant Unobservable Inputs (Level 3) [Member]    
Assets:    
Cash equivalents 0 0
Total cash equivalents $ 0 0
Liabilities:    
Derivative liabilities   19,780
Total derivative liabilities   $ 19,780
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Additional Information (Detail)
$ / shares in Units, $ in Thousands
Sep. 30, 2018
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
$ / shares
Sep. 30, 2017
$ / shares
Jun. 30, 2017
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Warrant exercise price $ 1.23 $ 1.23 $ 0.00 $ 2.50
Volatility [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Measurement input   0.8540    
Risk Free Interest Rate [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Measurement input   0.0210    
Term [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Measurement input   6 months    
Stock Price [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Measurement input   2.08    
Second Tranche Warrants [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Warrant exercise price $ 1.43      
Significant Unobservable Inputs (Level 3) [Member] | Second Tranche Warrants [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative liability | $ $ 0 $ 19,780    
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Summary of Changes in Fair Value of the Company's Derivative Liability (Detail) - Significant Unobservable Inputs (Level 3) [Member] - Second Tranche Warrants [Member]
$ in Thousands
3 Months Ended
Sep. 30, 2018
USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Balance at June 30, 2018 $ 19,780
Change in fair value 18,886
Reclassification to equity (38,666)
Balance at September 30, 2018 $ 0
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Income tax expense (benefit) $ 0 $ 0  
Unrecognized tax benefits 0 0  
Accrued penalties or interest related to uncertain tax positions $ 0 $ 0  
Federal corporate income tax rate 21.00%   34.00%
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Additional Information (Detail)
3 Months Ended
Jun. 11, 2018
ft²
Sep. 30, 2018
USD ($)
ft²
Renewal_Options
Caladrius [Member]    
Commitments and Contingencies [Line Items]    
Additional subleased area of office space 1,381  
Massachusetts [Member] | Maximum [Member]    
Commitments and Contingencies [Line Items]    
Construction allowance | $   $ 670,750
Massachusetts [Member] | Second Amendment [Member]    
Commitments and Contingencies [Line Items]    
Lease term expiration date   May 31, 2025
Lease commencement date   Sep. 10, 2018
Additional Space leased   6,590
Lease renewal option period   5 years
Irrevocable standby letter of credit | $   $ 150,000
Massachusetts [Member] | Original Lease [Member]    
Commitments and Contingencies [Line Items]    
Area of leased office and laboratory space   13,650
Original lease term   5 years
Lease term expiration date   Apr. 30, 2019
New Jersey [Member] | Liberty Corner Office Space [Member]    
Commitments and Contingencies [Line Items]    
Lease term expiration date   Jun. 30, 2022
Lease commencement date   Jul. 01, 2017
Lease renewal option period   5 years
Area of leased office space   3,000
Number of renewal options | Renewal_Options   2
Lease renewal rate at 95% of market rent at time of renewal   95.00%
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) - shares
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 10,369,196 6,898,655
Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 7,984,469 5,740,155
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 486,812 0
RSU [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 1,395,829 948,500
Performance Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 466,668 210,000
Deferred Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation 35,418 0
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 182 268 1 false 73 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.eyepointpharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.eyepointpharma.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.eyepointpharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.eyepointpharma.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.eyepointpharma.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.eyepointpharma.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - Operations and Basis of Presentation Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Operations and Basis of Presentation Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Acquisition of Icon Bioscience, Inc. Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisition of Icon Bioscience, Inc. Notes 9 false false R10.htm 111 - Disclosure - License and Collaboration Agreements Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock License and Collaboration Agreements Notes 10 false false R11.htm 112 - Disclosure - Intangible Assets Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 11 false false R12.htm 113 - Disclosure - Accrued Expenses Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses Notes 12 false false R13.htm 114 - Disclosure - Term Loan Agreement Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Term Loan Agreement Notes 13 false false R14.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 14 false false R15.htm 116 - Disclosure - Share-Based Payment Awards Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Share-Based Payment Awards Notes 15 false false R16.htm 117 - Disclosure - Fair Value Measurements Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 16 false false R17.htm 118 - Disclosure - Income Taxes Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 17 false false R18.htm 119 - Disclosure - Commitments and Contingencies Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 18 false false R19.htm 120 - Disclosure - Net Loss per Share Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss per Share Notes 19 false false R20.htm 121 - Disclosure - Subsequent Event Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Event Notes 20 false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 21 false false R22.htm 123 - Disclosure - Intangible Assets (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Accrued Expenses (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Share-Based Payment Awards (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Share-Based Payment Awards (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 25 false false R26.htm 127 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 26 false false R27.htm 128 - Disclosure - Net Loss per Share (Tables) Sheet http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss per Share (Tables) Tables http://www.eyepointpharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 27 false false R28.htm 129 - Disclosure - Operations and Basis of Presentation - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureOperationsAndBasisOfPresentationAdditionalInformation Operations and Basis of Presentation - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Acquisition of Icon Bioscience, Inc - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureAcquisitionOfIconBioscienceIncAdditionalInformation Acquisition of Icon Bioscience, Inc - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation License and Collaboration Agreements - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssets Intangible Assets - Reconciliation of Intangible Assets (Detail) Details 31 false false R32.htm 133 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 33 false false R34.htm 135 - Disclosure - Term Loan Agreement - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureTermLoanAgreementAdditionalInformation Term Loan Agreement - Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Stockholders' Equity - 2018 Equity Financing - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureStockholdersEquity2018EquityFinancingAdditionalInformation Stockholders' Equity - 2018 Equity Financing - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Stockholders' Equity - ATM Facility & Share Offering - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureStockholdersEquityATMFacilityShareOfferingAdditionalInformation Stockholders' Equity - ATM Facility & Share Offering - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfTheCompanysCommonStock Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail) Details 37 false false R38.htm 139 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformation Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformation Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanysEquityIncentivePlan Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail) Details 40 false false R41.htm 142 - Disclosure - Share-Based Payment Awards - Stock Options - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformation Share-Based Payment Awards - Stock Options - Additional Information (Detail) Details 41 false false R42.htm 143 - Disclosure - Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedTheBlackScholesOptionPricing Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail) Details 42 false false R43.htm 144 - Disclosure - Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformation Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail) Details 43 false false R44.htm 145 - Disclosure - Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivity Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail) Details 44 false false R45.htm 146 - Disclosure - Share-Based Payment Awards - Performance-Based Stock Units - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsPerformanceBasedStockUnitsAdditionalInformation Share-Based Payment Awards - Performance-Based Stock Units - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Share-Based Payment Awards - Summary of Deferred Stock Unit Activity (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfDeferredStockUnitActivity Share-Based Payment Awards - Summary of Deferred Stock Unit Activity (Detail) Details 46 false false R47.htm 148 - Disclosure - Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformation Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail) Details 47 false false R48.htm 149 - Disclosure - Share-Based Payment Awards - Market-Based Restricted Stock Units - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsMarketBasedRestrictedStockUnitsAdditionalInformation Share-Based Payment Awards - Market-Based Restricted Stock Units - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Share-Based Payment Awards - Other Inducement Grants - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsOtherInducementGrantsAdditionalInformation Share-Based Payment Awards - Other Inducement Grants - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Share-Based Payment Awards - Key Assumptions Used to Apply Option Pricing Model For Options Granted (2016 Long Term Incentive Plan) (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsKeyAssumptionsUsedToApplyOptionPricingModelForOptionsGranted2016LongTermIncentivePlan Share-Based Payment Awards - Key Assumptions Used to Apply Option Pricing Model For Options Granted (2016 Long Term Incentive Plan) (Detail) Details 50 false false R51.htm 152 - Disclosure - Share-Based Payment Awards - Summary of Other Inducement Award Grants (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfOtherInducementAwardGrants Share-Based Payment Awards - Summary of Other Inducement Award Grants (Detail) Details 51 false false R52.htm 153 - Disclosure - Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwards Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail) Details 52 false false R53.htm 154 - Disclosure - Share-Based Payment Award - Stock-Based Compensation Expense - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureShareBasedPaymentAwardStockBasedCompensationExpenseAdditionalInformation Share-Based Payment Award - Stock-Based Compensation Expense - Additional Information (Detail) Details 53 false false R54.htm 155 - Disclosure - Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasis Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) Details 54 false false R55.htm 156 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 55 false false R56.htm 157 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of the Company's Derivative Liability (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfTheCompanysDerivativeLiability Fair Value Measurements - Summary of Changes in Fair Value of the Company's Derivative Liability (Detail) Details 56 false false R57.htm 158 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 57 false false R58.htm 159 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 58 false false R59.htm 160 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) Sheet http://www.eyepointpharma.com/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageShares Net Loss per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) Details 59 false false All Reports Book All Reports eypt-20180930.xml eypt-20180930.xsd eypt-20180930_cal.xml eypt-20180930_def.xml eypt-20180930_lab.xml eypt-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 82 0001193125-18-323795-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-323795-xbrl.zip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

%]J#VGP(ZBC?Y^;C638;>E _$ZLC$"Z=# M@+'YX.UJ8[2=/.;FEFCIO[[[#\MR'-=M/XMIM*A\L6]O2_;8CXX+E@GOW[?8 MF#7CA85K\I3V94H2(TE'E90DT#%9ZFR>^_OJL.*'JF-*QK?>D$O7G0 XI#SPV_B,K6&[Y)AB0=A2JWXD!;D2 R[L>!2[TVZ<=N.T&Z?=.(B\E.-6PK-\4-H*[^B5<'',R_R8EX17 MJ\&)9^(Q)-H\<1_E,V%7)_;A;R$_5B7UI(2?1-M)T3CTA9UVXY 6=MJ-0UK8 M-N+H/2E"[;/TUSYP1C@-G'GM?0[Z5Y8?0Y\#N^Q=O5VO@4:'V5N:8LSPV0R- MO-4NMJN^7\RC1Q\;JV!O7E@--4?I1+$'/VNJ3J9[B+0(9\SP8T51JT_QZK38 MI_\^T +KYYUE"0&OCE#+N\K2T>+;OX-?[?%?/F0R#V:S$D)L=RKI8YW3:H"% MI*%QC/UXL>'ZH.K^76O1?[^&1]W;]E MA9FL1VLQLQ9%=-:B%\0H#Y=YGVZ<09,A"KM__\"?B?P(NW[33CVDY?'4IUV" MC&FZ[C"LG>I6;P:=-<(GGYES;_(7>S6YB^;8L#9#]R(. M2%_M^VCJS\M)C/41]G_Y./XF6=Y3')RZ>YRZ>YRZ>PS7W4/1GM+=0^.W[NXA M;==XXI1^\J3T$\IH0>+Y3*.X]UG[;RVZJ_B/N*??CZ?P.NLF70?(7.T,E+"!COQ(ZD>-%][JO-BRFI2^X::U.*V ML']0DBE'H&1JTN]P\ZES[5OJ7(O4D#&0N*0&REAP+$GN :M-[;J\^KTYNQ/[ MEM-A9L2;UN8P*R9D>R7M][9OO MZ-G:Q['0ZVGGX_+AS1;(I8I?_YSH^^5MI>)_TW/S#P@=!3*V:.1+NIS5/R(C M:ES0]NH?__'\/6I/KMYN?][G*,Q4[V-NE*GIVI@77F]],'\F:\,#=_)[O_JN M:<)8?!--T_@S;0^-'%]_W<>IC\MI+PYF+TZ:W&":W)$7FVJZ/-9.^MQ)7)V* M?TZ[<0LQI(O*EF2)"!Z4O M8O\AB);)_#&KK:(Y(Q,_3H'WE-5_-/5B47G3) KIS/L$RYRB28#Y(+3PC;"G M+Q@5I[DJF'/A)5E0';#SDU?Q#&%L'#8<[@GB:9%EA\L=,\L%)J6$C&L;C#>9 M YJ^]7'(#T"#QX&YAW >S*Y"[P'_SIF)&Y'VN(IY?07$H8!"+S$BQ_)).[EY(ZF MVHP9)$ $8X*9F;"I__(G*:%.0&(08GH3I4_RFO0NCI:W=Y4'G#$&3=C JLR< M:*HKRSZBZZA -:J !?\U$,WKN=26M+$H"A1EI>5,<(3OIS6C^(8(_HCIY1*] M_,:?>/1Y2^[I@_R^ [B\F:513-GBAJFPDF,4R M[=C*KO-,U8V<;A"Z,1[+*,9 ^_QQS$R6]TNLZWCPJXEAHUIF&#.+H_LZAZ 0 MY1NX+B.&+*!()Z-I-4B149PGXQ1+;:;?CGH71Y^TJ->JAH,,BWTJ^ 0)B]0U M2BM1O=LQ83I 2VLI$<_V?RU#OX5^B*S<5ITG28PT:Y%H]DW6N\JX1JNW,-3YH^,?*;D9P#Y]# GX+7W!-%./4%>.Y-[;;F%*Y:B[<_\.#X9 MB&_50-PZHWF:$PS1XD:D\*!A3]HK]F1WDO-:67-*DIQQA3G8A%VUA"AO(#D.A??G_*<#RH[IC$1 MZ6@SG45L\7<,,ZMW38S1]S![\I3H_+KGU4O\'IJ^'QJ0PIFXA]D+KS]G[,VG MU9[VXG#VXJ3$G<9:5E0YB=]#&O!;5^6.7%Z=LFI/NW%0NW'*<7X+R14.9DW8 M5[^3](:$Y/1A4G*9[U/OG\1<+6\2_]]+DKL5%:V>:'J239*-@OFS>1?#J\%E8R#S#Y+(V8:#)9QOB0GX)*>A]F?8R8?*1 M/:N0=JDOXF-YTZKLV>WK,"./)C3:V2,3DC/R4U!]*&TF<\FYCGZ2$G'*67NNQVD?I@%WD\M42A+0S M+8O;GLCI#142?/+BO_PTJR$XM:!\Z]DBZQG.FKQ'PHNR_,H1(W,2E5!.@"(Y/P7ZNWHU!_TS4G0"U+?<5[R&1(#.TG- M-R0UST,4"2$(BJ)B!YF"L;Q=)I6DC[RZ[ YLPO4MY:V[P)\Q+EB=X01>PUS, M9L!@X_JLLGQPGY>LBKD$S5M&U%9&^A7-[O.G4,8\RCCSFCE_M4;01$"2^7=D M2CW 48B 'X0S02BYZB^%X]Q(@! +U+(KW(>]H[VG,9"5V5)ON(\"V[C;QKW=Y(-5<*G(_]P=X]]$2 MA_^MD[R 3J -D+&Q_^"'2Y_LW?:+!99 %]NQUG)UM HP]%,L,$UPB:+$Y5]UC5S5-51Z>QJJ?JD4J\\50]DI_>AUC M54_S5$_S5$\']W7/4P6Q4+Z,+7\4SG3A-%GU-%GU9'F^,LL3_;HK%B4U/A/F MSGOP&6][[R//K?/2DO06[$@%ANL\O2,1V3!*BZ9V+0,0QZ3%6;4%%[9\NT4W M2ECZ#/'!U)M2Z7B7N2&+1]5;_HR*/)RU .O!4CL:I M \\K9W_]71?'POVV:K?2[7VNL(AL%BEEI9EOKJWERFBS9^[D-#LYS4Y.L^&< M9F#%/,%IIHA;.\WDEVFYM?? QF;PN7QNUM[-^N-#4Z!_P@.YK4/WZ![D:O@:.NV9NGOO>TT![4WHB: M'X^RG84XAFG' %P+W/9 MP:[W%$!\Y9W;:'W#,1S,IP$JG E' >6)_9R4HZ$8DAO%,S\X-I;TDR _11/Z M^8B8TGY:=!W;(3^V];[^%FAOODWD:2]>\5Z9T M$L[THW Z/6T?U3/E]6ZAKIZZV)[ZIAZ$XG 00!_LPDZ[<4@+.^W&(2WLZ>+H MY.9<4[A%LK%H3X^C5\H5_G6KY.(9?PSCLYZXB_*9_'HG2XC<'F [J>1O0-"= M=N.T&Z?=..W& 2QL&W%TJK1_]O MK@7Q=7?C]9 $.DDKU"2%O["BF'0QP&[KL7\'!(+==.=10AH)3^;+*6G-GGIS M7-E,NFS #^H8]+2F%91)Z1759FR M?BI?/I4OG\J7ARM?5I4G]?SK[N"W8E#OUO-OVX]?Y+5OH_QLD#)"96T9X341 M&)^(P" ?ED6K*#WJ'[6+DH:J\R1?V6E?!RH/+?S8 VW,,0"L/B\EGF(LW3$6 MJTV++33=(%Q1*H\Z)>[8UONV4_C$[7J!^HGOQ3A$ VRERM",YR7@W0(ODG8, MV6R[!I6DX6$[,?VG')4K;TYGW63#W[+N'4<32A<4\<"/RY/?W7S *A(*MP H M5-(SK?,DC[:H&O9#/_;F=.#,%(>-)&E,IG,=U5E3I&/(=W@BD**JOLAA.?+$ MAU,)TVDO#F8O#EHE/%3EG!^+^AY8WX% IVA[R$A\_6S]E"5RVHV#VHU3SLY; MF([1-J243&FDSND;L*=F09KD/>,Q#V--B_@9+-V/L89@LB0CD1NC2M$LRTRT M$?/)"[U;'"+]^Q4=)%W,#ITQ$S].O2 LAI%^PZ&EDXD_]V.2.!+@3,@)@#;U M0GA#,5R5#LC(9EID-]-QR/7YHV2,,HY'CDS*@1(DD7(_*Y)Q=DR1\PW/\9F_5F;&3K&(^NQ?Q]-@UDP\2@V$(W9 M=4A-Y$:*CR69\(KY+B1+Q6?^O?1B0$K/"9DX)7G$^+,9#B$!+'Z["R9W 'RR MG%.L,Q[S Z_R9%!L$$Y 1TO(")%*]LVH/4FG$MY@DE576#U'9]0_22>#,QM" M>Q,]G(;(OEIF9:0;*1A.$.$5"V!8WP,<-],)]GTRZ6(4[ MN V#__6G[70;^W/"<7 <QFDC_GPB]:)/O173B._TH$^C5$[V=UD M>'B0D'=.Z,N \S*5I7E)OJ 1':WL%0-^V'R^3S8;'J"J0<_P9PIM$UL[&/@O M^7T:/. G?WN_3-A;SUM\L(-D,H]PROG%K!JIO*28L*(D3:YP6C/)[_Q"<^V2 M:]A )XW_T)6Y\)G) <0]_O2G_WZSH_F7[\X MBL*+HL*RO,9S[#\XCN>^7EW;7W7A*^XLIXO<5^X=$TQ_?1=,O_*NJ6/5?P+> M7F3-XKO?4*:VK;I8T\J:KQ\7_G,OE'OW&SZUOE!<"%E=3E..%Z/T3 #C.>D$ M$R.OO5_97.%!?R5CRY-UO+'49V0#/6MB+ MDS+85MF2P F:Q+&\8"JL)(DFJZFNS4J<:XBVZRJ6:M*MPA.?'?@GR\:&1%Q- M;6]FA?/B&5R>,A^C)"$SWPDZ"!,:.A=\[=J4E0A"EHTW8L@^HA9$TH_+P?3( MG5$\$&*]>:13#?-1Y,7E-X^4P^>LN1B]%N:#(? AH-K0AR8U@5+.-A]EK/P, M>PYF/^/XI4P=2\O4:A 1BR@&]1R7 !I6=.^/1[ X>JC*#^N Y(/8*2@T!S/3 MZW'4>3 9[08!T<,P37M4N9PL!DV![#Z4FV 1DRE2]!'+I+@9]&GV"J)9XP2^JA:* MCP-V.EG.B^%7%38ZR'.X/8KJ8A-A=T7(. MFX%*? VJYSH15$]L/Q(%8HN=)WM3[B.J)AE622;^*EY+DO0S7EC!ZXT_\9:) M7]U=B@XRF_'&]\,&5NAN>DF>D?_$%/QMO2A;9'^OX+PSK?N9\J/5[CE"78G* MW0.A!OGX15Z[2Q[MREY^,?[NL.:E8_PWG)FK<]LYT,39_^#(/P-G0Z]-@&8. M(._Y3>S7\6ZYTYOZY+_.S5NS+RR%>5OAR#(RV6>J&-=D\:2 MHA]!$/:)H,IC5>+&O/PR;?^>KK!UC'FKI MA3F@?/;A%_7UC5D3#RM[X/:TL(5A,/.Q.EZNE4)$<@>/#/26K+M??]TDO]2W\2A9-@ M'I"< R-U_2EFF5^E7KI,H_BQ=O$ Z6;GG]W5/"Q+4US.D2U65FV.E53!9367 M%GG!<.6O CZHR#=;+&/_W6_*3( M2SPGT$S!UG6U[//%S/D^N?/"6Q_!N@@M+[G#_YTR_:3T$N(71CBM?U"Y4X _1^F??GI9I"CG MN;1Q]A%>QP]&:+QDZYKLR*SMR!J@6-%9PU4T5G LF==M799L%5,YW_WVA?]3 M_:38%8P^*\2-@W?IWY(.!&'ZV;L?+C>WY[D#=#B/_I?&XYE*,^<<(XP.35E)DA^ \$_'L*_I2)L(PI]B?+F&3<8LHK/"3= MG+[Y7\O0;_GJYI&\@3"*$7,7@%B.)W>/PW8*/JXT15UX2IJBI&R=IJB_3)KB MZ;6#O?:4Y->1]L9+:_/>.B9TG5(O7S(9D2B0Y+W@\O0/E)WK*K" [V);F3*A D,[K7CGQM>7+SR061H(2$ M!#A89"N__NWN<["1H$1)I$2*J,PD(HGEG-Z[3R]9K8@<:U^;H(DO4W!Y*.A2 M@_$RWP!"]41!V(!%'CT,:C5K<*?@Z\[R-Y[ENV3T=RV2N_6^WO6^XBRWA_7S MQ%!FO=3P>;G^<0W05*/G[./0LMO>T])ZMMKN068==: YU9/\TTX%ZK#08:'# M0H>%P\'"8?GEG8G8;>\TS+P.-*=J 9]Z#F6'APX/'1XZ/!P:'K91.UE3[5Q3 M4\%_OE',C2JG=DDM 6+#]5UNPN,R1C"-K4L6.9S3Z#)9I,)#=$UUOES_"EW*4^2-VSU:/H;[_%6_O=86( M.]"<:O3\M$]K.RQT6.BPT&'A<+!P6'YY9R)VVSL-,Z\#S:E:P*=^3MOAH<-# MAX<.#X>&AU<=3[JG%1=RC5K??UKO>P?-\]RX"''5,-@R2\\6FX::V/ MV?-*@\?YLHK3L^P]#+/H'+8.-$<;X-D74[QR5_VT0\,=%CHL=%CHL' X6'C= MDU@.2[5W1ET'FL[>/2U[]]1#P!T>.CQT>.CP<&AXN'-LU;[&8[ I#^WS,<9A MY$>3T)^+891F24X3/,3LVL_$99S!!_AI?BNF^>6?P22KS\L0LUC H2<3&K2$ M RI2,9Z)DR28AIF8A.E?XK5_$XC789K%"4Z&F=-TJ#3$83B"N$Q">/&2OL;[ ML)P")V%,5NHJ^J*;;1B?(=PW/Z.'"\=)O'P;\"]\%^Q":!_[$6)!7I!FTF7@ MTP2/E=6(E_XXKK[_8 HWBW$4B%_ZG_OBK_%-D$0(30)LF.4((0#S M BZY%5G!J#C+<;X(0?O:Q[?CI*!%,4\*(85K $CAN!(&I]6GNU=!-+D5Q&EP MF?78KQ<)C2.Y%3\%RSR9P),#N"P)V'@6 M?*4P3^F/8[^CA%!;Z9!LLXQ?'& M"_]6O Q$P#1>,17S)4XGF08+?#3\OX<03H)9G 0]$1Z,P\1@]40.BS#">5=$ M(/3@#9A8)0/13P)Q,O?3-)SA )9O878- %\I=50$',&"5,I&KP# ;HKY*:F( M0WVNQ/]0L6^! E;JVU]EZY?@Q2]+OG8<+H0K9:0*Q _$, 6T N7!1_QOBA7( M,=+;"N6K!N>*7H-7PS3-8<\M3_O=3W P4]H3OUV'DVM.U], ^ !0A??$B.OB M[.BVAH/BE@31E-#C_8PQ5W7Y96TZ3G-H3N##O4N:=$78%-E8,F0#H7[=98"P M2 R10? J0 W+$ 8"'] XPB0"- #&]D;T?>P2@&<26P?T9T3%(&[DN"ZP!X M"P_$X":D02"4DDK$;W[:LG]?G%,ILE:[\C*8^#GP18@\/IGG4Q1K]3)=D57G M$IEO@CL!G.UTR@A4@)=]P&%2HNL#^-6TRE(G"$)G3P&K6OX"4^ R=\8:*BR:[3$K05Z2#V!([0D@!^4/NR?1!2 ML(57SD@OQDD*B)\#TE&6!-^#9!("]T5QAA(<"!5^8.Q3:OF-3#?-DX(7N 2: M)?&B,C- AAJB)*HV1\W;%&CR-] ;HOV.L7,A69. \^[ZZX3J?17^PP5HS!!0 M H1H!\G2&,9H^XEF\U9[DW@FR.4I1OV5 *G5Q.T*1.$P?<)#M7C-Q9<7V/. M@J-7H,DY_ 8!@3^#MLF!J[^Q[5175^2C]'4-0T#"/9[DV#Q\PI%?K_7UM_C?+T' MS*\3:3(=&%>@,GT^RXZ9T*7^)*2A"A6X#KU#Q+<+4W@\U^[UQX1I73->WJZ: M7QK7-Z<\G\ZTGS*?SE8?/)].4;K9:0\.:>R]C0L)Z6H-7%K3[V6CED(]T (O M'Q=0?D1@^_6DPCTL'7; M0HW%)M]RDXT&>X5YTH_L)T'*4_4G97K^;R$\;#3 MO'4*L7NVO8?2OY,2* ^CF4^E43IAKE5IF!X5Y;S5[)YI/I9TWIWN*6N7P_-* M5<>C[8H-$W.?11*\KOR35RXZNH/0.PY"_S$-;_#3?_TC3Z4KWU_^- :;[-]H MD@W#%,-8>1*D%\'W;#"/)W_](HCB?TV#\*=A/*$#S(\4TAM%TR&&L2882_^> M?0IF_WP3Q/.O'T>FJ6B:*4F*K9!XL*FK.'GV M1>MO?ODMCB1_,@E@%73F0^NI;Z*Q0%K\&F7]%F15K11U\BS*)V\_\+CJ>006 M7YY@Z'B QXM?:F<]9QCX^H1>_P3N(7/P K\OJ71G8 $X# >R,I(\\ @!-KHK MN?I@**D#96R-9 M.IY@5!? [ 1*%\#L IA= +,+8'8!S"Z V04P#S* N>\P4S.X%49A%KR'-TW/ MH@SLPQ N95-JQG$2 - ]> ]F_E-2.83OW8@-4TF&"*?_K/-Y*V M'KZ2S:%B*9XFR8XYEO2AK$N.:=J2J9@#5U7UL3RT*(PJYK!X>GF8QKJJ6%^_ M?!Z^^46N ?4IVVL JOCR/*J0D5-!T$XR^+X,H??P)PMT[-CW='6B6*SECSY%T MUQA+SD#S)-OUY)%M#<;R:'07TG7%5)HHOWL;C2V?19-X$5SXW_F/ [AW%F8[ MV.K9;^/64/Y85CU [-A4)'UD H$[E@K_&HX5#U /^Z68]?W8W;#R]MU5QT6[ MC\,/5&LP\ Q F*?;DJXXEF3#5]+8,5U5TYPQ4.TSQ^$5NS$8E2)RBM(7&3Q$ M $BP&JM[AO1F\^[3@2J3?A)?1>'? <;H9T%"%44@&@() 0H TOP6J1J0SS5P9U%P14[XH%KIKBF'M5=8?53@N<^ M?P7S6RJEC+"&@2&;"D$2T8$16SU=15H;5:;3,,I M;8]5PXE4VL=X&[<2<'V%*+WD KUX?G:-956\*"B(L,RHO:BVK*FE.D+K(&J" MQH_>!.UA!2G7/@)13&N%7WE4DP;$70Q\5'TLW/N23=7']1),]E:<'3M)L%X( M4.7/B5'CI%;0%2^2B;D!P8-P")'01&SB-Q&$Q68**JO0K>J&U$ M+^>"Z;_!A1%=D#=O"145XWL_XW7P2_75\.=W6/E3BBV22#W1![Q? 8AHGJQ8 M%CL*]/PP @4;3K%*"=$W][\5I\D]X-1O0<(KM&;!E.HB:[?7&(C*Z8BC-?U' MQ(&J_,@%)8J>__:CW$]NJPTK#-%]H903=8PODQAE%=:KSG*0+IO8G]6K"21@ M5L4 EP*\HAKE'5 N%]U"PB#T &J/_GD7N9!+GL$[P?8.07&&P<\\1*N=,^$97S,1_61?-V63! M&JK3,-:?L,-[(#7DY/,)[9Y\7][+EO!0MG'8[MW#EK3QT;]M!5NM#_H+0V.C M@V,9YI;DL<4F5\#%5,M!.+.;R<%6C!4 -):]NJ6&5[]/+T\'=TXV1XKDC4> M64V5)6>D>Y+IRKHW<"U%-4<'X.49Z.054.&#J _.TTL:<4NRJ:LU_F12X[V/5V"2%\*;\F=/[K)\DM MQI#]!7H>F!YR&5R%4<1[D['..<]+L8]+/C7M'CAFN\_Q.)#M:4;/5(XOM_:8 MY3D=)+. +++"&3@VXB",TTE(ASC@OJ^'PYXU<>I)#SB,#*I#2S/5E)YC:4?' M9L?#5#QI1YSPK!TQJ])V1'_Z9\Z;HW:<]**6/QHLZT'UV"ND5B\(."X> A7.YI]AQ3?Z2 OJO<\_!V:O14_84*6T_5/B@B\:=:#3NK:59+\-8G?MSL(OJW)]#6-3+NC]';=7=X1 = M;TCNK6;U#.NQAR='9>WMS>GK]-(KEH@=%@X!"YU/Q9?R6Y")EW'\%]4"!B^L M>QZ9;";W+'T/63"'LCVEIQGV[K?WRK7,J;>#ZO!P&'@XN 'K]>X-W._ _AM9 MVE+[1E.09]2]2,3V12EVR_!Q5FOBHX"2YF%43K;FDW3#I#$YM.R'DJ?!+)^S MQ_17@MJMA7=9G/ESN/$'4S%ZB#2LJ/M!L57Z\,B:\*H%@U!;YOPA@SOWAYJS M"*M$HX"-TB;@XPXIE[>>WUL-?]7>L=8&B*+0GPOE+-/:)%1-[)GS]@[XG.'H__[PO@C8*6":3[(UK/ !SXPD).IHM7:-B(UHV(SL@KZH MRXJ_F6R0^HIF+HB7A1_2<6!),S/:BJ+V#:JEQ*6S&;5\W+"_A!5_)TK#KBL_ MP(7K6\9IL'CW5GT![BWH;:UI_NB'4S2I7K2H6S4WUOS;6FM-,U]V8TOOX^CJ M(D@6P^ RVT,5\\"UM?'8EH8C399T31E+KN-YDFR,367H#3Q'LYY_9D1-I5SB MGQ;0.\ZO?A_[P(%7(&BH21"2S&5I_;QL&?-Y)'[P@> MG[>,TUZJ[X<_OUMM$D1D09P= ]MZ\'>85?MO>3!=(=1 5'\Z:Y12;P72PU+G MRSA)L!%*3_S\^_^(XSRB:?#OWWL];#4D^E>MKW*O5A_?*T>*SU'\@W!8^DEV MRQJ49+' ^J?@ &B2^9W>N/)?U2\%545<4'&(?X8#L%+MA%J/BYT@; M((+R)3[^![5%UJZWF$&":KRLCX@D"-5PU -UUR+'6)L5@5$ER?'I#?9NF:[O MZXSI!=%E5ZR\\@*?4DG;'S:^J^55\%NSF%,U>ZR LS9=)07UGL[\2;W7U0=X MV2)?B)Z_#$'!BY]\'-S]%@=K3X,9M2+CW<]6Z>Y="S5,IZ024?5MW"-;_<*_ MQ4Y:(>]C0<-6?E!:L)4OB\8U"39M2[.562\],U 5I=!4O15@D'7+"62L(F&!R$G5+"%*?7Y*P=VI)U 4&Z M6)5'%LHC56MA@P]^EB463< G(YSFV11>(69C I0%:0'@[T8,@OBW^9 WY M\H#92O_)08@%R?R6VTE(0T&$O1, OO6.3P9G.P#9N!IK1#8A6YQ$BV/QG&8' M,&HQ=TDR@'4AQ8TM_+^"VMO+U3$;G9[88V!+@MJ/PLK>@7X!=_X5P/$*<O1G2VOPQ5)62QALRV2'WA3:;\4'ZC55\)[-!4Z MIJ3XZR3.KZYY]T:*$*;YY+I$U3Q(4_'M;7UCU' L1#>M#8"L1QIGGQ*:"W\: M%""EYS.8"LQN1P>ID*U-2EZ" 8OTEB]!V2/+!<\=KA$I[YKQG9XN\62/Z$;YL'*Q8; +O MB\EW$**$G,SS*5.?K"7=',PNB1DIM8933+-0WS^V2P0VJA[,*YLV&[-=\D;\ MZ740'(;N^;+D8C:>\#P@Y@#"4J._DGR936ZEHF M%XHH7@TV.CUH)6*4,3,+3..P#&:71 &^@\*. ]Y>OA,MJV>ICUA0I=.*-97S M([=?$P;8E;ZCD=]"*^!AE1ITJ?9T4T?P56?%F]C:JH0;!@ M9&;AG+$N!J]IL9?8A!UM=2Y#MW4A+ DM\*:_T,(P:ROGPN:>#=^/BCOV/.%[ M+JR8]9 0@\2S J)E%+9Z8MCY26'GF>BB -W(/6(O[V\JF.@31A\"C(T$PF2\S<0J.(:F*6H/R M&@66J/^&@<4?U+ZR'NA#VL28)KI!24C.^4Q\J[Q#CK9;3LS0WQ(J-PO?1@YF MS>ED0KCPV-@$!%#+S-TE-T!@50L\^#>)4^RES5PY; J. 2L0$K?4D7M2;"SP MX>GCJ6KNWZ\2)'I\BEE7*&GD_&Z=QB.1/^IV1SRI*6L#)F!"< MS\[+62<[.YWV+&_@#G1;__@MEBRS_+'KG[\\__20F5Y=OY1[\\ZY8Y<4?[VMO./_T\5_PK)]$%=YV M-CS_G?VY+KW>CRXN1I^JQ10/:$@U6B&:3]*-GX0@Z*5Y>$7H3*L[&K]/_&7M M)^E;I*CQ)(U&WL7J M9!7R4XDRMVQ-+SPV?XX"DWGDYZ 4@FE?$#T>" ZC&>*$E%8QQBR.LPC3U:9E M&E5A6:2UF6)"'5S7F"&"8\+#\O_,HY5X3>M$' [*!BD)&T;C$ (94)L'/WA2[491S@XV03W3%)XQ8*29 MH[J-JPL:\W^:QX7E(ZHC[>IX[LX!!^+;.E#Y22FU^VX"]XS;1?$26(]E1U33 MV7J<8AIDPL?G,0,S*:/#0$S^HD@R])FSVP;A.V8/"0^;X=#C)Q*$#'[25!6E M]^BM89I1J(+2!69<>J$ER:;K-F_ \+= ?!:!T9M2>*$$/'I;RYKV63EQ;I!6 MG8J*J5T]C,'D(!I$]^JD1@LIR"E65?D M-[ 0!\-$N:IV_F[AX"\18>=S1A,!&P3SI?^YWZ 40;QBPT7159[@T1,:[VPB M#0*2N[WSU0?]ZKH?5Q[$CZ?2&J&5>1!@3>>+9:7XBW1F/KS1)P.W)_ ,-VZU M7\,"TEXSS)<0,[)2SYR?\51C$H7Z >W/*P&S2FA2KE!,&Z3!B^WW%[FQ=0_H M7HK_66@[%VA;-<\0X/!@SER9!L&$,-U%6" "Z?-9*RWDUCI=1=A%7Q%G) M&>'\MB!#)-O"Q2]>2MCB&6#EU,CBW;!_P'\S?2-AJ1]\B"??1V?7/<+6/Q;# MKG9@[8L8G8:?,R"8,%XVC#5Q4CM=8-8(9H9,@2WFJ+6NB#$H72O!9X1_XW=A M%,4WG#:7UT".\T4X*=+LTUHU Q@.67&Z&]R2R83IBFD]NPNE(7R,6;ABF.17 M&$BH)BQCCE%=Z(V'[HJ)B.GR-_Z/+Q=G_UK]>.]?/ M_.0JR IG?PH\-,G8VJK=@V3RP?RAZ"4]L1IMB^>N1?H0"C8?TW>!]U!GL8W1 MRN &H78'0&ZV=GG'F:^5,UNH\^TT^.YC',E/ 9H86DK\> +&?@+.4XKZ")[V M3G1^['$Z1S/ZDO+!1> $),!Q<)G@X,PB7SE9YSVPDS*)*ZH;&LHYF_L+YM?T M2$APAJ-,>0IQ8MQK#HR )TQ>^E]SW9[_^]I-8%#P7ZGO$ B/PB*8S,04!!H2 U424"0-N&[J0 MQ;&(/R^-SA+&8?0G/P,GS9X$(\$8MC'[ HP)@%'##DH8$%T,4%4K@872VR/0B6)/U(?-9E);,X ML**MD(:E:*ON:LA%E'(4525A2-8QAM##!?,!)CF=6Z*SAS->JX3[E<7>]E?J M_28\$ZMZ_VHZ 3[3;\R2$%:'2?!H14/%X"5-'1/R1/#V4:R=@'XE KK%3/ ? M'FH L$O H%.LN-L4 ,ON+5]<,Z3WV]G' M+PU&ZK$3*JX ZO(?F/)\DL4-!TE1>3D AE+^9'X.E7$5;V5Y^?%LAMDK-\CE MO<(P2S%' ,S2))8X4$FX%0CE%9:XUU+D2(>%*> M?_**52/HG@!^)O)WB"0SH:*TZJ.DZ M@#2;AR 16("6C,@BSK&BRP!>JBP;]SLU7%,R$5D'?5'+0B"'IPQ 4-9K#^DO M_+_X/EY<(NSB9(G4C>*Y <2[[VRI36PG-$Y(/!\YODK\!2OL(Z.=: ^-^)"5 M"]:"1J4R$@IM6$6'2 USGXT,]((V"1:%>U:CT\J)2EEF"E-4)>"9QD)UC5 N MP5O%FBXV8I@78HXK MMJ$6%DNKG!\:(7T9UT_@.2^+?E$HL],DQ4[A')+"J1LH>"S,SB]0?N!Q0G66 M4+$6"7$J$R(O ]XLEM6MD]')#W*GRO2NBB;JDK\F@3ADJ0.IS$!\]W@E@70 M<)JA^"MK9?!\(2 G%V^O\_Z,MS.@6$ 2WU(L&5@&^916AVMOT#45&D54;;6Z M83#+K\.4*G6JTQ/,SHK3E!W$](C-J8@";\"3$:R 2<.K* 1+G[(NJU-&.LK# MR!#%57 U_%#G+LD&SP@QD13MR^I1W"ZE)\(2<-MUE%" 87$)"&-Y8A1BB+!J M([YD0^;C/.&%"HW*M!]4N^^LIPS# M]C$ULSK)X@%'_GJAR@&GNJ<;I*^D*-E(6Y(16 7.!<_.Y5FRZ3NAUA+(?D?$ MB.AGR8*$&SJ3P#^0%V[04. MN?F5FT:JUX[7R\.[$OH$S. [.UE?T14U]=!C*>Y!Q#*?:\NGLUYL8L32)P3> M7YZ)!-!&$96/533]EFD^3EU(<543*U1EF)_]D>IE-'$"_AH=&H%%!X8FD2%S MJ(J'5T>@=YR<7,99&3/$&^D1[RK'GE=F5;Z84#EC=)Y)'ADF5S!_&U/*OV$[65P&[/[HU[MY'PEBHP;+%/FJQ89=6;GPIES'A.9_\!8 M;ZV"@B3TZA741 9,&A#3B%,4QF!\4'I%@F6U 4DHH28OB]-J1K[@+!>G=02, MU3X?*_(O7("WO%A)MT KC9 85@VLF,6UI- _ MEQT_KQE *,LHU: B[P)J3;9@9]@EW&KYQ&D1_@Y16U"> ZNC)19>K0P1RK*0 MFD:I,@%*A59P2_WTTR_#R)R "Q;HX5_5K?RDHS#LRH=358)0@683@^/3,*&< M%S8P6JLV+Y00X;!CFJYR3*0R+ER5V9Q4JI*51S4I57H.4/ M$OU+A-5] A-PW]"LY+EC^#QP3;XU4S@*NZTX0YUP;[VH'<8E%0RS$3AEX2"K MT,?>#GCD@558\)9)=E>,_JZT1&$E4:PT)IG7@BH^IO>B!7"[4LJVHKJKQW32 M_A2"! 75MK*C!_P[HSQ!RO=N!%(_-W.]15,V>\VSPY#I$]8D"2T*#)-APL:D M:)?K4<<+;":(I!:RH"D_P2]2,OG2"^NUM)#^.Y_76WL5SI:+_BSCBR8'HZ^? M+UE6)[DN=3Z-X=$L8;AHZH05>5<1.]<'ADF"V9R*L*\QP_@;I><2D&K>I,JC MG012;O<"F! RF.?)$I!Q>2R77BCR>E?3<)F,(6&QB!->ATUEKCC1BR]0:*RP MS)8O#N3NLL_!!4INP'3DZ;#T(M:^L355G_+S\4R37A)$URR@5*M/6,V<0$PA M2?&]5T5N"Z(G"HH :1<=A86BTHV>PB>]4$-D$MHU(IBSA]\6SP-,5/ H,<*P MSRL?Q!]4\(?Q#(]#>(NI6J12**-7[&QKCTWGS]$Y <1#,"XN*%Q;X MU!XO")C0Q:('^ INY?VRR= 2ZKQ(Z!=GE_0%]\75U*O1[%6LPS*(PC)%^81=1&/7LMP"==:Q0U<3:TDN/A9 MAN%53%9FP96F#."*4<0) MR_@<;] 9+LI,#-P1K2E.&PG_ *=!/:.$5X85J<<;C->J7J!2F(J.O?D>Q4F< M>3;0'4<@ E*HF?[8A]>/D*M79;D#AL-&[42A((8C.A7$I@_U5FV( $ZT133> MKT+["%I.@65.9Q;[IG#C-6$(]SU=EB"HJFZJ^>&V! M^1X_3RA:T"W1"J-H*]+B-&262='M8K6Q(RP NU7X)2US?R5;L78R;&M0DBEA M@5P=M![9(PL!JOP'R M%LMY? L<2UU3)";0/O+F:)4O5-.ZQ!(%;0O,&&<): O@;@#VHC@'6=$"5WG( M"O=03E#;*XDR\H2JE6L6$T'Q-:65.;_IWEI/9#R?*&[L-9F\ZC.)\8ZBBRJJ MDN*YO$ZZO@-43W3,(-747VUUHO^-?,-"2<["[[@7'@F_HE8T4^KAB #Q#;4 MU1W:2MA"796=<#?H*6%%48U\[*1;BJ@PY2VJ0?Y4C2LO@QFZ6=BP#)".YSAT M0[KJ8I10Z^^%7GEC(VR7$E3++MK'M_@?/?#!IK5X4O,(^T$AI0T2&/]I;SFR MWE"DV6\DR#P_O?[(O,KIX/8+$.U9=$;'MH!K%XF!56"^Z/@/9>/X#TF1G<;\ MC^VWM TDQL59RZ% 0I4W04*U;5/;!A0M>]H&%.>%G70HH%"TS42A6*:Y#2Q: M-K4*BS,R]-]CT?A^MFN,9-FV55,:PU,DW39-:3"2;6E@C[31>.2X\DC_"D1N MXK_D.W:M:8JZMNMJ^8V-G:.3Y-7KXJL+X:[SV87_?4_[-3W='6B6*SECSY%T MUQA+SD#S)-OUY)%M#<;R:(24KFS::&V#VVQC?=]@6)16/[M^Q#MXO>B.E8V\ MK:A-(7?W+IH4')/D"Z:?X-])B*?YG[%Y*&M#Q\G^]@+=B=V/1#(\:Z2.7%M2 ML?.4;GJ6Y,JV(YFFZ]AC?6S9KOW,(Y'N:TA7%9[18+LBXLK"U9AZ%<[#,EWB M$YA-/@=A<:J/:AS=7O'CW(]:FP'_?@9;J)LAF4:O $#=SY/P;P!:/[SC/_O4WO7TW\<.'E^Y MX2&W(G$!1<$7ZBK)K"1(_)8W62N>T4^)^ ]V824.F]^3<*QNPP8NJ]D2.Y[# MOC]PE,#XG2;TK&[59=GJS2]_I>;9C:^H6^78#Y/FU__&QJB[!,V>)UB+EU<4 M\OCGF__G>:/1>'Q,,ZT++5Z<&3M\_JYYB.BVEN??X"?$0 /3;R M\O:B*C%SHRE]8EVXW;*S\8&;CI.XL49KZ4_GWDT=X]DS OO?R/2 MZUN_;P\;=\SK[T?EV+67W>Q&WEW/=KAK%ZO;G879'KEWV\T]X""_6G-C*Y]X MKPX@YF'5J>,@#K,WLJFI:DW$W;F)QG8_3ZZ#:3X'4G:C+)R&\QQSU:H9&*/O M;&H$D@"JN)P5MI_/1GZ"J6OIQR A"V'W)]V6;2D#QS0E;:1X@',' .*-QQ+< M,+(&JCMV#>6 3KH_QM@=(&2MOZN!HO6N%@$'9M599.+/)WP "17A$ *P:)-# MMQH8BDG=U-\O*T=FU8<>XW +UGU%*I#()@76QCROFI/= ?C& W#CP0?@VLL< M@._UM:_T )QO@Q-90?55C#!C,<(WFX^&S3N/AB\H,>4#2TP986(*_52=A]># M7K3 9SOM/5%\W7V47X8=#R(?X1EV:STOT9ULJ/NXG;M7H6;K<4PSC1<+=IY%L4#2B.UI^T&VS9ROJ@7/#D]^]^H!U M0 BU?H/Z,ZVSTS,;&:N*V'.G$\,$Q\MF2D\[FG/5)V[5T>V>\>A4ID[IW,\; M']D4'M8KIRZ(QR MNL;:,:?XG'9R8X>%0\#"2UIX!R_[P7;03*>G..:!R_\=[-7L81&0^4*AJV,6 MXZ>>(=CAX3#P\,!,S=WG;&Q("<$"52I)=;$#8>I&T_>\[R"\Y0/KG#0]CSX5 MO[=(Q-B0H*/J=&0H;BL*Z))F73!NYP"EA]*G,8T*EA W) MJX7=[+I_Q6'#Y'_S&$OGRS4L$^PM7WT.HR; J*]13=^"-?!7P'JA5!>]?8\9 MNZ+R[G3@^#DLNS=6"Z'Q)$W0Q)?8OY_,XQJ,P;YM!Z%ZHB!LP"*/'@:UFC6X M4_!UIRX;3UV8=[5F3>\YZ/0BEW7K/='UON)\!.U!S.ZMC#I]7JY_7!L U>@Y M^P@O=]M[V@'L5ML]R//A#C2G>N9RVH>V'18Z+'18Z+!P.%@X++^\,Q&[[9V& MF=>!YE0MX%//=NGPT.&APT.'AT/#PS9J)VNJG6L: O'/-XJY4>74+JDE0&RX MOLM->%S&",W7[))%#N8TNDP6J?!0G3.75W7Y(UW^2)<_UJWW1-?;Y8_PI1QE_HC=L]5CJ,1\Q=M[72'B#C2G&CT_[=/:#@L=%CHL M=%@X'"PF8C=]D[#S.M .>P M=: YV@#/OICBE;OJIQT:[K#08:'#0H>%P\'"Z^Z9?UBJO3/J.M!T]NYIV;NG M'@+N\-#AH<-#AX=#P\.C!XSL8 +(AMDB9U'F1U!"(]3*C,?;ZVJZNO@GS;>OJBJ%;2 ;$WZ[1=:)W5^_+ IF'AQYR!8R,.PCB=A$$T M"<2S:-)_/L9XI4/7=Z\^'K38=393>HZE'1V;'0]3C>,D@-6)&'P!-KH5L\2/ MTCF+%OC3/_,T6SQOCXB.LYZ%LRS->1&V.N:SJ=/.?.BP< A8Z S$A[M0031] M*>?IB5+Z:+RH ]UGIY!>L2CLL' (6.A$^4SV\UL^>8^B,%]+LCTD1O-:.GZH]M1'+73CO+;3/KU-DE^+X,HC0X+OXP ME$0'6]([JUF]0SKL8N M,@]>6/<\,ME,[EGZ'K)@#F5[2D\S[-UO[Y5KF5.O2.OP'1EX-;U>XWZ MOT_!31#EP:=@$E]%E WZ$?3IY';WU7ZCH3TV5=N55,6U)5UU=6DPUE5I8)JV M/#!,;ZP/[ZOV6_C)51A)H!E_HDH]_IGA]R?"W@R6*Z7AW\%/2O5YYB_"^>U/ M*XJP1A"7A6P*\0\.%+$&%8)^6$JP\OK6(KLMEHD@E<)H&D393_J/CUEVL<@P MI;)$6.??X!E^NP[ (Q0G>0JO"A(QOLS\,$H)BTD\)TV=Q(LPQ7+$*Z"/5(Q! ME@?)#4ZZ[(DAW!T5R1[9->CW))C-@TF64F$B/"8-IT%"GJ< ;PLGU_0#["/, M;NFT@:Z-<5$!=AL,\0QB<@VT&?#ZQC@-RE<+Y;O[XD4L3H,L2!9AA*66;'M) MA0.ZW4\2?!0%;MD"?5@(?WUY>PK7!>*W,+NFNLA 3"?Q,L#=NY\]T93-'GWK MQ8NE']T*:+W PQ=LDZRF$H\79[B!- N6Z4_BV[#F@X6(N'!VB]<+#+C^)'N; MOJ-WUA#P,]RWZ<;BK7XT"7 6)@@K@FLJ\D47SZ6'U)]2@8DJ33&LC:-($24T MLA1ON*E=[\.&)GZV=CF[&K'UL.5@K>K;^@M*"BSQAH0HB&\18P"5&HFD\-!T M%B**ZF^LO;!/M;8E;N)H?BOZR^4<[R'\ %8DQ(JXB*?!')=?+"UE#!!FR!9 MZ)IWV&:0:PR!I( MQY5'E5BC2N>"L(CCN( ""&R@:%PO/+T@_&F!C21(44(!!6W:"J.@.N%NN"X$ M4!;$/.V+G_TY"E#N%TVG#"(T]%;,_.]!6A <+ ;NO@RN_?D,=H 8#9.IN/23 M+.2""TAMGF/U]PQ 5^Q\K1ZC3=^P NZ]*)QU/>EAJ?9EG+"VL@#:P$\ WXR" M;H)YO$0Q7:R_384V3ZL:).!'_OP6<4\T%,Q)Y%/)?<9 6;Y96%$*=36"^ /9 MD<1 %R@ 6]0*41Y@(4#YSRD*3" \-1?]JR1@+U[XM\BSB!9 U2U]QVFJDE0S M A*"LD -:,@,A-72GP0_U?RL*(XD4*QY-"4##^&!=U6 WN(9^5("\F#C@ #J$"#$B/)I#C(B15IOFP;J(J2-CG7)N+6'R@TE*M7ZDJ2DGPI MXB('-"\WK@2$78)33I%(HN*EO'BL709?^BD3=6P+(.87M,PDF#.!D8+#,O7G M2)QIP+#-!JX7SZPL54YX36T+W!,D<\I.9GIFLS4AE'1:4VV;WU]?.M^-G]7- MW8TJ <.14W@<2'/8[/RVSU$O;'P;WA3%66T6.K8.B?,KV)"?PEMKD$V;BKZ M*=/TFUX 3_#_PD_ *C%P^(0E%D:T%=I FJ/\3D4VR!YI8QIR[*-4 M1V9+(N)3$JH@*>@=^/2K/$0VC4@ S&L$N=%F>&FFW""^2+A)C 1:Q&=EB@A, M6)% 8G*S4%',[J/3.B)T?&)ALU2RM[#F:C8AH2>9$J3(DT #;TM]L-O+P*J4 MP+TW#,DT^@T5L_D#9MPP@[%5\3#V036#.P::(6@Q ,83GJ43D$E$QM $X)> M+LAR-(EN\!E-^J_;R-S"!\T7!41Z AK-A5T?L-XZI,!3XE3NTOCS23ZO!%F< M^7-AQ1L@&ZR!)VR] Y\6@'V.\!L?S MR-9KWYBG78>"JI)DT#_\*D'<8)2S M1H[!L>))M%3C7S!OFYF +*#2:0%BF^27* A3! =CW4TZ=I9PL MG]47?P7R9) ((S!483= U'!G@BHA*_5M SL0.(&]PW6^+C2UQ^8@F"A5-0[;Z"!D>;&U_>?VBTDY3)<7N;2OM&B0_C0-. MNL2WI0?LWP<@ 2XP&B6"X5I$8*;?!EDWX* >Z-UH5>&JM /JD=IR!Q:T2BH MM,LGE*0 ))(BR2#SW7(> 68$B_XW^$HHV(._L?+0G)_36J2%&XZ8CM*^1Z&V M29^,NCOZG[TT&[9%@@$C8[R*5%RVPL MX%.X$6VMB%GO]&)< 7?N,%B0D4HEG->]811T36=80(H$"B-VG=YP\D/\UI?0 M>#@WME1U[2$0?H MR07N!6\%Z-T$ZPYM,DVY]\*RZ%.&'30G$%7E5LA7\,4K*IF\Q):+!TC.A2/_ M, K>Z->7(9(ZN1'<68!F 9(&?/0YV7(1*.VZ' '5S*,( C^2X!3W&1T0_B(6 MDN!!%R(%%HR@0 P(,O"M(N$P+>:M=4@97A%HLZLG.>37@3D'GC<)"H!8Z5^4 M$!8*$#4SD^9O4/>J3%][%(,]5R_,E4N"99R0D1TFA+]&-(@8@GBE,A * M=$WS8"565C/6>!#:E,4IJB5&7"Q63XDE9++^)X=E80Q]4'CFU\#I<4*61&,= MO>*M I,IRRRM!6+!,PUN?(H\E4[O2O!\,DER1$>Q^(+JZ^N@)U9XF3=/GK:. MX&7P)BE?-BFB.,#@$K&Q$D0 ]$F)NN+_RH!@]*69/+3%E2KE!"O?0RW7J)A M$BXP] !NS_SP9-TX !G,W8;/63Y]@M032@( #<$[NP*F"RZ-_%+^1HOV<$>9?A0P(\YAM-FE*H,7^/R*8S# M'33^'*$6RT9/.&4<\2U,&U+'+\[#%LMY4(OO"7?N="WE82U/X=X\@[:LA#$0 M>A&M_!W$A,<-V!$=CX"$<3DH+OSOC\Y3F 83,&GFZ3_?2-IZUH+IZ>Y LUS) M&7N.I+O&6'(&FB?9KB>/;&LPED>CK\I7N#.';='+PS365<7Z^N7S\,TONFW* MLKP&AX?L;$._9I<$5;W]\][:-*N#X+9D#PU/TF1Y-/#4H2F/ MQX?3IIF#I;+8"JMP6K)L>;P/Q-[ND0A52^;V_LM=OV666?6(?LMFUV]YJVS* MKM]R2\/@KH7R*D2Z#LF'DAKOS<.(_)$,C>):M.C \^&5GKR/[G4'LCM+?YE& M2*=1#O(17,XXBH(7(?$=4=*CW+/+Z>K\>L"#XF\0R<-_!Q M00U@'M91L85U"AWR'/6Q/8DZK7 _ YRAF1JDV5'1O::= -VKQAXT7J<*-G+" M.<98CXH-'MVL[8BX0.O*8[OR_V,LCCUM+'3#XEM$64][S;T,>I;Z,K[K,ZSF#P0/)'KA#:6AJFC7R[)$N/Z1/@V+OOE&#BGF" MF+M)10$U^(@5@,0"0D1LU>G7(_LU=&TENK8275N)KJU$UU:B:RO1M97HVDIT M;26ZMA)=6XFNK4375J)K*]&UE=C^LJZM1-=6HFLKT;65Z-I*;)1V75N)KJT$ MW=*UE>C:2G1M);JV$EU;B:ZM1-=6X@!D7==6XF7;2CPS 7R%_<5\ZHP] RPI6"Y9X\P#6#.Q(NJ:, M)6=DV9(R4*R!(;LCPS4/IXW%'4HUHF1;XN@T@_\PHB)'8K%, I#S*48'YV T M"I690S$HNJ1,D>+6)Q/\(-TG?_'P9.'K^]]\,%6%\F0ZNP8:%A> D&LD57SL M':X7:3/XP^J!;!%X^D/:=WC]/J;8+*XWF)[F0+%;TVPZ T M'L)H34_ON<#O12X[V/6^XLIR[4%D^FE#K/MYJ?-QQ4RZ?0REM8^=J=O5E3\G M'WPN8Z,LI0823W[WZ@'4@-+-4GV>=G2;A2_DUB(+$ MG[/\\BGF2*09R_L]*D8R]3WT,CBT36J6]2*<<,Q%P*?=*J##PB%@X; ,N$.U MG96>YNQ!OAW([DQ;Z61WUSC@**7WJ>/AT0T<=GP&W#QI9D4H;C3]4+B^(QZO M?-$1$!M[/FBFWIP!L7D'&X[4*_A]9">S+A[,?L83VW-*XTC_[<]S!M0TS1?L MNSV-@Y!E<^RJHX$TL+R1I"ON2')59R0IHZ%C#8>*;IG*,Y^CKSMZY3GZV7H2 M_%6"F5IX@"[._##AI;7QC*?$\%-OG@-+.2H #E/\./>C>IK%PP[#>T(S'8SJ MSBFS31S,_SB 7%+XI(O+">1/S[ MO\XN1M+GCZX'\*CY@VK?LG^L7B:I?8Q"_-XD^6-#P'##*R*=/2?'&0>)@'_3L4I67J>?,(XQQZ2 M56U9M4:Z/9!&(]F2])'A2(X]'$A#3S?=T<@V-54[K&35RBAE9B&O3DNIN!; M,@&-419$?^, I#JR99Y,KC'1.D4\IO>4"2X6V$^ %%$C+55X>%[J@9C+6R2Z M/=U:=M2G6,NFT:6>GMQKNQ3-#4F+BKYUIBU+KJVDD2!V>;2'D W]VO)H[]WM M,^?1'B71/2Q+F=U&$/TM;UH:\8Q^*M/I"WOQ<"CND0G9OP=H[ZY6"[@W0>)? M!_L"?4\,"/Q,O@ZLPHB,/[(- M9VJK_LA!IWSIMMFSE6.8R/7(I(_^/@9;'!H6357KF;)Q!!M]'!;5OK%^7-#E MZ.XP:ADFP3,*KE>:]-W!Z/A$Y]NGR-J9Q1T6.BQT6.BP M<#A8Z,(2]XP0!BLX3>=R[MR*(@P3-*[?I M3[W>I,-#AX<.#QT>#@T/C\],?5CZ*"6A3H/PIXO$QP2^S[>+RWB^LZ128^RI MBCZP)%WU#$GW5$<:Z..A-'8\SQAZKF&[#DLJ'?WQ\>*__K&VDF:2;-FG>D2S M6O:0!#L2/AP[DJUHCC2RO:$WL$:J/;IW$O&.DV!QFO%J+H"B M8W_YLIDZ08,(HSKP?DR.Z>[2<\\C\;?X9B4;5N%U::P$+?83#N'R1S2<5BN%&K8FYLS#%GNG4:)CZR?YW'@7UW%M*]1T&D]6D7%A',)NQ M88'8_#N8AGS"6;UQ-DW^F87H-/+)9:SK-6\>#W^-XV1! -ZFE "H\'\N"#-E M._(BF3@-O]$-9$L::YH"\F:H2 /'TB79'*CP#,W1+7OW_$M8^D\>9S^O\$OUP\_B"F$D M"W\.7X*2H>_.?OL57_6=,]3%)_>WS^/S3Q_PTBC@[_M]=/;KOY#-9/EGT3M_ M?_[I)S&YNGPK]^"?=\4J+_YX7WO#^:>/_X)G_22J\+:SX?GO[,]5"?.S^'YT M<0'ZKEQ,\8 &@],*J8TYS0F+/]J[]3@*K\?55,VGVQ3H)U\2$R M>MR+T#QR. )Y" .60@P/&_SDW(4#E8&[:$%3]RNQ1 M/@"!#16M:]2/O$Q($-URXL1;O+62)-[/XS!),Q&,U@AL\'ONKNX;_OR.:>+1 M[^*_ G^>74]P3,U'/ORD)[[O?^PSE?Z[4+NBZ3)L8W@4CY33L,!KP!Z.+H'C46[AS/B-57?HG)+:)9NL6'-1>%7.8KP!Z6OR'@:P)Y( M^!7NV'F!59YEVD H&G3577)R HP5RYVR!(NC:4T4"175WB'(^&T/EV1L8%9\ MQ<9$EO[))L'8MIIU>7/WZ],62;K^SKH"SP_-CD]>*Z>X1@ M$T3"!C'8!\^PJ$QE/BV;\KI94*4U*Q4]RZ8GJZIUQ[E >EU^LG4)K1MO"E!5 M[BFVWE-!@GZ)PG*&?0GANEQ438,$(UY(LHU-!=PHT 3Q!]5H$6E]<803Q^@Q MQ61#KCR$5_HV"WW]\ME;/GI=#ZSPQP8Y MW,X,P@IEUFY>IS)FHPKUB]).U)^$J,< 5%FI'J9I3M*IQN-M%"2^I8E^_IWD MRB/ O35:79-XVSQF5?[BP.M&G@4.1@1Z$OA(;*S!3_AD,"ZS, 9$_'B)H\5Q MT#"?:*88P#/EEU.<.UNK],=IKR3+HII]68K.60NHJM*H:C;K-U M61#AF&.4 M=^4H[W*H(PYA]SY\%J]]$*M^%,4X2YP/9_"ZAEQ!!0I_&OI7:DY.+W?BN$(Q M=BQKZ<1@U57HIGOK9!Q,*?IA'+&)4_+RC+7TJ+J9X#.28(D3N:.,7.O:*'41AU%^1U(F MQP"N*TCW+CN(N]8T<3W.YRA'P"))JH,0'$Z)1)VF0;4$=DDQ\'K"1U"FXCST M:=8F6/)\##<'#G5!+/NSW,W3JQ:QT1,80Q+SV7UUW8_^YJ4./_$CJW+5)"Z9OKVZ+A M 1L><- MD%AS'Y16N4@K:WT$X+C.4'XYXWQ"]L2L-#00)TPTES+['C> .V6%48)346O* MC1Y>;IBKKC2_7* N TU^2T.6A0V$7;EGY23>50U2/)M[9'WQRY*F9/$WWLTP MO6+)C!KOIY85PM/LOK6&!H&@#194-=(>D4Z^2J>Z7O]AFGOQ01S[DZH+8W=J M\HI/3V!C#39@S\7"U_%G2 M-JAC<)/F,QQ+?L6'Z5 AX\H;BYZX8-_"PH0E\%:'O?8@00;6YT&\WGM5*&8 M2E^U?B,?$2B3'!+\+X7[:_$U@3T.=4VI9?(E7OZ#*O?E#8JMD6^R1&^78 MP-;DWVDX14.0R1$*T-F MV"D_OQ:I8^-[7Y&%N#'E^70UB_Q*G8#?JRZZU2ENH11(WG6NP6MW#4ZS]?)K MHL?7)ITV*J#M^U]OA]%UY&ULD[T)KQO0LSTV]@S2KKMW]]H#ZNZ]%5]>)H'_ MEQ32,=F+M_1M[ZQ<2>V3Z/=]HF@[_@[@N][PBSK0P>NY>7%LMM&L;CE=V7;D.8G-/Q&+7-OS9VH;OUB([&I'7=18_0(;J M8/0LTK7K+-YU(6SKJ]6(-AQ0*]^]K.NY>?80]GRHZ^IP<3CKZG!Q..LZ*'O_ MU08]NJ;DQ^,X'T'XHW-B'O?NKBGYX:K:P^K_NY^%'8_ATV&CPT:'C0X;VZBC MU6;EIYOV_-:LN>1,C+ DK^W)52>!O MPW< =:BKY5"WI;L')TM6\[C2 7!#^PB!M?N(\RS-?&I( MS\E5I+UAR&*%P.&J'C94C!.\>G[;$XI>2EB,B8VLBH)D_S*^"5C1")5/IG4R M76^_-,OG<_SO'$L1F[V8&F2,_]#G]4[UV_:@;W2N+_*->(81R[,ZGU&)TWD% MEX&?AA,WF@[#>8X,^=@V]H#8$,@D_><;26MI:N_I[D"S7,D9>XZDN\98<@:: M)]FN)X]L:S"61Z.ORE?%>B/F0 _T=B;!WOQB&8J%HTLJ@#QN:P2=X':9,8"> MD51G!<OKE\_#-[^HMFUJ!)P'[ZR"QQAY,'B/;>7. M(@#>50BT[5)KI'&< + CCZIA)[?4LF]._'L^3?)$C74_=19QDX=^L7FH_ M$)/-H6(IGB;)CHES361=-/W$JK?W 11WX(T,P](D35552703CD\F?TM$/92 M\6T5>/5^'G[^LM*4]'%='>PGUHD^U-/>5**X#;@W%A]N7<5GF4^IXK.L!U?Q M;;YC)U^_R&L?4Y:R_1CFG9[?/>4$96=5"85T;'Y+LK*ZB:0F+>M$ZA9^1;53 M+0*[_#X2/MTT\8T']S6WB'70G-^*O)/Q(R*Z+W=6KQD],"AV M?QQY,$?USAX2^/?,%\?#!22@GC.!?0<4K_,"U,,F]R>G'&M[R+]YI3D&Q2C? M@\KEV_VBGIN$7WS#![FHSN3:D+@S>: MCDUU*%F:HDNZ;AG28#QR),-RM='(EF53L5;.!FKG(%^70?*U/"OHEP_^0%- 6EM*AB6PBUR>)1M4@Z!/6\\,MFB\?%)G!D_L M_*<]^,Q@.I[NX5N0=YOPXAE@K\[KG4+(JR\>F!V'>>I'TUWL8TN$OOJ M#[^5GNK(..YGF[N/,@RK]67S"#;W,I<=['J[_()CSB^PC2,1*4_.,5"/8I>= M;.G,FJVDS3A.9D%X;/+FK6H\Q88YID:*^SE4/C8./K;UOO)#^]/.5^JP\"JQ MT(FPSB%[_3EX2L]0C\59>VR/?^@;K[="29/WL+?.KG[5 M^JO#0X>'#@\='@X-#T\OV'MHV=F]S3]9<[S/09;-Z8G8&C );^!E-\'[T+\, MY_C,V)W^F:<97H!_3T-YGFY+C@4/\ P/'J?"U3+6=JCGP3O9^ MB-"T'$TS=@--%:&IMD!3T1S#5D\!FK8*_^P&FAI"LZTA*P@/6U%?/S!54U6U M'3&ZCL#4VH )XM2T3P"8CF4Y.^)S X&IMP!3,W1E+[ D7?<1.RSCA54[A<_Y MY9_!!-07W#/#@0+1)/#BB*FR89!.DI!*0L^CX"D05!43(*BKNJ7QSS7R7&NG M $]U5$67K('C @B'NN3JBB;9ACL:&YH,?[M,\2AO?L&%9==A,N7Z_&E[O*^K M@HO-%Z[()!C<5I=\]&]+:Y=- CB+TBS)\%8,L=# +H\-M@D ,.4#'50[H?.+;_%N0*[OB,Y5)G=_@85)1.?ITPD=GM40L/M#8)D*?18Q MN_IIP"W-+?ALF9JI 7"!.C7U'B=M-+ \3W4\:3Q6Q^ [:. V##Q+DE7X4U'5 MH6EZA419%\JJ5A]R\8S V@V2Z%_(2:5SH^P-"VM.FZ(.'7T\D%05F\<[QE@: M@"<&Q.Y8B@X:TE+=2JIH?^P S"W;?5YBQ\$]*R*+(B#8=AD;+9-K^0Q\T((. M5]&'YA!>HE@>^- #VY2 MOZ;+U34UWMP80?38[E\U7. WUKT^@**,#<,Q0)./=4"%HPZD@3U6)$\>*L.1 MJZO>8+PYQ9?:@,AHHY,E3](:).-W8@ZAX'L&=27\U5[0%+K;RR/9[:>,6@ M$Y+G4$)-Z!PI2M9"&"VV\F#L##UUY$GJ6!M(^EB5I8%E.Y+ER6"NR<.!.FYA MG%)X*=:)8.,9Y-P:NEKDG&-J0\-U'$D963KHFJ$#3B08 ,,A?#&PP9$?.-O+ M.>SW_OSX.T&KKL#MFJ$>B#XPJT$?K\-;!+ALJ(..\D0(.JJJYDCL$JWFLC6U]I ^T MH6S5K&9YU4/=Q>9V [*26=PTS1<,<_"F8 (X0\0\W>G?!$/PZ%W9'J.1:X\ MAHXIN1I()&OD:8HRM#P/3[\+&)J[ .&]F]V-2KCK-?^.<00EG@-_ E'UP?\> M+O*GRX4"QO=83=N#O'Z:N 07&EL,F[NPF!X,F_VC9!ABW]YHBB_= R9:DA*V MQX/1@H?=F*[;0N3960+4PT&RA-*""L-Y7I9@L-D?2CZ%Z5_C) C.L,4=Z.^# M1HC6QAOJ3H*+#X3-4<=%UO'2XB]L;_!L%Q=1=^'O[2(N,KD.IOD\X!&NM5?0 M*5EAT,+=;&D54>RD&_[]MI)INK*B#A1IH*@.@'^H,_M^;%G6V%4L=V1;S]P= MGS6*;V^/?Q8!-0&7+,C4I_[U5X@'<8HJ=@:8P#Q7H-UX5N]_S]I("T7K^RDE MUFV8F'M7\_M>H]V^Z"^7\Q#NP <-YO[D+PFP'L]A:[S5_C()L<4\/'\:S$6R M&D7XFAY2=?G_*X!'59@_J0[[IOV4#ONV\N .^_K#FK]WE7V;>V8P&I^'LT!< MZ;/[+.5\+6USS7Y+;5[7Y(0OA52.>%,:?B^**L/Y491$4_ZQ8[GM,8B6HC1# MC15R6U%,>,OV%T,D7CB+:<@,0>CW?YU=C*3/'UT/X%&K+E3[(*VKETG5GVK? M41D9X'->0@P?#P44[ILXY9YT^J+(![_H'@;>7+6S'TOYF5W80PVSZ:TNK+.+ MPY0'PF:G612U/EU;QO_5'>'F_H07Q[(-PQG+TL##06/V0)=6K[:S MH_M-H+]'@(T55U-U0\94,%O2+=F6; />:EJ#X= U#<45K[X!O+U R=@KX%L \#/#IPS&[PGJ-:9;/@)6V9.21YXT] MSY5D5W#[\E8*[D:RMI5;%\1146(J# M&7JRI3DM5N]('RKV&"?9FHJD.XHBV::F2;8Z&HSEX4 Q/$HI4K_:;WZYN Y2 M=(^I)$V\S#,10 5^:";.PP46,XA9++X-WXF^&$>!E(%O!KB^">;QDD+%BW . M]BO\A"'D'Q2C+^-79+%LL59V&28D'?8H' ]>=BZL_I M_N'H__[PON ->-F7_N=^#]X-+\<+TMJ[E@R-*2PN R\KNH*'XT)_<.H+*%_H M3ZY#6#.+;<_$29!D8$?PIV)(.[V.Y]-4!'M03%D1#CZMN,XC!XZ-@/T03,,) M@HA<0?XQQ"AX<@,DDHIO_S^:*.O]['WXS/X<_OQ.3()P<9DG*5O#I"CJ2<4T MR/"YV76QZP]!3! $/PG]Q-8Q?Q6#/PDDF+ 5 F% 'ZJCY(SYGPT/3 M')Z"3Q0O@ZLPHG,&OI4)7!U-X1>^=@)@=3T\&J\"%D"8^,5 /W MM,KB# .WP%<&C\25\:G"G%R1A-["ZT$X7,T#:1I>A?!BH'-X,\N+9.0%"\"'IB.(,?;WMX6SY'Z2/.DG@ASG)41>($> /H M!@RO-9,7B;]8IX@O U M907UGJ-H)I5UR+:C5H7O:P>&WFCLNJHF6:8[PH1 K,O43%]7U3X"";=HZM:+0+(0"[EY&:T#7Y7M; M@6C6<*PZ\E :C(<>*"@9S $#/$UU:#FVY[K*2!FR&NL-AMR;7V!]MFTVC.P[ M=]H.D]^"K.H+XJ8@B\OF(!] ^@$'3<^C3UBXC3P'!D28?HGBRQ1D/6JVLV@) M(N!38\;X!;PNG8&V.,_A]>^1[;2#![.V$KIM#QS9D33-P%0,+!@RC*&D#PUEH'H#VRU* MKC>2,;RM =SM]O"3+D))KW%*K(H/ITV78E6U:Q4$492K:F#JANVR0S'N\LTKLQCRE)\1;+0VNPD8"(+715X9?5!-Y2#=U ML\5ALQU/!9A)UDBS)%VQ'F-I""3CJK*FNP.K$"2_J+*J2K(I:36":%M] MA?[W#"J38%G\>( [4W!G&!* _RD-G;?0=/6 M^ZRK6K[VKWSQ &^\?;-K6#T8Q*#7Y'=GL]FX'BZ0/M>#(;B4VS;K8'05G>V M-0@:A8#_F65O?M$J+KY[:Q4(SI?D(417= ,'%)X%?"Q]K?/9!S_Y*X 719F; M\4OV2OYW!L&V!U!;KCD&*Y^\\6<0>8XCZT8=,IIEM\2H]#%(?AO,TI$-'*]; MN@,>D:)+ ]/P5,/6/,,8,)/(,238D37E)D;?SG6DD\FP); -%WD+D51T* M&TRR4\[?L,D[.7_['>MKG&\:3K'U^[>W?_+5T1-W=H1DM=38BB/)^D,U]C[P MNVE_]ZBW[;>[+MLQ3-(JW##575 M,QSG:WOE25<=]R@TM+BN6R+![$KC#H(9VDI%N[JXE\)&>T:AM=H8J"N*>RA2 MGJ20K:TR0[1=E"Z^9+.@9\O'W0OKM-9:J\Z^-,I]R;@[')>P-Y-TX+J*8XX& MTM@:@X7N#17),<&Q'!L#5;7D@34RE6>N2S0WER5>8!)(6<_'*NKP'!H4>BKZ M>/9>.Q3"0^B42G'*LD0.6Z"2:9#4#Z%Y?CYZ7#_3,3]>%488%PEOX!US/V)I M'%12^+!BQI.J,W34I]09FNJ#ZPR-A]49/O3K[K5[?^W]-4?VKDN.'COB[B%% M/7P;G*4*'B]F^RC+3$SC.=;)K<(<> X8+2*#I;T,[!+_8+%^$'+T32+^HUXM MRJJ5+K=$\U'#H;",FF#@=E+SRR(IL_DMI6AV\&J!5YDXU/RZED;4_ &3BDX' MD&Z1>-@$ EB#21BEX:3Y-1F/NP3.*Q6;=R#CJ>_M%KH%>:]T&#B:=0O8&Z%Z M8'8=YZD?37>QC:Y0?G-OBJH:$J=._W<^OQ658YPWW=--N:?J^C9W'^6X8K5O M.4>PN9>Y[V_5CX$NAX!@S6H]&J"BFV3,LXQBX[FD;5?O:44RS[V1+9]9L M)6W*B4Q')6_>*G+/;&G,M1TGOCLJ@6.9G< YMO5VQDS57 H+'H],N!AFSS). M0[K81V&T==+E@=)E^?W^N.;>P;"%).(A:Q(D5;SZ.XM7/_Q$^!@6]=S,\^(; M/LA%=2+LT$78J7ID*X'F,MU&++)LCLJ8,GNZX?1T\Q@BLH\.-Q^%A_8T/%I] M]1AV^3@4FCU5UG:_NU=NIVF@C*=Q?CD/#LE$V.&JCL12Z_#0X:'#0X>'+OBX M%GPLNR2_ DM:ZRF&TE-T]=6:85I?.X:LE"?BT>BKCPTM'SX*E9ZE6YTEW6FL MSG(XQ%5U>#B,575X.(Q5/43M;!X[M,/JUX,?E-XHLL7/MJ&HU-[+5I7'EC,7 M:G#ZL<#84.V6PN:M8*P64X)P%LWQC*>G?_T[2+&;&VL/L$.XVHJE*=BJ MSC"5)[1,T+X:V,-HE79WM-W#'1]S#SCO:72P/73UMO$QCB/OHD_(KJ;'O"3] M:K)A6RU]U;>%,).]6D>_37#NB'Y7&KX5#524 QM_]*($K!FR^00"5FDP0"> M5\"Y(P)66P>G*:9I'0'YEO/RBM: .YA7Q\&.HP;D^\&LN>;8M65=&KAC0]*Q M@;-MFZYD*8.!I@XTL,[&*VWZ2A@;IF7L4$BT0.%X1VFN8&&MI[PZ]@S3Q5;9 M U72'=N17,O3)'LH:V">.)Z)K=/YW$SM@W9H"*[CG7&Z M&Y9A TW5#XK:#31]1@71JH1E\V2'E^X%R&V32L'2,:R'R)N3F52Z!_&_S5A2 M3+CLQI*^*)JVFT'ZH!ZA>YI!^HD-*QPG\:)0(+^'V;67IUF\")+1=YSJ"=H% MIW/!_Z87_O!/WP-) M1DC3;#;D)SXU\U,Y8=(M!DP^%93@^!N-T12F[L3!7/)NF%>]Y0"CNR%:-_[^]:VU.',?:W_=74/-EORS3 MOE^Z>J>*:R\SY/*&I'?G4Y=CBZ >8C.^).'?OT>R 4-,, TVLJV:J1D"LFR? MY]&1='0N,E#-.*CDC4W=K*->,553R+;]*&G3W;19CFAYX7)$ 6I=585^K]WO M:@+,=T-2L525VGU3,12U/^S!4/RP.OQFOLOQ3IMW[Y&DR(^>3PN8WJ$ 6;X] MZ[A.?U,K.1E\9Y"#JHOB.>3P&UYR;7;-79WG3 G@"RZII(*Y(??)_-JRU$P)ZHC\GW8D;G.@VLM%G-,5GLHOBHI>GR-PK%')N'3 M)6AHJGK8R4 TI*&@*KVVJ'1@.]O7A79GV!FV85[1#:VK*XJ8L<=:4TA))%B6 M6-X-15)GX9R\.[?4LBJXK'F7^0X[Y2+2(MTKEAN7C%#2@ Y7]L20I7_68OCI M]RQ5(YU;)%D%2F3Y>(VT/;RV!904[]E#U65 M5=%-U#:+W,O**Q]T+%,W:V,E"3GDN\/?M>F35&89!0$LN/N1OW8LH7HAN$:O M]*?3>28;L!T_7(>Y+_?$H6%*;;.GPP93'O3ATQ!6BR"&GJEV8)LEQVX?67YW MZ=.F7*_U?H=)%E[D-\NU$3$6/3][+NUK?=+7>;'PG$;MG5\F;?44D:C[=A6R M(0CO=YI'O.H68[["CV0TW;A]D.D+W9V,W"#T(VHIA[$&PR\\Q8"SD8\J4XNA M!'L)LC!5%$$X)"^AH_8'LMEI:RK\1U%A8]Z%_1NYIVKH@[X&&[&XEMB>T_Q? M?A,-4]BV7>=]YPVA-NW&.-%"L+6?6T& IZ"A[CTJZIDWA_DE&,2%CE@7V%Y3 MOVSH:8;]Q+MO,:SC_(B"D$KVWMN4%;ZUL#-R>]8"]/H\^TS_CI2,"G"()LA_ M@8UE/.KAYMZ32WOY=EI1.V*[5HGM6E:WR^YFF6'5@2# +EAK#Z'7MF)H6KL[ M$(QVUQC(@^' [ @#Y;M)G(B)L54T]M)1-O4M-A8MGRTP@-NQX65\THEXD9+; M.Y!3,MMZC=0Z/WN>H&+XKT4. ,/5\=T)/A=%OKRRUY9D&(JT&93'O.E!^<3S MZ 2%X9P:;6ZF&6.><'-%U+T\+4"H6::YW#(5]>R%13G2R$=,1N5^!C)K^V<8 M3=/RD?EL.%1H.E($Z6Q0J-^-#Z>CNDQ$!&8A//=D8J)H@G0L#\;O:B*FG )E59^HIX.7W[X'$0C= )4CGA*E$ M_*X0X:@9TPFYMR))2IY9I=I3\UGER:?F2XYR/C4?AX%NB,K9ED?*=[T)4W,1 M,ML[-;=E692V'6V9F**+$$)S=X?OI'G"%*3P*>BB+&9K"OKI8#\2HAK<3.GG M$P0=9W2 N5Y4]/>B583.<&CH6EL7=*6MZ*K1-@1EV)8Z8G]H&(HN# SB($C. M\G^[GZ'6[>0A:,'CMH+H\0>RPU;HM1:^M_#\6!"MESCU18O.&RW/;=G1,XG0 M "FVGI$51#Y]Z];4\ULA="BW207MUB*.F$5QU8K?(Q"EC>EEUI4-/&-H@7# LHE45N\-#[9^)L<*$7RPPKBW((+_I"_!=)X,HN=G: @ON4R_R:]G MB"5-TXL2-J$8I<@)%"-]$?WCALF),?T3.^2+*49^*[!G\&#__F46AHO/GSZ] MOK[^&B#[UR?OY5-O] >,4C(;BXI((A$VEZU["M 3>8?5W_#-VZ,_=_!G]$8 MP>%5G*'9P= L %G\^Y>5K.YQ2'QM1L"Q%^Q$UKSSAD$QKW[NS3":#K%KN3:V MYC?3*2QN_+BW+Y\R;[)^J$];3P5J)O7V7Q;K..CX!8CO=!]0I1N\MD"BY:&# M];>K=C 44JW,MDS45_)=YU4?S93[4T.!I+;TZ@/9L9-% 7)H>E/2SDZ?_7N9UX4 MP,*YXSH#FD,!N3$;DK63^Y0+YV.>*,FGEWJ."0)]E"N M*)\Z(>PJKRS_+Q(P,$5^7O;4#<4D!J&B*-Z"4/S.'"[RK760:#-QC ,S*XKC M#:R])ACF:0?;UOSACS%^QK!(:R:2<3AY19',')$P8]_X'?CD((>/UDWJA(IB MS)$\F$B&060#GX9W$3OTC9^DV\M9F15&-^3_#R(?&_1,$O= MQSD'*T6;]2%)G$BAU%FE:T4!U3]C[_FQP0RJ/V/J@]M6$EP&<5NAWY%GNTWL4K$,WA# M=D1NWL<^LD//Y]1*58'BU/I9:@V>%W-OB1"G4ZHH'J?33],)[N^[UIPD#(OF MH=6X#>^'-4$9Y!59A]Z1O<-FQYGD'SL[;PJB;OVY0VOV5H0[<98ZSIU+'H7&&*XC/KN^2XKLD/"6R<*RFT8C45.,^"#78)(V*S1C/_@U@<:>'8=V MI7>TB>'M&PG#]E% 'Z#C.E\1(&S-KRS7>FI:"%."KZ0IJLCD@5Q^?&E5"8 S M=H]MG&=L@B1L-@V%R1/Y7$AN0M&R?"X&;R1FLYDJ6- %36;2>G 4L(FR!5P[ MSC-V<1#&3C:-A%8S-$,A7C0FK-*J%/,RM+!/$P!TE^N/_X&^R9!=CLF W49] MW6CD+J(PH"UD'O=2"LE%N@ MNMCS 5J2)( $YH^] @Y'UJ'MFZ3XVYQ.Z-0P-BFZ:)+X&]A@,FF)6*'33;), M=.PX_]+V6G$$ NAB+[ Q##V-Z2UB M%GBQO2:NB@L+>!_;8>.1).9ZN4IJ=*M(63JW5F-G0D$W99K(HJJ+JY0I[MV@ MO)L\\!76!7A%3_0D15=22E^3)+;M@I171#3I@&OD3SW_F13JZWENG/X&T#X[ MJ;(FG-2]FSS-K+@DUY%+-VX^4S+GTAFX)%9DYP!].7A.SX"I]1"8@H+!FSV/ MG+@^/5FX1"%=M]Q,5UD0 >(X)^@RNP.^#WE'!?;52.%4X(IAQ0;V3QH*94/# MCPO$S5ZH\10X92=5.TIHIL2XK:H,2JRB]B@A;A:DJP;1H5CXJR84G2<6/P_% M]5QHZF6CR1.+UP5(GEB\Y@#SQ.)U I4G?JX-BCSQ,-Y!,N(MA 0?N(OF*0N97-H46DG&^5$4#24U9U=L(5/8'$.F M&%BZP#_;_HZRKM&_10BEE DL423$ZMVQ!+-/,3:M"J86%LE%*M(M!)+ M+'(N5X3+I*1C7;A<4,E'SF46N0R,3;BLR;*IQ5&O$I-.TYMPUA]1$)*K R#+ M-7KMV+87N<2>_#W-.6@$37!AX8! 00J*8+*2;T,O$FM- MTC*K09"(9R7.YZ\R;3>[<#6(M0[KS:T@N)G2PZJT'EE'6G><%^(R5CRKM+:D MY3FM(:U*9M56C1'.LLO4'.'T+H7>G,[ET+GZ9)(^] R"[]E>?57.,XC\+[#L MD7 R3RF(8G6V9#L'ZB%$QDANGR]O(MV>D8&])6S1&(!7%U0PD:-0; M1FLN>7X."KA7%MKB[FTLZBZBQ M:R&AA[BB=]L4^48=.^XKQG$H, MV9S:G-I%V+4/4WO3JD1JORMR4D=JLU_TA%/[M/U +FIS*C-?OR<'E8RBJ;3M M>TNM!4Q3Y\.,>-@/PL3L1X--S%7TD^+J .TA*3]X[KXA?D!Y:_)(4-W!N?%CVX]^YGV$__RE<0EQX8 MJFZ(?& 4/S"HD6GON'@W;/C N,C :!CQ:X.ALI[E93/9#FDT6-#0F31+$X^G M]9;@*_*>?&LQ(QE8ME=PUY[[#ZUF*2SK _^]V>OA+KGK+*K:6RJ/(BBR=TN:N%V(9IY MJ$1:%40E0U1BMPM1E\4W618UTV1ZLWZ/PSEL.T? D!?L1*OU;6K;\@W;"+;* M ;UO\2 :;5$Y#&+E,XRF:V/TS70*B/IE()DG M+MXH,BY^A62BR4FZ64.O$K)9VI46

LHS@=PM?\&24YIT[A%,])>B1XV 6@ MH&DZU^CJNZ) $4PI=OH6V3YF7]N6XBA:4JG"<]&[Y"9W*+1@O>ZLBE?4"B1- MU00F339'@@3?/WLN7>G6"Q]%D.HPB#JV'3U'4VP8KSX-0.EJ"\)BV"R&8F?*UP"60%^I(>0 MDS!RE@4&2%P0(E[5@5& WB?/3,YZ99W-::F$9)D'CI.#<.%_ONI4'7A-UN0W MF6R-!::-GK=SR]U)81*O1& Q2.[S@DB+>FRV$E D5=9EIC=;&:"D\DY-\!O) M.;4%4#WPD:'1FPP2%;8]8UC6EB>KLF.(,48DR',SC>Z:0WW\A&&/0)O5B1(2 MK&\4E5/B>$HDSIKPBT-^K1\S%%E7]30S%$UALK)2'F9<_UX>,\88KB,6!]]% M?GQJ,5E81<3S7((=@J":M'*SIC&I)]8N11;VOUGS"'675X!7Y%.HAC[Z.T*N MO=RV JT;IYH&=\27MI@:7!< 3C,T0WFC )IB18%2STZM)Q_6[U&F4 M9CH_=;AFVJ'7CMM796QAEW/[:J@5;N7J;>JZR?1Q;!8S^FB*?!\Y1?I:7Q"3 M:KC?7\8%_G*P"+HIQ[N)BBK5C8M=$/K8#M/CYVZ2+WR):]:/Z7+)JN&EO:O. MO4_/04B]9)"X]RGC^'#OTVKBQKU/*X#5JDJ9(#)Y;IBK=$UX/T-7EO\7"FDN MTZ*M%J6 P\B*J=AW-4!)\""JGUFR:Z6 PI>QU0&)+V,9QXLUL?V^B;!\M0&MY:+[AD@^T2;*<#Q8(BF^H262B\>#,'I M52B]># $-TN=1)U&::9&!T.40R\>#''LG=ESV2V3*3P8@D%,># $B[#P8 BN M60_2A1'7OL+?5=(RZUFF*F"K3.^$+ER_'!W%4$S<>Q,$V5HS8 MQ(I]5U.0Y4T=RKT5AFE=2LF,)VU39)JW]:DX_%.C=6(CUP)J;(_2U;=#ST>V M%>3;.O_L\#1))6-9+&P'LJILO@J6(?84I@^>/JR(A/T@3!;ZU+ "Y$3!;>3; M,Y(NO*SZ2'$5\X(!XW;WFMBE+LT6MK>-C+-E!!,0KC=5^!%-]8YH+D.4_4I& >C^(.C8?T72Q%]@8P2@:N781"@2':(Q?D#-R :$G_#A'G2! 8=!=7ED_/)\.\+3W MY.!_?_;RN7M5BC5-8PFCX(BBH#)C]#/:HM@6BCK#U41)E'@%SA.XJ+5%"?[- MC4\$RHZ"$Y"H\V EZ>POO.MT$LK^D,WCN61>37MLX]<[QD6D=F] M9@ADT^&[2[]\VCQTU@O?6DL:-+,KM-@\F_QX4&P+^&VW!_+=P0L3XU[V[5<_ M'NPE^'L:[O80A?YG\OW!B^^0BUZM^?>;!5'AV4^RT^9@GSTOY&-_K'9J/QP0__>%[X MSB,5D@7\X]'I\(S//AY]?N@-'H;7UT?_^.FO?_GP;[V>LY7[?O_IZ>G8FTHW.':#17_*..$N(WY/ M4O'(7"K[3J^7B/P2-?[>>7O\^NSX;>[.?1!R[[WS0^[24%"B@-KQH/WWSNN3 MT[_W3D][)^_&IV_>GYR\?_/ZO_/4P7(EV&RNG%?N=TC\HW,1<$Y]GZZR9&0>=!67'X]R-CZ='0=BUG]]2T=W9:Y"SE*:<.96]&R-+DB&]L MY-J@7'*GG(^NEJK0!71%EP'C:CDG8D$T#)'QY-W928Z- QK"17EW>TKTL<4^ M$/6 B@KFYEFW\QD\2.-E>N8]^Z8?WGFG&+8W]HXECG54&G[SI'5W?T-63@"SKP%14<+'FDAD=- M"KL+WU1S84HBG6 *MQ;0G7.@@P:_K>E\]/V#"MP_XO;_YD0:=-ZO[OTAD?,K/WB2U]QC M@KK*\+!)8??BCXT>86C$T:UTSMOBO$^!HG(!L7N<>?_QOX?!KY/)H'0:?1 ",)G^D93$-219T?"Z3H2;IB+;WS] M,L@U W@8S 2-FN^0T!@)UUBVFK&)3P=2PA"V*0*JR+%[_O6ZYS.13B2SO3WE'5@1]Q#VX(D+JW3 R83[H3!N[OJEL.QS.S%>"%NIS_IV-,7J&(1$;=\]];$D,@PD^!+K:3" QHKW2G/5P\*N;=@1 M\M9 "(KJ:5E.+,P9/!'A=:&^.4ZN"!-?B!_F'N&:*+!+L/OXQW4?HS!'2W-N M*<&+70*_:P*/U? Q>6Z>N5L$V-UK%.\B6;A&JLO/=AJ>+Q9,1DY^!X3&0+@D@D,_RCLJ]-NQGL\W/M;/R39SVWUJU-4R08Z6U'GTA>=4D@M[ MG%M)1=I];U36JL^Q.*^27]UBEA!YX5K?36@446.W?%5ZWZ=UU^P1E##X]MDV+UME '->D'GZ,K;C;*XG*Z$ MA)1.KX,<3?.K( >>I_4DOKDC:4OD*@&C MH10[-AHMZ^O L4=PK%>-[BD\CB[S&8E#P-K]=5C4YK<#8OMJ/[A6;$/'$+-$ MU4%A5RA4"@O5F.Q.KU!Q[![Y?68)NE:7E.KPI XO]&&\OW;#3 TJ\MF]O;UV MV',2V?ALFZ7%SN5U78Y+*W%E9?H2K?1L5^2RN]NH$98L\^P>[SWZVBSQXB$; MT:]XC,]GE?R_@R0[)LP"8%G=N*?/-$K^2AOLP/*B8!F,;Z\()E=JI4LTH^F4 MBN:(J2?.#ANC?+@!-M"FDS3J_#M9+/\CKC8EC7<0>E$(Q>L(1M/UP<"O!/> M*3D.[D+ASHFD,2;& JJT M64>WV^'GY?&C'^[14M=17>AZ<,-G[D7GVN ;J@0/%9'41+(=4^9*41NFHC=7 MI("3:.!H%7*ON5+D=?AZ"7SM%)>VR[%CQUQI6A4[71CZ&C!)LNCXR1PLESZC M'J3*YSYQ_WAP(?^@,G+(G6 X"*\*G :2[5 R:L5V*&4)>:R!$ZN@$VZM1"_6 M(HE6L1X=OO:&KS%;T"]4*NK=P[_0O?!+/^2?0>V= E,3R79\&=5I*[ZP_5ZD M@)-I$$6."OT8 M0MJI;^XG%M65:D=1G36R/2?7=DS2A:!O$X(NZ)0*L8< M%F0'3AFD;QB^$D: M[(+/BR+%\.M.0:>J-#MFS/JV#3,E0.EBS%= SBT1?U"EK^\[CVXDVHXILY)M MPU2D0'RWRZ2_%<3TJ=K7W M=O2[C9SW'L NP:@BTPNE-O9*V;M;)VG6BACL( MO3R$?J&K@93A(BK??8;;XP!K+JM"E>GHH,ZXAR>UG*] J45=4#3M!@:Z^J\0FT=5#=:3E6LH'_7 MP7G_B?U:)--WHZA2-[.W2+)#K689/4OMC7"HB9*@V(%E7V#);YB-EZM>B6"A MDQB3NB)N:@JU0ZA>^3S?=++^UIE"XU%>MF'';@>G_< I\W )!'9(RAK(M8.J M>LT\F=V+[Y7BJ\O1]@>L=,MV?G=UO%&#YP\"&1(A&/4&:IT#=+ZG^)E$2$CT M!LYUC+U$$W:X&07V3;O(>\GN$=Q-EM/$B55QB"KA]1S 6JI0O&NUP]Z>L%[808(X?@9#7/"4KK,F]H((]$AS)),^K43C?NWP[ MABJ?65%<;1"IX3">IS?6^6;JI/&IJ[4WVKH8'U9;<2GO5GH[)JP'W';!9(^. MM9Q/6\G1M?GMCJ]WPFV'A#TBX1-5>'9,LG'TW\'CN/GA9^0**:PE6$FQT%!\GL'8'+4 M;Z_E13=6,!P82@R_2,4N_AO^XCR(J*,+8'H@E,/)@LHE<6V*,RX5KJXZH8=.W^ZB23,MFJF0Q]L;_9>G*@,T8N8)Z#"YS MAN?Z80*G0 _HCQ!D,A5B;_PL@G"9M,Z@5:NI%_21^L$2;]PR'Z *ZFZTUTI\ M0$9?J&("XMK MUGITLB]CTQKAP'M$X;=T,:$B;^4FBL@\2"$A?WOO!0O">)EUD6HVX_9JQA!5 M]/VX!):61)6_PE-1L,2$> P6D'+B>=/L?Z*A8"#30^?6K-Y-X&%AX(8"C.^B M$?9J("@9HH'4*^V8S<0Q,@ 6!"XW-'>OACV$($FO18GU'4VGS*6H=:EM5OK6 MF#>;"3HCBN:F&Y.S6?)66#\Q[C4(G!0R+G!1N3Q8YJZ 0 M,F$-?4;Q8Q]!J))/^HSX)ZIT7KVE^_;41O9&7T;DW^ZEOJN5XSF,N_#,MANV M8.IK]&OE%EO4RT-X!CS!0FF$3P4O8=07#2N"?]!A*!*XS08LH>+,/Z:V+8QX-XD'D*NEOO@Q2/-?5@C6KB$ M^LD;"!.H=J&/:K'E.P*WV?+9MWN4MBNN/P]5S]:8Y2O;Z:GW\Q7&U'"B>[J" MQ?=40@S0.6N^-FE$P^H\K8J3V]6^AY\\W.C>+4R'$1$WKS\L?Y2KD+?J$=ZH ML/GH;B-MZ2.;GA(=K8J[)<]L$2[2858R9,9=N^OVUF$\&#S'1B7UJT&L6;GI M)E6KT+N'#.7_=DZ"%:]K*4.4J^L$]Q1?*WJKEFX,;/:)E&R*YSH&&ZIH.TDY MC&Y:/X?'>(]O)FG3:[MD@TS1-^8IZ 4;&W ?1."[N/SMG\//IE,+EUOER " M$):QN'<)$0JG1-/]!R4ANQIYBV+WY6+I!RM*1?1A:O/;]N;$>'660YB12:PQ M(XUQITVX+#OCWK3 0M0J8X!A@5BZU_G< '0B?G[**%YM,LN+@7!_K[W+ M9^KJ+2=?((7%Y=C,BV+(SY1#'N3?$DYF5)C^KMT[3))48%K1P(N0Q^?@Q(4;B)I$^"N M*)$LRJ4>5.BM-L^];Z5LE5FX10?2Q$>]4JWP#=&K0% VX\-X%;">J4Q*P+EQ M53YHYGMASX(/8?AQQ814:(X[S^U*3": +8BIQ]OU^R)JMP' M,3R]=@-^S@+I,@AL>+R!\:AOI&C30WU]\_G+]>4G4_GB]5:I',_77M!DWC8I M]-P71Y_;" _A\^CQL8J)>=,59RFEB)^=59#Z-#&&Z^W[1PN_QVF^![ M$_G$I?J$T8OB6H6RFWFO>'#EVV7X%59*MW]]=$'#;(7S%E-*"%MC$)N@AL- MP$@^TO,!-T<9S\8VPE8]): ,LA/FGYY9>OU;>HMC MPJ,3D>23R9?/\)O2W/*R@H'5&%JTT*Q,Y>1ME&TW. ^$")X8G\D1KKV++C^ M%G(:K9+=T@F-)!Y$;EEN;?[%MK5KBL2'4%TOL^-.,.ZR)?'O!%U&BROAUX*% MB\J/2C41+7]XLLG;!.%# I%;?X][\B_JJG$PA- .-"GLY99^:2;R$("TY=,: MQFNQ(GV;WH[QPI8,P:/I?X7PWJ/"!\ '4Z8PTP>?PEM>@FUPD3ZR()0^1DTL MQGD#[GWF)/HT(]R-N.(9Y/@@KL)(_NLUV:)G\1,.CN*)DPLFX*D(A D@*U6; M8 .*QDN^OW(RX=+QA6=4?'M^RC9IC[B^&A"./9]O4:PQ/S- MI+M:EKX']FC834!X7%J7Z4LLKGWH&0?+MJX=9+32R?>4TR?BQY\Q*3%TG:!5 M5HRX&SPP_Q9R I?XGW_1FVRH9T3>+71MBKVCI8Z@?*;+"G'OXZ=D\F_4*!6Y MUWOA8I*U M%N8EH4L6-#\/OFYMJHLILM6@F5J5>VI+ST;INT%S/"X\E62,D^ M$14* $VR(VY]%7DU\J]L7[65Y"/!9HSKQ3[P&M^XX]Q.=@"+@A(#=$PP@V39 MW5:%QK)/UIEFV*C:9$X^$M_!"(GK/0?1^3A)LA@?$320\<[10HZ=,WH/LEH4 M\_/6Q(.+:+2HBGO&M]"URZ+D,]!IF63$S6=P"UW+X&NH.GX**IF4HVNI298Z MD)6J5>;@8BDI2* M%ADZ%TT:SYFHTT$-Q;6K@T#5];.ET Q1]7RJQA):WPW53&VG.;EEF9 UZF)F M7,*G>J]P@ZWD^Q1Z""N1MB[P3*?8!H^$^6O#ZD;$1STR2N3[,Q0 M5IA@JLEW(%V1FQ?C: <,XZ)I@UOP;6$^3;\QDAWKOA\\8>/1L >9=IV_:X$N M;1JW67JC=#JL*D.+;(Q'SIEVT=.$SU6L^/JA6)4YVF)D%W,ZO%I>B[01M<^8.AM[*G.TS\QXOC,WL[G!NLV$ MK34JV6EDMVB=JEWFQ"WF!,*4VK3"G=39$[ M+_)\5?X]^&2S/6BKCX"0>FYC/"<\GH[_0J7Y#<-T0) T6\WB8 <2T1^@'/:MHY9FVG3 (FF MVQIV4'V!K>RHPF3Z%.\*\ M:SXD2P"$7]9?+]=68KC"W MQST"MFZHC[$-;(?1$[_^@>RW!7?A"($JLV$;;HM9\>&Q\?(I8<+%M8 MFYNO!M\2\JHQMRJ@3W<=!]DVF M[(BA^&3 $ENWT+?*Q.VUN!LVS7WV+O)CWNBF$EH&\*(949EE[6AX"TTAO:A_ MA.(.&]D^]*,/$\//_P502P,$% @ #8-I3>@E^$0Q$ 6M$ !4 !E M>7!T+3(P,3@P.3,P7V-A;"YX;6SM7=UOXS82?R_0_\&7OMP!YSC)MMMNL-O" M^5H836(C=G:+>RD8:>00*Y,N*3GQ_?4WI"1+EB5+MB1+RO5E-Y9(S?R&P^', M\.OC;Z\SN[, (2EGGXY.CT^..L ,;E(V_73T..[VQY>#P=%OOW[_W<=_=+N= MJYMQYP\#;!#$@7DY M-BUI\&.#SWH69809E-A="6)!#9"]3K<;$/CBL7+>>7]\]N[X?>3- W>9>=[Y M,?+H4H!'TT1NSCMG)Z>_=$]/NR*,@6W#LG,3N3L(^YF/;.3D[>]8*"1]]_U_$*G[]*NE;AY5U0_+3WQ]WMV'B&&>E2)AWD M9JVB^EA2U=,/'S[T]%NOM*3G4G_EEAM:.#D8[*264+^Z0;&N>M0]/>N^.SU^ ME>;1KXK@1\%M> "KHWDX=Y9S^'0DZ6QNPY'_[%F ]>D(EG.GJYKHY,.[$U7_ MARMNN#-@"-6\9@YUE@-F<3'37!]UU'Q&OU)1C-W9C(CET(K;QZ]$"((CPX2/ M7&$\8USFLSIY!N6_$;:4^/^,,_W1"J14&FN5"G"3&9^T8JDBRU\.%V6*19%! M%U*%6TMMU5Z(,'W>T*_")^CICVS"JI)(40:J%X9NM.%<^UT&7KG*;*-= MO0A&(+3$T7#IES7IQZYL'% WK@ ]35&'9J13KA[^!NW#ZD->\M4+XHZ(;^#H MY[5;T;UXJ5Y$.D$]8*9KZ/#\LW:K#RJ8'3BH7AR_P[(OI3OSO*-'?#WARB%8 MKHW_=]P$^X8+WXG2+(.)E-[?OW6:__*[?,6TM4+ M0'F:P*16:C^Y=R/X3%N#S=)5R6)'+BH72T@X@;-#FJ0]&"E1.#>$BB_$=N$. MB/KM35AX*6]FWE+RI#)I%.0E$0(#E;X3KV$.V0,8KE Y-CW155A.5?!4N<@J MT9@=2%4-, Q4C M,PF4"$;E-:GC:9F:SL1Q&D7+#%H5N)T)E@CV'IQ;+E5 J0WSB#O*+R&VO;RB MMJL49JQLB+8TUZ^&[9I@JB%+*9;K^.ER713,KZ#6F:$I6H @4\_2%S>$U7-8 M6)P/6///>V1,3OAJH=!J:8>\)XY:#&&%RR'V%,I.)*I&-:931BUJH /7-PSN M:JT=<9LJO9W JW-A[S]K4YAL,] '#VJ2PHI\U=*X<"5E()5_^T295L#HA'15 MNI"3;-7H(RM>%M!7TV13_>(0(MB%=M5RB"\7.03^/#0;@'M"\&WY9B _Y:IE MX%LAB4&=(HA^C+^2)A*I'$(?]N6CH?*I2&^*<5.UK((DV14\.=5I2C*5ROV& MC845JNPA>D9^RHV1047:ORO]JN4163!M1=-?#V!C$0P()?(<3YM5Z&(7Y:?A M\JI(J\KAJFK9K=)#(;L5:M)V:K5BK4@+\M"LWA_UDV6'<<"W$*L^\DK-G!TF M^-J)?-72N":"(0.K5%EUP-,IU8:QHOZ<1:]R7\E]DO"7BW]>+ZH=]=,I^1B- M<&^TVAJ]AA7+ C/5EE'OJ:)5XH97CX%>C(-#L)5S,ZMF!9E!>:TQ8*N]RURL M*X%/7V]0MHA\TKN47=F=$C+O*>7H@>W(X(E6E^[)J;]9^0?_\9]!#!=L>7P M ^A":^4].)>N4+M2 \(V>0+[T]%N=7LUHO(CTWPP8H5WXWNS2ZHG?_H!\14L MP.9SI0%W%,7C<);"5-Y:-4DU%MUG"C:E?$W]%IFWO5#!%J[M!"1R0= MTTY?J07I:KIO1*@Y8)=D3AUBK^V"20:77;$6//Y.RV2>H[LBZ^ KHP^LE:F# M2[4C7/F5^)]*4RR(K3U-1ZWX6*)3HN.,%.[SU:T%5:B36P'$B]7!Z^:R"32% M]YP96S4GJU8=2-!YH0[RLP S/FF %B\%2$:E.G!$))K"=+1$S1QB!]S,-6:S MG5RM9BS;C65#/(5H3C^SFZ84KH-O[9#L8F*V5*B#_Y&(;D#89M:32M;$\1P] MI6"%J1\'Y?$+\M2L!Q&?@W"6:D6Y@VPILZ$CD'3[OK5*'1C";1K)_DMFO]CA M _7@#)/;IM&\\B"9R^6&>=""/X(/ZYD;U9 M/^+-+]&3:DVL^EH7G9=94-\2?+81>P3$>)K;W^$"6=;G"?YX=$+"/5O M_#47E O$\NGH[*CC2F2.S[THK*GHMAN)$.Q/;P%LEL\;PGW_%N#N8CQ#Z#^W M#7IL=(Y*(&? '((_?4/@<^:#0_!G;PA\+GPTV)3_"&@_,O;Q!RVNQKB/K#6T&=>_8\[.$G[<&> MKT]OSG&%8%L4<.4#FV?2.H3?HMZ=#WZ>G%X(OT7=/&?K[[HX(QS;]NGV#5X$ MMGX/0".XW3SMOYX)_[A&9"S5V5:CCC3W9^S@2HF'+ S-!DPZPO4V7X.#+JR3 M"B=W]5JP 0-!;+4%S)Q11I$MS:"?2DF#E%&K#B0#AFJ./L9VSN.EZN 46SRT MC"E\KI>I95+:.TN 3<-3UY/GHC?*U=+%P.Q&0CO MM!1U*KS$7JO.LDM5N'V^5,N$--BV8H.9WN&/H55*FYA.KU"K\YW#:8IZX;$1 MI94S #M"WC'::%.J/-$_6,.>--BU]*%L:O(S%HMD ME:YEA]P:.YMW)R8&4QF5ZMI#%UL/N+%.S#,E'/3CGLV@;U#\1-E,):D3IX],0SM*(B&[)" MC9,"M0I*?T]\E#U=$.]1FZ?BZ6%K-41G[STL]LUF22%G6C\:]MO7X%8=#T.=RM56K"8%%GRRQNI$ M$TVKDQRC9SVF33(E M%ZYWMJ66P"@V9Y7;J+1S0JNI(DXZ-JW#GY7Y;N5L5#&1K"=W M6SDAO9\ ,N=Q6CE-74P9TB*?5DY;%Q/%'JM7]IO3;:5T"J664Q:S_9\*+->, M1%M7PI4JL8TL>2MWV!88K;)F/XJMHZMEI4;D9I75]9;8%?2=QD,+3:Q4Y\;K M!DJ\+K4)G/<-##Z]'8/H5!J<75 N#0H8<6"+-9?O6VKX)^I$;AI$04\%;+N( MN0FLQUUW''4X!H4V37/MFW4L;V1C;=0#34DQ[_&AAAU#_%FD)_LSJS4,2_$C ME>L8=?(!RGG"GM^8DEU#(#_[>P;0U(JE'F52;"G9.O5*CDJ_'V!R9[?7Z%;F\7,)(J_9:64B?^>.D#;LM=(SW:G]LXQ@L8Q]S5Z=.@SVEI,P M$]%.&[/X+$:8/:L , M?()!MKJ^H'T@="L-M17U$_C+1R0I JU* -D2."ULBZ#[^\+OS^ M-!+"A2LI ZD1^ MB@:1#]Z:B4LN M$6<\^&RX1U$04X-;:Q6+A1 ;WA9;.6ZPI%=Q9%N,T9:8LBT0@EO3@A"SI=PV M6*O'[I.$OUQUI/@BIQW_V%-6ZVIZQHST3J^O__6R"\Z> 41^%/[\YL-W[]^<@="-/#_<_/SFR\/; MQO?NV[=OWWEKY$;?N='N'6[HA*[O!&\1@,^^"]"[ ML[=OC^/_FD'RT]D/WWW\]-T/I2^K* F]G\[^4OKI @(GG=/#P/QT]O']A_]X M^^'#V_<_/G[X_J?W[W_Z_N/_*[>.]@?H;[;QV?]T_Q=I_.]GEU$8@B A[/K M(U3_^^SV]N*[LT40G*U(8W2V @10X'V7CQ4<$<24"]'/;TI8OCS!X+L(;MY] M?/_^T[MCPS?_^B]G6>.?7I!?Z?#MT['YAW=__WS[X&[!SGGKARC&T%0ZDL%H M73_\^../[]*OY=88#B\^-2^#]?V[[&/6&OD_H73.V\A-22F SAFS!?G7VV.S MM^2GMQ\^OOWTX;L7Y+WY3S+A7V$4@!58GZ40_Q0?]N#G-\C?[0/P)O]M"\'Z MYS?@L(_?D@5]_^.G]Z3_OUU&;K(#(2:,=Q7&?GRX"=<1W*50OSDCXWY9W53 M!P>PC_PPWF\=W"[=?'&^8=^1]N^X0[X;"O!#C'H(N./A(2-P[$/1=A XSQ%L0^ZX32$7K!M]V.[ (8@!#O/+/8#@>S2%E M OR (0#;*/#P57GU9X*W[2+TEI@V\"+:[?$G$"(\9P;$<&2Z32<3T0L';:^# MZ!NZ"3T? C<>CDQSR,$ 7_K(#2*40+#L'OI,O M1>W[8)0[3Z@0636+*C:+U//JP@1X5R][LID0X3F]) #+=>V#A$,J.)%$Y!X! MW-U&3G$FU"R:X#02$7N((_=KY1DF#;._/Q\[9"[(#ZD M3,IRO09P1"ITFU\I*1Z2W^,28$X3ZM@9[)G5H]^8>]S](#J]>D)\=N!7$*>_:[]%>\&B MGD2I@OHF]!(W%<]_2=GJ40G3 0+UY/@;."P02G89=_0%?WZ,"$-PJ+S_GR,/ M!-<1S)FH%&3@X9E^N(W"#=%YC,+7J@%VQ.NYMO3IUVS]E=_/G*G5$X!PFB!$ MZ:;.E7O7,-JEMT&SM2I:=(1".5F*B2F0C7DE]0!$(G&N'1_^Z@0)^ P<\N_, M8)&IO$/OUG>>B";-!^C"@1 +*HNXWL-;ABO@)I#HV%)#UV ZJ8!).@F/#6KZ 8O ?2?4_/Z<:&&L[_2 9)JCB(6]D?G194^LG4" MB<@0O:8?9[N,F#/Q.XU)&[J^*N0Z3R@1V3L0WT:(")3IQ7P?Q80O<8+@<.D' M"=DP#^0.26^:JQ+;*PDSM7E:5/@_0:(5QJ^BIX!=#;933_\(E0/ MX6!RKG#/W^\P8.@Q.CD*G5P[T)T3$V>(=>$.T9,HG:90C=6#OPG]M>]B!F[A MNE&2[MK[*/#)OGT$+_%YT-]J,WA:,[ __J")"J?I55/C/$%^"!#A;Y_\,-V M98.TJKT@.*UJ[$L>+\]@0 M^,RJ:9#?0@@+=61"S,?DGC0E266,_= 7#D/IHVC?#(-&-:V.2K)+\!2KVRGT M693S#0W'"M)VC),A/K,Q-%"T^[O.KYH>)8?I=5G]M0(!;H(%0H1AKJO-%++8 M0^$QG%Z*=I4*L!5N)/XLVG%5=$N$)E3/3^:*\O&8< YDZF7O)B: MLW&$KT[3JZ;&E0-##,!)5:8.[CP!KM'#_L#6K66R6DZ0QO=V#W!&!',"M=%<*XQ4- M-WD";T^4Z08I;8 <7N^4@N 60U:!&1\R$'HDUCK[E0PE,5(\F_]=%8 1@!*, M 3<;O&I@MP&P-H.WT_DQ!/B>KDP;D)P)$6Q[?,@OOU=4R"2C!-[16\S/7()G M$$1[,O7G_.1FH^'6(,B&Z]#Y72=8RZ=M[:"G],@EZ.W&"SVQN NS$ M"<4E>R,SQ@JB4.^E Y-?\!M$C-#+L'"DN DQ:9/,^@KB>PABYJ82[JX%-Q " MZ 1$!^SM\#5&-@P!,'>^8J'4TDL')C':WD%W!@+/: M1@>4N3-!N"G"KJF0-ML9 6W+5%0+0=02!OPDO$H@Y M*/?P")T08985368:W090P7B<\'ON1Q[^'0(' M@4N0_7_;(1T^L#9ZW&$FOGI6^0]32R<)>" 8EW# _ZK#CW_Z_1Y&7N+&2_B0 MY]7O&-AYH9)TDT@_*Z2(!GFE=9G)(T8MS$5C69:8(T.3A ?J$([ MO8T.*!] $)"%#;TL3J_@Q!@@O\_/9^:<\Q/QH 3>SV]BF(#B1TPF\!)? M!>D(>">!#?G#T#T@1I#F3BF6V-R77 PW#I=8(&GN<]P1R;+YKD!/U[,J#;T6 M>T;!0)CWTG3#M.%#4*!F[D,CAIJX$TN!L[GBMAC.-4>+ C%SI6HQQ-BZLP)' M3_4P6Z8;J]$5/ M <\>4DA(8I>X7M?F;J6<-)AG%JZ;[)(TE),%%M?@*MY?A_&IR#-U[_CX2KEP M]G[L!'R,N'WT8'%4B:+'B %>NM&>ZID&5R KV@3R*R:[6DE9B$VV^].83B8A M%$^KR77^6-Z"NPN:[31#FUVN-P@E3*LPJ[46R+-;@=A^UFN 7[GU'?A6RND$ M_=#U]P&^(K+-L5POO.SF9B'7?T M00+I94\.1122O$4T-RY^6RNA_OWC['C^ MJEQD5UBTQ@R_=Q3<^-Y9],9:W89JVQA1_$+%^LS.6M-QUFJFTF'"VFBH#=[L MM;],2&+D[ W,N #\3J:?V'M#J',WO!A!F=RY'D 7-J9PR [8H MO;]&%TX>'USS/ZF+DS8H:X7Q:U&@:%?%RL25QC$TJ]YY[J+R447"^KZ$9[];>1:UVABBPT.]6+8,96A-KC1"Z(X M0&MJ@VO],.\&@_WI^8CU8)UMB/N19_(WP/=3Z2*S9/CIN$,*2O;VNT:.I""8 MCI.EJ&[2?F?+L32&@[740?4,WH>=# MS.MJRT19RG!_*C.V"+VTMN1R?8^/+4E#FL4FTLK6Z?':RD6"!^(G1ZJJ?ME[ MF+:X_5_>_]CFL2705[.?TW4$:Y(/7K D=/,Z+VP;;;LJU./O/X'403\<>P ?,!Y%2FUH(<]EG2XL"O]>]7V:,Z 30KMX6T^!.ZQLC6QVU9 C?]$P+ M]8=O[Z>#-U2&C29/?QI<;&T J[4AD)/BB?@VR.B:E[DI)<9*:RN*8R8TFB&8 M9X\;?N4N\9V6 YU]8:D'.@YB")XLS8)0%RE:AO-F,?G%9@/!!M/L/H'NUD'@ M G,EOI?S)_@NSG+SM.Q$V:.KPI;PQQ40\AJEF%'&[Q*&1!"O]G%T[KDRH&4@ M4S*O <0W0MO)$AK"AEA2>G""ANY1\61&T.(1CXZ( M)^"MO_/C42DC.K4])VA%_EJNETE,_)90JE?Y;W^SE7J3[\)@8A0C M23E!EU=__\?%%W:%O\IW'32^)C(WN,7LJW=#REQN_*< D'R(,3H_?';^B&!: MLI$CW709P3 ,"^CNG!U?$NTZRJO!5),$SH%R!0A<)/'/+H)QKO'+/'-8S&?? MT:3<$0TE%/NZ8#4=JS309TR)7;*C MC\KB4'0Q1^X8?_EUM(6;^"Z5BN[QT8 MAP">DCBN@ O(KL*/NA8>R)E&1AUK(IOHT+#W)_EK\9! MI.DF?7"WP$N"DBFDI ;"3WCI7]Q\"5V'&8O^#YF)]1<0;:"SWY)RT\QR9NRV M5D$K9R>)P7OTI2Q#P;@-V&VEW,,GD6\1A@D>^*@!K%R+UQ$D\@R >E5;"9B<; I\[44Z*"&1#='0GJDA0T-D0"#W. MG5TQY-L0+3WTZNGMIV1#@+0$>4#,?5![!+1>CK@L&AE<'JGI_W]]/A4G45,3WQ(M?T=JPI5C%[Z MUZZU JX((J9O0X:Q\8A)S7:O/6FJ>$J2G@;*-IVW&>%:HY"AQ5*7$^'C](E0 M.N5:C>25/(YECR#]693;']56D_KI1+/)H/U::W]R MAZ/9YT'6&GMZZ[ND[BT)ER\*S1,- P1Y"+$IX:=YY"\ZU@G,U&3DMBX]M5-+7RDN'W@JF O55R>D^1LN4HSKV18A4^DAQRH3JMXX80N"()T M&9?K0KL6'$B..%)S$E.%9!0F&02<()>224Y2NB^*I)'E8+E+S\4BP"<=.J<] MS'9>Y7?0DNJKI-#::=W=!884A.@ER29.0VVCVQ M]Q>MF93Y+TA.$\^!_P ./)I)3I:6ZP@>BP3?A"6+"@W"?@-)PD'@OBB59>AP M*Q 9! MM.??_N*=QX)UA?\,&TD.N_:6!*W,\SC2"93S,EV"S$)"7PU6J['\#'WCX:]8K]UK#W K[PAEM[BF$ MN3'6#_/2.<]7=2T]T91&^/9.?N+PHD5> MXL9'=YH5V)"G)H*'Q7X/HV=ZM4$Y \M)@XOE_P<_^ P\HE_Z\K?4=0QX[/N. MWT%Z8&&^SMD)BAGY8O@=Y,!$%&QU$9YH>F!G?4#?H=3AT1%6N? 4>26)"UJZ M\?.;LZ8P[,'/2AQ=*K;'4UW ESR+_LUC$CMOU23= U.P5ZT7$=[D9#IJC]E(BG:3D_0,)S!#SV9RUIWA2 NX6)B<2D?:JK=K@4W.BR.! M!^KGSFUR6AP9C&%O#U23<^/(V"V2'.=-SI4CXT&&*O&Q;0$UA#YLBB\HQ!Q>(3XP]94;9%1AK8C5; ML]_T"HXMX\SP0M">&D4=YFP?=/,S/ U>;H:KC/EIG@8M=S.AE;ZL36HQ;<]? M]KT)V8Y869UXL2&ULTN+=M!^:[4G=!J$H0W)%5N#4;I(\4T?)//DD6Y(UT+$ M"_<)BU>3X;=?X*9+42_%$XSVLMR+)EP=8BGHHB/9CD0<.U6B)8'L,8%2! ML<'EZ+5YZ(]>F-T:R>35E4UC5JOO\CC0J]:W7P<3#-4;2KXV*<;D +VAN//VE>B;-'0JE<&.P;)(4I;+3QA)R&M"K3< M/3P_Q*@@2>V# ;J^1P!WMY%3U'DR1]E7Q"U57\Q+\!3?()20<):T@C.Y9Y?K M"_QF^'%9GT M!?*OB*4Q[3>6%JS3@W_MN&D /D<+2&FH'U[^SJ(UU5-BY2G&$L S@"B3!?!? M,6$8$)8,R65;;(5E^L(CY\80Z&@>/MP; M1:CK!''2]"(+\ZJ_P AQ=Z'X('+,E_4Y5X"0T0\WYTY ?EP!EW (J>//8T2: M$VF%!,A1K9T#AM-DO,)0^42Z.NXKOGF1VEJ.,8J(EP+"![6=#MJ5=Z< 5\9L M;@KL)->"'Y-%O0;LG.)]1C %P\M4O7GM0X1OS]1:Y-T[!P(OBZ7I.HJD8F[- M2:]>?$)4Q,_U+MC3E/6X>MG[F:+]DL-6BO0T!:-KB'<$"-W#UVX1PT<2_T\#*8VU.1_?"V>,O\:$#9LPA3,$Q M$YU\-[]N.Z!6[ZGL_KJ'/N:Y]TYP#\$^FPS_M?/+B3U%;S6AL91A4LA"]?WP MD#S] =SX,;H ,,9M3D\$5>,O;6PMNQ!/'X4W80S@DQ-^7:[7 &:&]]N;\^6* M6Q-'K*^4]3MF($LG RA>AB0O+(J=(*!Q-6)]I$)&S(3$/\/= G1:8Y+5ULWM M9Z5HC504YX'/,Y,=3+W#;2RHN=[P8TF3!J92S"$.? M:+ =>" Y@<(E3!/%/T8/)'C$*WWF5065,*X*#!MS54%YW/JP%X;]QI53L@B$ M> X,0()OAZ-%G0TXK[G60CYE>Z-(,9]&>SG4_.UOUTE(TH#=WEYPJ$AI)F7^ MADO$+<-3OJVU&FAH?M:\EE*A.''0Y/DC[^!U$$74Y6GIH:7T4^Y<6*152-/= M4Y2LB(0O(OHGKK0A=0H=-"K;U3A70*.9;EBYJT)I:!F\FJ34W%C.Y9&K;:3< M-D<;_YIH]U)5V0).3Y"11$='C^KOS*?6 H&<=^,:C)*$6\!_2LMM)G5D<",7!SM MV[V+\T-SE.N>M98*]VX=%C=N@3S&U^?LP1>PK%[&E]T)UM& M(C"3R_ET7?Q!&12T%P 2*\3(]WIFNV+9DBVQ(Y(TSM:JXJGBJ(KX+%E2-U4< MZ:;7M24%4\519#K2:"^0*AM3CDD]Q_4'D_T\5$1)E,E3\RG77XI3S"&$%1C! M.L:6^8'T0\\(]P^!/Q; M?(L0YML'[)1ZM+:2,N?5ASY4);WF6:\!V7L8*?"G5K9 M)4>^BAWQVVT '3OE%_RRW$9X6X<%E4M,T1T@Q@=\53,VCW!W*>N1*D+O8>0" MX*%K_%X>#Q_BY_\6ZJ<&PJ/: \O"T6X7A>E6%8*1WE,^E(_1.=&_ %+U@#HO M?K(;ET?O8?06 TMI>'Y(+W*QZE_-'I+R+Y 0E%YWBFA7B7#F-UB)$6D#C]E# M/E3' RP(4JVYEOU(CD+*+["V7]% 3W8-O.D21V9R:)0P8IV$49.#HP9@ M+"K8FAP%U7DG#W6M,S#H:>"FI^J(3 YXZH9O+QVKR2%/G;>\N K3Y.BGSF@S M=/S: YUZU%UEJN4JR4KHTK!V8ZXJ?"MRM':G*3&;/%=C4?&0["JV:%]F0:>$ MIO*#LJ;F>%H(."+0E"4U69JM'S8Y(*\'AG5=<]?8,\,<*Q:/GX^^F2DSG/J/ MS-X54G33B_AQ"SX[\"N(CV3E5$MF-GX-GAX,"I9DU$Q4R].9G((FCJ2BF5+Z MC#!%"["<'7&,L,X7NN++S]@8W"Z2LO2WD.H49;!X=OR E82\SS"S%3M[&QLK M^^ $ "TVQ)68Q"PCPC#EAXY?BJ;O4+-]U%Y[(RN7-DBM$-[B&4"\Q$QK>4MC M>VTR'-9!NP9CML"H5>=U97HF8889]IA,PF#3W_QFN\V&<]U/PC+3TQ1GL1U& M3&J8C@FFER"BW03SVO3TMFFP#=,5/B2[G0,/R_6**$2)TC#/:7#4B3Y&1T>J M7)>(F5A\!O9.>$#E.\Y$Y)HXE%T$C%&'3B@$:YG$*';27.M\!-C=M.#"3*!? MA[[94#^\7(]7:E,+8>Y<>(RAAJ@YS60\.2_*B-]!!R5;2H'4B,EJ/2L[]0:= M,.&QNH3K7-IR-?/9N%A,068AG?.#G#TMI4F.F'D M:FYKC2R!4Y.R7J=A3V+VMO2&(-XM^#%PLFOXY/QS?J!?(L>:-[E321)O\3WX MSX8V5MT\-E/KZ#AW'<%?R.NBF&B-Z63GJWOP7TBBI_2VB7]TOIFNB<4L57^L:!Z!?IA 2E+JA981F1V!?T]DQ6LX] MWC.@W4ZC2LE1772[_*+IXF&*=E:8=.'B=<3P?\%3PJ/_,T5\["8HLGP4*6(I MFXO@M)X%0+L%P-();'LJ$>NM%!3"!HYOE1#2IDV1,+ V>CRU@_U4!SNOO9Q[ M%)#UO ECZ..GP4VKE[(JIRBWOLP[8-N0JJGJ\J9;*08%M77P(\Q[ZV:8K29;*38 M+YFK6XY"7CQ>"<5H,]E(L9*S7)6]4$0W]GR64T\I-].!F1&>WD9MA MX\;B(3XJXF;Z0&+D7F;*\FPF0\6FE@V&E;2FL"XPE+03=HY01'MUHJ -'A4* MB:K(7J#? <-6JO:2=[0[%5A+[E[*AJ+29I*88EJQH:*6F<2DVD5MJ/%M)CFI MAOFN!=%F8G T7NX*88ARLX8[FYL0?9PI+/ O'D[O:YA57M;O: M[8/H #/3[_61%(ZXQA O%;$./)I0^!BSMR MJ,%K/H4\:W:0;.[IQ0\ M:KJ+]..E$X-KQX245(B6ZP9Y1Z"E$E M.AOK5)5T2AJSQ+O]3M@B16&Y@GXW./=)E-K/_@B:=[[ M*0J*F*FZU=,&%\>A2',-G04!?IPL =@VYZXN@4;Z8APKHN=9_A;[?> #[W$+ MS@/'_8J?#SP,RIA4X@E)2C$-U_$A&)?T>_A?==T>_NGWS\Z+OTMV5"58\[L$ MS:,85'BQN%!5OL^V?:-L^T(KO"*, X5XU6^C0L/<;>6O<\I&WOA&6M%8()^T M) N$DMW)MQ(_OL"[),\8?A963BS=JBL\KU5V7!Y62O+!M4\XF=WX:T08*5+& MB^R+_$D>WG33Y.VX^U< MWO16T;9A<-"=N/D5>C',IHUVTX:150RIDAS!L2%4F;QD# GPB$=-&:%?"]T? MDZJR1[MB46\*JMKFU;Y##4[(I<\&-R?D,NAZ44Q[A:H'&_S.# N/[2$PV^#" M9B^5CX*S#0YQ%E"9*T#;X#9G*XV;^WA.QR7=9-'5)\Y$L_DC9H,SE\T5_B_T M"9:I@] 7#-.K4(HUUUW":J MKTY1'Q1<%RX^ZQBA65\U:WYFS<\;INX&GJJIV#P@F26&2('WT M'(-R@9O6NMQ%X7,I9[THZE^V627MMFY3FUT MZ"Y.$'#5#O56UD#Z^T=]L!IOXS2DT&#I+%]$879ZER$]'YI !V4P8:&_&TQ% M!]DP%=>=$$2-YG+@B6!*^74Q_$/R] =PX\>(1HY+@%SH[_/5HH(\;$3=6.'U MEHP5&5&/K1N$#N8+, \&7 ?1*W"V--8)]Y<0[8'KKWW@\=7IS/9S;,FHZ?O* M/KDKPNP3#H]H5#&[SS.%2)_+2/O1;$$VDKJ9/[0VMY3:]'.S@J= !L=\_FH!:N^J4H?PY&>1;= C:#?&* M4"RI)(I"%;HL;;,KS1P0JN!*U&@"I71;=T=*W[ M9H27:O^@<+N\<47P9*@HM/O9*EW70O*?J[H*F,'UIZ 7$YJYZC;:;4:Y^KH> M=!.]ODXI#2[!&D#X2A(:,$PU#1IP?$&8;>= ^M<32)^ZS2)MYLK:]%.FK7D1 MQ5WAF];JS&X0I@1*Z"+\Q'9\0U,P!](;98J?+6MF"]1CA?,::&^WP.YQ577[.U?%,(XVUB9U;X[AS"^7ITT:.' M7,TA&),*P;!%-S'33'2J9J,VK.7D,EBKZ ,,86R MG.D]7(ZRS(,0GSA_8JW[CT$R/?P%.RU8CQ^FC=N))V5\JW8>=8%_@1&2'IC"FYAZ3K*J\%T%%^Z MV6(Q6RQ>E^H]Y[5GXP135Z#=\C J:22S,'.>TX&V0G-#"-63K2J V1#1IS[5 M=%.=-(DDI0;8E37E(YWMRN92A2&(:D\!:HK5G6O],RDU)B]&BJMMX.Z&-K%7 M^RD2DVQ5$<"(2">!H])3G5&F#->?P(;:,0-HT&99[IH(VT2?F[^!PP*A9)&ELW6L97%)[B%\K%>879=M?!.>URI' QY6Y.[A MNKVHF7 RN_'7B+R$ 7ZVR+[X[+SXNZ2>X$(# %.E+W[I]=(W!\!Z^JY\]/4: M G"#&1',E\4C[U[>]-.D[7@[ES>]5;1MZ /G5,1&.=C,QO;7IO8T31D\IR(V M4&.DB/8*I1\;?!P44G4DGMT&=PE[J7SDW6WPJ[" REP>W@8G#%MIW-S'YCIU M6$!CNM;4!L\0D^S4]J;!/M4UK&&:?LW0G:U-MEB;CIN90[1*$YTPGWO96=8XFZXFY'>B'R'?3IUJZ[:U]0JOV4Q,=-846F?-83BT5<822 M9K?\' MF6A[A@ M#8N->OH[@&O@QYG"599G@S&0CQ>:4"5WQ6"8QBIW0PV>F M^E@JHAM[/LNII_1M;LYC.;4TO,VBL]OX-K-Q8[V('Q6]S7T@,7(OV^*)8 7- MV&R&CF0?7<&PDM;,V2A"^?1[\EQB L!)9P-9UBG6< M?7^,#=:B*8?+Q#$/K78;4(OU1G"S%W%&FJQ=9CAO53>(]N4W@RATCS9] ;RS M1YN!UY!A=GZVW#T[LBG*?31[K$G0VLZN:1+-7[-_E'(-W"2\I-206*;@K3W1 MCKUD[JQ+LB'CA)FWAK!-O6M6BXF1>&P%?D'N5\GRCNW+4)![9HFE&9D+HKY* MQEB17UU!58NC-,9S8Z.1>IAT)> @1N,9DSLK%-UIK\7 9!M">@B9P1 MD9YR2N4Y 4!XEJRP*$GNQRZ4QVBJ-]Y%SFTJ%OLBZ#+Z+4^)=K\!,6\8F4C;DJY8B DH8RWTVMI@!!7& MG/^"VV"@[+S(@H*']IP6/?R!%' R I="/_\I _4FA7Z$\KX94S=^['KF(RI& M[J+P&2"B=T\54X]1[ 3E[V1[WD7Q/T!<;-PA*I)>\TV*>MFQOXY@_A-IQXK0 M'!D(*<+IU0MP$W*[5Q+NX[L_?P4^.Z&S*0H0-$76;@,8I.J854Y#]PZ> @*\ MOV_"7MKJ?F/,J3]XX\^5.ZU65K22L^>YTZ]YD%C832&G9(/HJI].#)Y(OS \ MNJ)G8FJ>/ARAC6H !6%!TQ']3TDA/^,W!O\[I<<"(1 3%=BM[SR1'+(^0!<. MA#Z^..)Z#V\9XILAP5_##::@K\>!(H7X!%J!'\MG@ME>!\?)A&;QA%('NZY8 MG/KIP.;"05M2N/C9"=+-%).M<\"[@Y 3Z]K0ZH MRUE>&X>8Q)!B]M2*T4VX3V*4DO<#UQ&&U\,4##YVQN"C M81A\ZHS!)Q,PH.UMKMY1I.?D,-+D_$9EU9M7;&?LV&,8@^7IG10[5KRN.G J MO?WB(DI+)_/P:!%6!#OK4YP(2V&5 MXMPHYVA8DJQ#D2M_;8T?0;;R#+J6-&@W!S"0:B.T)R22PQ:6\@YC=>B0:,IY^ M"W,_ K3*Y%12T!1X-J1C44*!CTT*_/BZ*/"I00&#\\5TTPN446?8V&Q(K=4? MZ39UD%6%!>D.!(9%!_SF$&^/> E7))%-)2/3Z2/*OR*6PW>_L6;+]6RY-HU* ML^7:6LOUI&R,K\1ZI1)+3;;($FCI_CK6D29IX+C;4J"C"?BDS_FO48 ?1GSS M'3JA1.]K E;4BNI=4.,,8 )^J1=O2OY.6#6ZF8!+2_5K9G-38.=><9P.EL/? M^3YFI1$";A1ZCUB8<+?@*%5P4@EQFNN@Z*_X:;?9"6)V@E"Q#*VZU5?L^-#M MOM+N_F ZR;+KSRJ#G2HR]=0X:_<3-,YE9/:P:2=7A+M"CD>O@SE MO0V%Q(8ASM/OV^!+-@Q[F@W*!O^Q85@W;1[Z/<;$;G"*CIC"VUIV3W=!RI;; MF*J$+M(E\RP571WYS'-E>TAV.P<>ENN++K?/1'8B+LYWJ6$YW$BMIUY

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�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end